Lentiviral vector vaccines for T cell-mediated protection against influenza by Macdonald, D
1 
 
 
 
 
Lentiviral vector vaccines for T cell-mediated 
protection against influenza  
 
 
 
Douglas Christian Macdonald 
 
Thesis submitted to the University College of London 
for the degree of Doctor of Philosophy 
 
2013 
2 
 
Declaration 
 
I, Douglas Christian Macdonald, confirm the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
This work was funded by The Roddick Foundation and a Medical Research Council Clinical 
Research Training Fellowship. 
  
3 
 
Abstract 
 
Vaccines that induce T cells which recognize conserved viral proteins could confer 
cross-strain protection against pathogens with fast-mutating B cell epitopes. Influenza 
is an example of such a pathogen for which there is a pressing need for a universal 
vaccine. Lentiviral vectors are a counterintuitive choice as vaccines since they have low 
inherent immunogenicity. However, their efficient transduction of non-dividing cells 
and high capacity permits transduction of antigen presenting cells with not only 
antigen but also molecular adjuvants that directly or indirectly enhance the T cell 
response. We therefore investigated the potential of two such adjuvants: viral flice-
like inhibitor protein, which activates dendritic cells through nuclear factor kappa-B, 
and 4-1BB ligand, which activates T cells directly through 4-1BB. By co-encoding these 
with influenza nucleoprotein, we have shown that the influenza-specific T cell 
response to lentiviral vector vaccination is significantly enhanced in mice. 
Furthermore, we have demonstrated that intranasally delivered lentiviral vectors 
transduce alveolar macrophages with high efficiency, recalling and expanding large 
and sustained populations of nucleoprotein-specific CD8+ T cells in the lung and 
airway in mice that have been primed subcutaneously or previously exposed to 
influenza. These lung-resident T cell populations persist for at least 4 months and are 
sufficiently abundant to rapidly control a mouse-adapted lethal influenza challenge 
without invocation of a secondary cytokine response, weight loss or lung injury. 
Furthermore, dendritic cells expressing 4-1BBL potently trans-activate bystander 
dendritic cells, both in vitro and in vivo, demonstrating an indirect mechanism by 
which the 4-1BBL:4-1BB signaling axis can enhance T cell responses.  
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1 Introduction  
 
1.1 An overview of vaccination for T cell mediated immunity  
 
No other field of medicine has had a greater impact on human disease than vaccination. 
When smallpox was eradicated in 1979, it was estimated to have killed between 300-500 
million people worldwide in the 20th century alone. A greater than 99% decline in deaths 
due to diphtheria, mumps, pertussis and tetanus has been seen in the US since the 
introduction of national vaccination programmes for these diseases1. These vaccines were 
developed long before a detailed understanding emerged of the immune mechanisms 
that underlie their efficacy, such as antigen-presenting cell maturation, T cell co-
stimulation, T cell help and B-cell activation. They were also predominantly antibody-
based strategies, wherein clinical efficacy relied upon maximizing titres of neutralising 
antibody against external pathogen epitopes. This approach has been of limited success 
against pathogens with rapidly mutating antigenic profiles, multiple redundant 
mechanisms of infection, several circulating serological strains or a life cycle that occurs in 
intracellular compartments to which antibodies have no access. These are unfortunately 
characteristics of some of the most prolific infectious diseases of our time, such as 
malaria, tuberculosis (TB), human immunodeficiency virus (HIV), viral hepatitis and 
influenza.  
The last of these presents particular challenges for the design of effective 
countermeasures since it combines rapid replication, high infectivity by aerosol spread, a 
fast mutation rate and the ability to reassort in hosts co-infected with different strains. 
Prior to emergence of the 2009 swine-origin H1N1 (SOH1N1) influenza strain, pandemic 
influenza was rated by the National Risk Register agency as the highest threat to the UK 
population as a combined function of likelihood and impact. SOH1N1 turned out to be a 
relatively mild strain but its rapid global spread highlighted the inadequacy of current 
vaccination technology for pandemic control. Furthermore, despite annual vaccination 
programmes, the impact of all the previous pandemics combined is dwarfed by the 
20 
 
cumulative morbidity and mortality from seasonal influenza. Influenza is estimated to 
contribute the deaths of some 36,000 people in the US per year, whilst the WHO estimate 
annual worldwide mortality figures are between 250,000 and 500,0002.  
Antibody-based vaccination strategies are the cornerstone of influenza countermeasures. 
However, the rapid mutation rate of haemagluttinin (HA) and neuraminidase (NA) B-cell 
epitopes on the influenza viral surface presents a major problem for vaccine design. 
Trivalent seasonal vaccines in current use require annual updating to incorporate subtypes 
and strains of the previous season (currently H3N2, H1N1 and Influenza B). These are 
inevitably out of step with circulating subtypic variants.  
Generating T cell responses against conserved and vital elements of pathogens that 
otherwise mutate rapidly or exist in several strains is a promising strategy to prevent or 
treat such diseases. Traditional protein and adjuvant-based vaccines, however, tend to 
generate very weak T cell responses. The trivalent inactivated seasonal influenza vaccine, 
for example, generates poor CD4+ or CD8+ T cell responses in children and adults3 or 
mice4. Indeed, repeated vaccination of children against influenza with seasonal vaccines 
may inhibit development of T cell mediated heterosubtypic memory which may otherwise 
be boosted through natural infection5,6.  
A number of vaccination approaches have been developed to enhance T cell responses to 
a chosen antigen. In broad terms, the aim of these strategies is to maximize antigen 
presentation by antigen presenting cells (APCs) to T cells whilst also ensuring delivery of 
sufficient co-stimulation to ensure appropriate T cell activation. Dendritic cells (DC), 
macrophages and B cells are all capable of uptake of antigen or immune complexes via 
phagocytosis, endocytosis, pinocytosis and specific receptors for immune presentation. 
Extracellularly-acquired antigens are processed onto class II major histocompatibility 
complex (MHC) molecules, whereas class I MHC molecules present antigens synthesised 
within the cytosolic compartment. DC, however, have the capacity to cross-present 
exogenous antigen on class I MHC receptors. This, together with their high expression of 
co-stimulatory molecules and cytokines, makes them particularly efficient stimulators of 
effective T cell responses directed at intracellular pathogens. A number of successful 
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strategies have therefore emerged which harness the potency of DC in generating 
antigen-specific T cell responses: 
i) Ex-vivo generated DC-based vaccines. Culturing, maturing and antigen-pulsing 
DC from human peripheral blood progenitors before re-administration has 
shown considerable clinical promise as a means of stimulating 
immunotherapeutic T cell responses against cancer and some chronic 
infections such as HIV.  
 
ii) In vivo DC targeting. Formulations that maximise the uptake of incorporated 
antigen by DC after subcutaneous or intravenous administration increase T 
cells responses whilst avoiding the need for costly in vitro DC manipulation.  
 
iii) Live attenuated infection. Attenuated live viruses may directly infect DC, 
ensuring efficient endogenous antigen processing and DC activation. In the 
absence of direct APC infection, replicating pathogens provide a considerable 
volume of antigen for cross presentation and stimulation of pathogen 
recognition receptors for DC activation (see below).  
 
iv) DNA and viral vector vaccines. Genetic modification of APCs through use of 
DNA- or viral vector-based vaccines generate potent T cell responses by 
combining endogenous expression and class I processing of antigen together 
with vector- or DNA - mediated stimulation of pattern recognition receptors 
(such as Toll-like receptors) ensuring DC activation and T cell co-stimulation. 
These are discussed in turn below, with an emphasis on viral vector vaccination which is 
the principle subject of this thesis. However, it is noteworthy that for simplicity the 
efficacy of these approaches is often explained in the literature as enhancing a linear axis 
of immunity, beginning with DC uptake of antigen (or transduction/transfection) in the 
periphery after vaccination, migration to lymph nodes and then stimulation of effector 
CD8+ and CD4+ T cells by antigen presentation antigen (MHC class I and MHC class II 
22 
 
receptors respectively) together with co-stimulation through surface DC molecules and 
DC-secreted cytokines. However, this is an oversimplification of the complex interaction - 
both stimulatory and inhibitory - that occurs between DC, T cells, B cells and other innate 
and adaptive arms of the immune system. Whilst an antibody or T cell response may be 
the focused objective of a given vaccine approach, one is rarely generated without the 
other and these are often mutually enhancing. For example, antibodies targeted against 
an internal virion component may not be capable of neutralising a virus but may assist the 
T cell response by enhancing antigen uptake and cross presentation by DC to T cells. 
Similarly, CD4+ T helper (TH) cell responses are needed for efficient antibody responses, 
influencing both their magnitude and isotype. Just as there is no simple linear chain of 
immune responses to vaccination, communication between immune cells is neither 
exclusively unidirectional nor between heterologous cell types. Cross-activation and 
antigen transfer between afferent migrating DC (such as skin Langerhans cells) and lymph-
node resident DC may be essential for amplification of antigen presentation and thus 
effective T cell priming, a concept explored further in Section 6.5. CD4+ T cell cytokine 
responses can feedback on DC and enhance their activation, or alternatively, where a 
regulatory T cell response has been induced, this can powerfully suppress DC activation as 
well as inhibiting the effector functions of CD8+ T cells.  
This presents such complexity that to examine every arm of the immune response to 
prophylactic or therapeutic vaccination, and the interaction between each of these arms, 
is beyond the scope of most studies. There are historical examples of the perils of 
underestimating this complexity. Respiratory syncytial virus (RSV) vaccine trials in the 
1960s testing a formalin-inactivated RSV found increased morbidity and mortality in 
vaccinated subjects following subsequent RSV infection. Despite generating the desired 
antibody response against RSV epitopes, vaccination had also primed an excessive CD4+ 
TH2 response which coordinated an deleterious eosinophilic influx on secondary 
challenge7. This example serves as a caveat to all vaccination work that intends to induce 
protection or therapy though a specific arm of the immune system, including that 
presented in this thesis. 
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1.1.1 Ex-vivo generated DC-based vaccines 
 
The discovery of methods for culture, expansion and differentiation of human DC in vitro 
from peripheral blood CD14+ progenitors in the mid-1990s led to both rapid progress in 
understanding of human DC biology and also their use for immunotherapy8. This has 
principally been applied to generating therapeutic rather than preventative T cell 
responses against cancer or chronic infection, since the culture, modification and re-
administration of autologous DC is prohibitively time-consuming and expensive for use in 
prophylactic vaccination of large populations. However, this approach does permit 
optimal “loading” of DC with an array of peptides or whole antigen and maturation of DC 
ensuring T cell responses are both multispecific and polyfunctional respectively. 
Most of the development of this technique has occurred in the context of cancer 
immunotherapy and has befitted from key advances in understanding of DC and T cell 
biology. For example, it rapidly became apparent that DC must be activated to generate 
effective anti-tumour T cell responses. This discovery paralleled the emerging realisation 
that DC play a key role in the maintenance of tolerance to self and innocuous antigen. 
Immature DC can tolerise T cell responses against pulsed antigen (by deletion, anergy or 
generation of T suppressor cells) and mature DC can take on a “tolerogenic” phenotype 
and actively generate inducible T regulatory (T reg) cells through, for example, secretion of 
indoleamine 2,3-dioxygenase (which depletes tryptophan in T cells) and transforming 
growth factor-β (TGF-β) signalling9. Indeed, the recognition that inhibition or depletion of 
the regulatory immune system during DC-based immunotherapy greatly enhances T cell 
responses has been a further key step forward in this field.  
Ex-vivo DC–based cancer vaccines have been used in clinical trials for almost two decades 
with mixed results in typically “immunosensitive” tumours such as melanoma, prostate 
cancer and lymphoma (reviewed in10). A recent notable success was the used of enriched 
blood APCs cultured with a fusion protein of prostatic acid phosphatase and granulocyte 
monocyte colony-stimulating factor (GM-CSF) which enhanced anti-tumour T cell 
responses and survival in metastatic prostate cancer by 4 months in Phase III trials11.  
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Ex-vivo DC based therapies have also been applied in HIV infection. A recent clinical trial 
was based on successes in a simian immunodeficiency virus (SIV) model using monocyte-
derived DC generated ex-vivo with GM-CSF and interleukin (IL)-4 matured with IL-1β, IL-6 
and TNFα and loaded with inactivated, autologous HIV. Subcutaneous injection of these 
DC reduced median plasma HIV RNA levels by over 90% in almost 50% of subjects, 
correlating with the emergence of HIV-specific T cells in these subjects. Several other 
studies (reviewed in12) have shown promise using ex-vivo modified DC for HIV therapy, 
but since the demonstration in the Strategies for Management of Anti-Retroviral Therapy 
(SMART) study of a twofold risk of HIV progression or death in patients on intermittent 
rather than continuous therapy13,  to suspend therapy to observe the impact of any 
immunotherapeutic intervention is becoming increasingly questionable.  
The obvious drawbacks of this approach for mass prophylactic vaccination against 
influenza explain why only one animal study has been performed assessing this approach, 
with a view to its use in immunosuppressed patients with particular vulnerability to 
influenza infection. However, this was focussed on using re-administered, ex-vivo pulsed 
DC for improving antibody rather than T cell responses to influenza which might be 
otherwise be attenuated in immunosuppressed individuals14.  
 
1.1.2 In vivo DC targeting 
 
The expense and time involved in ex vivo modification of DC may be avoided by targeting 
DC in vivo with both antigen (such that it is efficiently taken up and cross-presented) and 
adjuvant (such that T cell co-stimulation is optimised). The current mainstay of targeting 
DC employs chimeric proteins composed of an anti-DC receptor antibody and antigen. This 
approach has been used to target distinct DC subsets with correspondingly different 
profiles of T cell activation. For example, ovalbumin (OVA) coupled to antibody targeting 
DEC-205+ DC preferentially induces CD8 + OVA-specific T cell immunity, whereas targeting 
dendritic cell immunoreceptor 2 (DCIR2) generated stronger CD4+ T cell responses. 
Chimeric antigens in which the antibody fragment targets activatory receptors on DC, such 
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as the lectins Dectin-1 or Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN) can also modulate DC function. For example, DC-SIGN 
activates rapidly accelerated fibrosarcoma-1 (RAF1), which induces toll-like receptor (TLR)-
independent phosphorylation of the nuclear factor kappa B (NFκB) subunit p65 which in 
turn up-regulates an array of DC co-stimulatory molecules that favour enhanced CD8+ T 
cell responses15. 
Another means of DC targeting exploits the existing physiological mechanism by which 
antibody-captured antigen can be internalised by DC for cross presentation. Fc receptors 
bind the Fc portion of antibodies and are expressed on different leukocyte cell types with 
specificities for specific antibody classes and subclasses. FcγR1 is constitutively expressed 
on DC and has a high affinity for monomeric immunoglobulin isotype G (IgG). It carries 
immunoreceptor tyrosine-based activation motifs (ITAMs), capable upon cross-linking by 
antibody-antigen complexes of initiation of both phagocytosis and also activatory signals 
that increase expression of DC co-stimulatory molecules and presentation of processed 
antigen16. By fusing antigen to monoclonal antibodies targeting Fc receptors or to the Fc 
domain of IgG, or by co-administering antigen with antigen-specific antibody, the Fc 
receptor uptake pathway can be exploited for improved antigen presentation and co-
stimulation by DC.  
HIV glycoprotein 120 (gp120), for example, elicits superior humoral and T cell responses in 
mice when fused to an anti-Fc monoclonal antibody17. A fusion product of influenza HA 
and the Fc domain of immunoglobulin has also been used to generate protective titres of 
anti-HA antibody and T cell responses in mice in the absence of adjuvant, and can be 
readily expressed in a baculovirus-insect cell system for scalability18. Similarly, 
incorporating an α–Gal epitope (which is abundant on glycolipids and glycoproteins of 
bacteria) into HA, exploits the ubiquitous and high level expression (over 1% of all 
immunoglobulin found in human serum) of anti-α–Gal antibody in humans (generated by 
antigenic stimulation by bacteria of the gastrointestinal flora). Inactivated A/Puerto 
Rico/8/1934 (A/PR/8/34) influenza virus engineered to express α–Gal epitopes generated 
much stronger CD4+ and CD8+ T cell responses against influenza epitopes than 
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unmodified inactivated virus19. However, it was not determined whether these T cell 
responses were sufficient to confer protection against a heterosubtypic influenza strain.  
As with ex-vivo DC-based therapies, in vivo DC targeting has mostly been tested in 
therapeutic vaccination in mouse models of cancer. These approaches are capable of 
generating potent CD4+ and CD8+ anti-tumour immunity that is frequently partially 
protective against tumour challenge (typically in an OVA-expressing tumour challenge 
model, reviewed in20), but only In the presence of adjuvants to ensure effective DC 
activation. Only one study has directly compared in vivo DC-targeting with ex vivo 
antigen-loaded DC, finding that mice therapeutically vaccinated with anti-DEC-205-OVA 
and anti-CD40 mAb (as adjuvant) induced more potent OVA-B16 melanoma tumour 
inhibition than mice vaccinated with DC that had been OVA loaded and activated ex-
vivo21.  
Unlike ex-vivo DC-based vaccination studies, few in-vivo DC targeting candidate vaccines 
have been tested in clinical trials. In primate studies, anti-DC SIGN mAb has been shown to 
target APC22 and conjugation of HIV group antigens (GAG) p24 to anti-DEC-205 mAb 
resulted in better cross-priming of GAG-specific CD8+ T cells23. However, DEC-205 is not 
restricted to DC in humans to the same degree as mice, questioning the targeting 
specificity of this approach.  
The requirement for adjuvant (and its implications for vaccine storage, production and 
safety) and the scarcity of truly DC-specific targets are not the only challenges in taking 
this vaccination strategy forward. Not all antigens are readily recombined with antibody in 
a manner that can be reliably secreted in yeast, bacterial or plant expression systems. 
Influenza HA is a case-in-point, a problem recently circumvented by use of a non-covalent 
system of binding recombinant DC-targeting antibody (anti-langerin ) with HA by fusing 
each to dockerin and cohesin respectively – two E. Coli proteins that bind with high 
affinity24. This approach improved T cell responses against HA compared with vaccination 
with the antigen alone, but at the expense of significant manufacturing complexity. 
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Nanoparticles and liposomal vaccines may address these problems. These can encapsulate 
(within a glycoprotein or liposomal capsid respectively) both antigen and adjuvant and 
targeting mAb can be engineered to be expressed at the surface by recombination or 
covalent attachment. They have the further advantage of multivalent expression of 
targeting antibody, leading to better cross-linking of target receptors on DC and thus 
improved DC activation. Furthermore, the repetitive antigen structures of nanoparticles 
and liposomes can stimulate pathogen recognition receptors on DC, enhancing their 
activation and stimulating phagocytosis. Indeed, even in the absence of DC-targeting 
antibodies on their surface, nanoparticles and liposomes are avidly taken up by phagocytic 
cells including DC and macrophages25. Many of the current leading candidate vaccines for 
generation of mucosal T cells against influenza and other respiratory infections are 
nanoparticle formulations, which is at least in part attributable to their avidity for alveolar 
macrophages after intranasal administration (discussed further in Section 4.1.2). 
However, the development of increasingly complex nanoparticle and liposomal 
technologies to mimic the potent DC activation, uptake and antigen presentation to T cells 
disregards an important strategic short-cut. The immune system has co-evolved with 
intracellular pathogens to reliably generate T cell memory after primary infection which 
confers protection against secondary challenge, albeit to varying degrees. It may be 
considerably more effective and simpler, therefore, to modify pathogens in such a way 
that they are rendered less harmful but more immunostimulatory, rather than engineer 
complex virus-like particulate agents with apparently desirable immunostimulatory 
characteristics from scratch.  
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1.1.3 Live attenuated vaccines  
 
Many of the most successful vaccines against viral disease– polio, small pox, measles, 
mumps, rubella, yellow fever – have used replication competent attenuated forms of 
parent organisms. This is typically achieved by deletion of pathogenicity factors in the viral 
genome or passage through a non-human host until adaptations for virulence in humans 
are lost. Attenuated live organisms have the advantage instigating T cell responses similar 
to those against the parent organism in terms of multi-epitope specificity and functional 
phenotype. In nearly all cases, however, protection is mediated by high titres of 
neutralising antibody against surface viral epitopes, achieved with aid of accompanying 
CD4+ T helper cell responses which obviate the need for adjuvant or booster vaccination 
in many cases.  
 
However, live attenuated vaccines tend to induce weaker T cell responses than infection 
with the wild type organism, since T cell responses are generally proportionate to antigen 
quantity and disease severity (discussed further in section 1.3). This may be sufficient to 
keep latent infection at bay by boosting an existing T cell memory population. This is 
demonstrated by live attenuated varicella zoster virus (VZV) vaccines for prevention of 
shingles in older adults previously exposed to chicken pox, wherein anti-VZV antibodies 
remain high but T cell mediated control of latent infection diminishes with age26. 
Nevertheless, to date there are no live attenuated vaccines in clinical use that mediate 
protection by a T cell predominant mechanism in the absence of neutralising antibodies. 
 
Live attenuated influenza vaccination (LAIV) typically uses cold-adapted influenza viruses 
(CAIV) which replicate inefficiently at human body temperature. Naïve mice demonstrate 
heterosubtypic immunity after LAIV comparable to that seen after non-attenuated sub-
lethal infection27. However, LAIV generates detectable T cell responses in children but 
does not enhance flu-specific peripheral T cell responses in adults with pre-existing 
cognate T cell memory28. Mirroring this finding, the clinical efficacy of CAIV is slightly 
superior to the standard inactivated trivalent vaccine in children but not adults29. Since 
the current licensed intranasal cold-adapted influenza vaccine (Flumist®) is seasonally 
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engineered to represent circulating strains and their HA and NA subtypes it is unclear to 
what degree the protection conferred is attributable to T cell mediated immunity rather 
than sterilising antibody responses. There are also safety concerns surrounding the use of 
an attenuated pathogen with a high mutation rate, which risks reversion to a body-
temperature adapted phenotype. In one Phase III trial, LAIV compared with seasonal 
trivalent vaccination was associated with an increased incidence hospitalization in children 
aged 6-11 months and an increased incidence of clinical symptoms of bronchospasm in 
children <24 months. However, subsequent trials in children with asthma have not shown 
increased adverse events associated with LAIV vaccination compared with the inactivated 
trivalent seasonal vaccine30.  
 
1.1.4 DNA vaccines 
 
Soon after the discovery that DNA plasmid injected into mouse model resulted in 
expression of encoded protein31, it was realized DNA can also generate an antibody 32and 
T cell response33 to encoded antigen. Importantly, DNA vaccines have the advantage of 
being self-adjuvanting. This was initially attributed to inclusion of unmethylated CpG 
sequences present in certain plasmids that stimulate TLR-9 on APC activation, but it has 
recently become evident that these are not necessary for the induction of innate 
immunity34. Double stranded DNA (dsDNA) alone can activate APCs through TANK-binding 
kinase-1 (TBK-1, a non-canonical IkappaB kinase) pathways and is necessary and sufficient 
for the immunogenicity of DNA vaccines35. 
Pre-clinical studies of DNA vaccines in small animals focused primarily on antibody 
induction against targets such as herpes simplex virus (HSV), hepatitis B virus (HBV), HIV 
and influenza with consistent demonstrations of protective immunity36–38. The ability of 
DNA vaccines to generate cellular responses led to a proliferation of clinical trials of 
prophylactic and therapeutic DNA vaccines against cancers (including prostate39, 
melanoma40 and breast41) and infections (including HIV42, malaria43and HBV44). Much of 
the early attempts to generate T cell mediated heterosubtypic protection against 
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influenza were achieved in mice using DNA vaccination (which are revisited in more detail 
in section 3.5).  
In 2005, two DNA vaccines were authorized for veterinary use in the US: one against West 
Nile virus infection in horses, the other against canine melanoma. A further DNA vaccine 
has been licensed for use in Canada for the prevention of infectious haematopoeitc 
necrosis virus in salmon.  
However, whilst human studies have consistently demonstrated the excellent tolerability 
and safety profiles of DNA vaccines, efficacy in generating T cell or antibody responses in 
humans and non-human primates is significantly lower than that seen in mice and other 
species. This may be a consequence of lower levels of APC transfection both in vitro and in 
vivo and thus reduced endogenous antigen expression and class I antigen processing by 
DC45. Much of the T cell response in humans to DNA vaccination must therefore be 
generated by APCs that have picked up exogenous antigen shed by other transfected cells 
or phagocytosed from dead cells, thus relying upon cross-presentation for class I 
presentation of antigen to cytotoxic T lymphocytes (CTL). This does not preclude the 
generation of effective T cell responses – a number of tissue-tropic viruses (e.g. pox 
viruses) do not infect APCs directly but nevertheless elicit T cell immunity via cross-
presentation of viral antigens. However, viral infection (or viral vector vaccination) induce 
a number of signals not present after DNA vaccination. Apoptosis of antigen-bearing cells 
is sufficient to generate cross-presentation, inducing phagocytosis by immature DC, 
maturation and cross presentation46. This apoptosis has to be substantial, since the 
phagocytic capacity of scavenging macrophages (which secrete DC-inhibitory factors such 
as IL-10) must first be exhausted before less numerous DC are exposed to apoptosing 
cells47. Cross presentation is also significantly boosted by the presence of CD4+ T cell help 
and the presence of “danger signals” interacting with pathogen recognition receptors 
(PRR) and enhancing DC activation – both significantly more abundant following viral 
infection than DNA transfection of tissue cells. Indeed, secretion of antigen from 
transfected cells alone may not only be inadequate to induce a CTL response, but also may 
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risk generating “cross-tolerance” by cross-presentation of antigen in the absence of co-
stimulation, leading to deletion or anergy of antigen-specific CD8+ T cells48. 
A number of strategies have emerged to enhance T cell responses to DNA vaccines in 
humans. The use of plasmids encoding both antigen and adjuvant with the aim of 
enhancing DC recruitment, activation and antigen cross-presentation is one such 
approach. For example, co-encoding GM-CSF with vaccine antigen has been shown to 
enhance T cell responses against HIV49, encephalomyocarditis virus50 and hepatitis C virus 
antigens51. Alternatively, APC transfection in vivo can be improved by use of nanoparticle- 
or liposomal-mediated delivery as discussed above52, or by gene gun and 
electroporation53. Also, quantitative antigen expression by APC can be increased by 
codon-optimisation and the removal of prokaryotic sequences from DNA plasmids.  
Despite these improvements, it is important to note that both T cell responses and 
antibody responses in humans remain inferior to those seen with recombinant viral vector 
or protein-adjuvant based approaches respectively. Perhaps the most promising use of 
DNA vaccines is in combination with viral vectors in prime-boost regimens (discussed 
below), which results in greater T cell and antibody responses generated by either 
modality in isolation.  
 
1.1.5 Viral Vector Vaccines 
 
Viruses have evolved efficient mechanisms for infecting cells and exploiting cellular 
machinery for the production of viral proteins. As such they are natural candidates for 
gene delivery for vaccination. Many viral species have been evaluated as recombinant 
vaccine vectors. These include adenoviruses, adeno-associated viruses (AAV), poxviruses, 
alphaviruses, measles virus, poliovirus, and HBV. The main characteristics, advantages and 
disadvantages of these are shown in Table 1-1. 
Many of the viral vectors that have reached clinical trials were conceived for gene therapy 
wherein an immune response against the transgene product was undesirable. Attempts to 
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abrogate immunogenicity for use in gene therapy, and amplify it for use in vaccines, has 
led to an in depth characterization of the intrinsic vector properties that determine their 
immunogenicity and efficacy as vaccines. These key attributes encompass many of the 
immunogenic properties of the other vaccination modalities hitherto described and are 
discussed in more detail below.  
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The tropism of viral vectors for immune and non-immune cells 
 
The ability to transduce professional APC such as dendritic cells (DC) and macrophages 
varies between different vectors and is determined by a number of factors including 
envelope glycoprotein interaction with APCs and host restriction factors that have evolved 
to limit viral gene expression and/or integration after membrane fusion. The former can 
often be readily modified by envelope pseudotyping, wherein the native viral vector 
envelope glycoprotein is substituted for one which ensures tropism for the desired target 
cell. For example, the vesicular stomatitis virus (VSV) appears to have a marked tropism 
for dendritic cells which can be exploited through use of VSV vectors, or pseudotyping of 
retroviral or lentiviral vectors (LV) with the surface glycoprotein (VSV-G). Sindbis virus 
glycoprotein binds to the DC-SIGN protein which confers high specificity for DC 
transduction in vivo, a property recently exploited in Sindbis glycoprotein pseudotyped 
lentiviral vaccines to generate HIV-1 GAG-specific immunity54. Accordingly, a high tropism 
for non-immune cells – common to many viral vectors developed for gene therapy – can 
be detrimental to the efficacy of viral vectors as vaccines since widespread antigen 
expression in the absence of co-stimulatory molecule can generate T cell tolerance. 
Hepatocyte-specific expression of AAV delivered transgenes, for example, appears to 
favour a tolerogenic immune response to encoded antigen55,56.  
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Table 1-1. Viral vectors as vaccines 
Virus Genome Main advantages Main disadvantages Current Clinical trials 
Adenovirus dsDNA High titers, episomal, high transduction 
efficiency of APCs, safe in human trials. 
Pre-exisiting anti-vector immunity 
(can be circumvented with 
chimpanzee adenovector strains) 
HIV57, Malaria58, 
SARS59, Ebola60, 
influenza61 
Poxvirus dsDNA Large packaging capacity, non-
integrating, safe in human trials, no pre-
existing immunity (fowlpox), transduce 
APCs. 
Anti-vector immunity (e.g. 
Vaccinia), expensive and complex 
production, unstable 
recombinants. 
Malaria62, HIV63 
Vesicular 
stomatitis 
virus 
ssRNA- High levels of transgene expression, low 
pre-existing immunity. 
Safety concerns regarding neural 
tropism. 
None 
Adeno-
associated 
virus 
ssDNA Non-pathogenic parental virus, 
safe in human trials. 
Low packaging capacity, anti-vector 
immunity, (disputed) risk of 
integration. 
HIV64 
Alphavirus ssRNA+ Non-integrating, high antigen 
expression, transduce APCs, no pre-
existing immunity. 
Low/moderate packaging capacity. 
 
None 
Herpes virus dsDNA Broad tropism and transduces APCs. Safety concerns regarding neural 
tropism, pre-existing immunity. 
Glioblastoma65 
Measles 
virus 
 
ssRNA- Mucosal delivery, non-integrating. Pre-existing immunity. None 
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Poliovirus ssRNA+ Known efficacy in children as a 
homologous vaccine. 
Unstable recombinants, pre-
existing immunity, low packaging 
capacity. 
None 
Hepatitis B 
virus 
Partial 
dsDNA 
High level of stable antigen expression. Pre-existing immunity, low 
packaging capacity. 
None 
Lentiviral 
vectors 
ssRNA+ High packaging capacity, stable antigen 
expression, no pre-existing immunity. 
Theoretical risk of insertional 
mutagenesis, low inherent 
immunogenicity. 
HIV66 
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APC activation by viral vectors 
 
Co-stimulation and cytokine signaling between APC and T cells determine the degree of T 
cell activation, clonal expansion and final memory pool size and phenotype. It has long 
been established that for optimal T cell responses to vaccination, dendritic cells need to 
be activated in order to increase MHC and co-stimulatory molecule expression. TCR 
engagement in the absence of co-stimulation leads to anergy wherein antigen-specific T 
cells become unresponsive to further stimuli (non-proliferative and no IL-2 production) 
even with subsequent co-stimulation.  
 
Co-stimulatory molecules are important in both early T cell activation (e.g. CD80 and CD86 
with CD28, CD40 with CD40L)67 and later differentiation into memory populations after 
contraction of the initial effector response (e.g. 4-1BBL and 4-1BB, OX40 and OX40L)686970. 
Studies in knockout animals have shown CD4+ T cell effector responses are more 
dependent upon CD80/86:CD28 co-stimulation than CD8+ T cells71,72, whilst the TNF 
receptor family of ligands and receptors (4-1BB/4-1BBL, OX40L/OX40, CD40L/CD40) seem 
crucial for CD8+ T cell memory differentiation. 4-1BBL-/- mice develop grossly reduced 
CD8+ T cell memory pools after influenza infection but initial expansion of CD8+ and CD4+ 
T cells is preserved73. This may be because 4-1BB signaling down-regulates the pro-
apoptotic molecule BIM in T cells. Similarly, in CD40L deficient mice challenged with 
LCMV, the expansion phase is normal but the contraction phase is prolonged and results 
in ten-fold fewer memory CD8+ T cells74. Survival signals delivered by tumour necrosis 
factor (TNF) receptor-ligand interactions therefore prolong the expansion phase and boost 
the final memory pool. This is crucial during prolonged or severe infection wherein T cells 
must survive long enough to clear infection75.  
 
In addition to T cell receptor (TCR)-MHC engagement and interaction between surface co-
stimulatory molecules and their receptors, cytokine secretion by activated APCs provide a 
crucial third signal for T cell activation. IL-12 and type I interferon α/β (IFNα/β) are the 
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principal mediators of this third signal in CD8+ T cell activation and these have a critical 
role in preventing T cell deletion or anergy. Indeed, IL-12 alone can replace adjuvant for 
ensuring an immunizing rather than a tolerising response to peptide76. IL-12 alone cannot 
replace the need for adjuvant for effective CD4+ T cell clonal expansion, but recent 
evidence suggests IL-1 can act directly on CD4+ T cells to enhance expansion77. Thus 
effective T cell vaccines must not only generate APCs that express co-stimulatory 
molecules but also secretion of cytokines which ensure T cell survival and proliferation.  
 
Viral vectors are detected by three classes of PRR in mammalian cells – TLR, retinoid acid-
inducible gene (RIG)-I-like receptors (RLRs) and nucleotide oligomerisation domain (NOD)-
like receptors. In antigen-presenting cells, these receptors recognize a number of 
pathogen-associated molecular patterns (PAMPs) and initiate signaling cascades that lead 
to APC activation, resulting increased class I and class II antigen presentation and up-
regulation of co-stimulatory molecule expression. The pattern and degree of stimulation 
of these PRRs determines the pattern and degree of co-stimulation and antigen 
presentation which ultimately shapes the T cell response. Adenovectors, for example 
stimulate potent type I IFN secretion in macrophages in a TLR-9- and myd88-dependent 
manner. DsDNA delivered by adenovectors is also capable of instigating a type I interferon 
response in a MyD88 independent manner and IRF-3 dependent manner (downstream of 
RIG-1). Some vectors, including vaccina virus (VV) and HSV vectors may block DC 
maturation or actively down-regulate co-stimulatory molecule expression78–81. This does 
not appear to hinder their immunogenicity, however, which may rely heavily upon cross-
presentation of antigen by local non-infected DC, activated by cell debris released from 
necrotic cells after cytopathic infection. Loss of membrane integrity releases intracellular 
“damage-associated molecular patterns” (DAMPs), which include IL-1α, uric acid, DNA, 
mitochondrial content, and ATP, many of which directly stimulate the same PRRs that 
recognise PAMPs82.  
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Endogenous antigen processing and multi-specific T cell responses 
 
Antigen processing through the MHC class I pathway of dendritic cells is crucial for T cell 
responses. Once processed, naive T cells recognize peptides derived from foreign antigens 
presented on class I (to CD8+ T cells) or class II (to CD4+ T cells) histocompatibility 
antigens. The former bind peptides that are 8-11 amino acids in length and the latter 10-
18 amino acids. These peptides bind to their respective histocompatibilty antigens 
through specific anchor residues, thus not every sequential peptide derived from an 
antigen can be presented. Estimates vary of the number of presentable epitopes within 
viral antigens according to a given HLA type. For example, in HIV there is approximately 
one CD4 epitope for every 100 amino acids and one CD8+ epitope for every 200-300 
amino acids. Immune systems have evolved to process and present epitopes that are 
highly conserved amongst circulating pathogens with high efficiency, yet these 
immunodominant epitopes will vary according to allelic distribution of histocompatibility 
antigens. Thus T cell vaccines can elicit highly variable responses between individuals. 
Furthermore, pathogens with high rates of mutation can undergo T cell escape, even on 
several occasions within the same individual. Assarson et al recently characterised the T 
cell response of HLA-typed subjects to a large panel of candidate CD8+ T cell influenza 
epitopes predicted by HLA-binding and sequence conservation83. This showed the majority 
of such epitopes were from internal viral proteins and many of them were highly 
conserved (nucleoprotein (NP), matrix protein 1 (M1) and the polymerase basic 1 (PB1) 
subunit of the polymerase). Nevertheless, each of the 44 subjects recognized a unique set 
of peptides. In a similar study, Lee et al characterised H5N1 eptiope recognition across 
HLA types and found considerable breadth of reactivity against the length of internal 
virion proteins84. Together these studies go some way towards allaying the concern that 
CD8+ T cell vaccines would apply selective pressure on CTL epitopes, as long as they 
include multiple T cell epitopes. 
 
T cell vaccines which express large inserts incorporating several T cell epitopes thus have 
the greatest chance of accommodating epitopes corresponding to multiple 
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histocompatibility types and generating a multi-specific T cell response less sensitive to 
individual epitope mutation. Live attenuated or live recombinant vaccines containing the 
full antigen profile of an organism ensure the greatest accommodation of HLA types and 
multispecific responses. At the other extreme, delivery of a single CD8+ peptide with 
adjuvant will leave considerable room for T cell escape. 
The ideal T cell vaccine modality would thus need to ensure sustained, endogenous 
expression of whole or multiple antigens by APC to ensure maximal class I presentation to 
CD8+ T cells across a broad range of epitopes, thus limiting the potential for T cell escape. 
Since professional APCs are capable of cross-presentation, all vaccination modalities, 
including protein and adjuvant, can deliver protein to class I processing pathways in APC 
to some degree. Influenza (and by inference, live attenuated influenza vaccines) can enter 
DC and synthesise some viral proteins enabling classical loading onto class I molecules85,86. 
However, this often results in instigation of DC apoptosis so antigen presentation is short-
lived. It is likely that T cell responses to influenza are principally generated by cross-
presentation of antigens from cytopathically infected epithelial cells since direct DC 
infection is not required for T cell responses to influenza. Viral vector vaccines have a high 
capacity for incorporation of multiple epitopes or whole antigens and since many 
transduce APCs, they can ensure endogenous expression and processing of a broad range 
of epitopes.  
 
However, one of the additional drawbacks of multiple epitope inclusion in an influenza 
vaccine is the generation of immunodominance hierarchies, wherein CD8+ T cells specific 
to a small number of epitopes are dramatically over-represented in the T cell response of 
an individual depending on their HLA type. This is particularly apparent in inbred mouse 
strain models after influenza infection or vaccination with whole influenza antigens87, 
whilst in human influenza the most studied example is the HLA-A2 restricted M158-66 
epitope. The underlying mechanism of immunodominance is multifactorial, involving in 
the first instance relative epitope abundance, preferential processing of epitopes within a 
given antigen, MHC-binding affinity and the number of epitope-specific naïve precursors. 
The subsequent expansion of very few of these epitope specificities of CD8+T cells in the 
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primary response is probably governed by competition for survival and proliferation 
signals from antigen and APC88,89. If a vaccine excludes an epitope from the parent 
pathogen that is dominant in an individual with a particular HLA type, the memory T cell 
response will  compete with an immunodominant primary T cell response upon infection 
at the level of antigen presentation, with the higher affinity immunodominant epitope 
prevailing. Vaccines would ideally represent a range of the most dominant T cell epitopes 
across a range of common HLA types, but also including HLA-specific sub-dominant 
epitopes that limit the risk of viral escape in the event of a mutation that alters the 
hierarchy.  
 
Particularly in viral vector vaccines, there is an additional risk that an immunodominant 
epitope in the vaccine vector itself may “drown” responses to the target antigen. In this 
regard, non-replicative viral vectors have a significant advantage over replication –
competent viral vectors since viral proteins are only transiently cross-presented after a 
single round of APC transduction.  
 
 
Level and persistence of transgene expression  
 
The amount and duration of antigen exposure during T cell priming influence primary 
effector and T cell memory population size. T cell differentiation from naïve to effector 
status does not take place after a single interaction with antigen presenting cells, but 
during a series of encounters with multiple APCs over several days as T cells re-circulate90. 
CD4+ T cells, for example, require a minimum of 6 hours antigen exposure for activation, 
but in the context of minimal co-stimulation this increases to 20 hours91. Even after 48hrs 
of antigen stimulation a high proportion of naïve CD4+ cells have not yet committed to a 
TH-1 or TH-2 effector function92. Some have determined that at least 5 days of antigen 
stimulation are required for optimal CD4+ T cell expansion93. CD8+ T cells are less sensitive 
to duration of antigen presentation, being able to give rise to 7-10 cell divisions after 2-24 
hours of antigen encounter94–96. Nevertheless, the peak of the CD8+ T cell effector 
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response is greatly enhanced by antigen persistence. This has been demonstrated by 
infecting mice with vaccinia strains that express varying amounts of OVA, revealing the 
magnitude of responding CTL population is proportional to epitope abundance97. Given 
that naïve CD8+ T cell precursor recruitment was recently shown to be highly efficient and 
complete even in the presence of very small amounts of antigen98, it seems epitope 
abundance must have an ongoing direct effect on daughter progeny of proliferating 
effector T cells - either enhancing survival or proliferation - in order to boost clonal 
expansion and minimize contraction. It therefore remains unclear to what degree this 
effect is mediated indirectly through CD4+ T cell help. 
 
The level and persistence of antigen expression by a viral vector is determined to some 
degree by the choice of promoters driving transgene expression but also by a number of 
vector-specific factors, including whether the viral vector is replicating or non-replicating, 
cytopathic or non-cytopathic, or delivers an integrating or non-integrating transgene. 
Replicating and cytopathic viral vectors, such as many VSV vectors, may induce release of 
heat shock proteins and other DAMPs together with high antigen loads, which ensures 
cross-presentation by activated DC and a robust T cell response. However, the absence of 
these factors may be adequately compensated for by the persistent endogenous antigen 
production and processing achieved by -replicating, non-cytolytic vectors. Indeed, 
comparison between OVA-expressing WT VSV vectors and VSV in which only cytolytic 
factors have been removed revealed few differences in short and long-term OVA-specific 
T cell immune responses99.  
 
Anti-vector immunity 
 
 Immune responses directed against the vector rather than encoded antigen can have a 
significant effect on the duration of antigen production and/or the subsequent use of the 
same vector as a vaccine. Similarly, prior infection with herpes, measles and adenoviruses 
may result in pre-existing immunity that precludes effective use of vectors derived from 
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these viruses. This has been extensively studied in adenovectors, the most commonly 
used viral vector in clinical vaccine trials. Most humans have neutralizing antibodies 
against AdHu5, the most widely used vaccine platform, due to exposure since early 
childhood and this negatively impacts their immunogencicty as vaccines100. Safety 
concerns over the use of AdHu5 in humans followed the findings of the STEP trial in which 
a candidate Adhu5 vector vaccine expressing HIV proteins was assessed. More individuals 
who had higher titres of pre-existing adenovirus antibodies became infected with HIV 
after vaccination than those receiving placebo. One potential explanation for this is that 
the pre-existing anti-adenovirus immunity was boosted by vaccination resulting in an 
increase in mucosal-homing memory CD4+ T cells susceptible to HIV infection101. Use of 
adenovectors isolated from chimpanzee populations (AdC) may have circumvented this 
problem, paving the way for their recent use in recent human malarial vaccine trials58.  
Not all viral vectors, however, appear to be susceptible to anti-vector immunity. Immune 
responses to modified vaccinia Ankara (MVA) virus appear to be preserved despite prior 
small pox vaccination102 and VSV-G pseudotyped lentiviral vectors readily generate anti-
VSV-G antibody responses but these do not appear to impede immune responses to 
subsequent VSV-G pseudotyped LV vaccination, although the efficacy of vaccination 
declines with multiple further administrations in line with increasing anti-VSV-G antibody 
titres103.  
 
Immunogenicity in prime-boost combinations 
 
The concept of heterologous prime-boost vaccination arose with the discovery that 
vaccination with plasmid DNA followed by a viral vector generated more potent immune 
responses against a shared antigen than homologous dual vaccination or if the 
vaccinations were given in the reverse order104. Many preclinical and clinical trials of 
heterologous prime-boost vaccinations have since encompassed multiple vaccination 
modalities (bacterial, viral, DNA and recombinant protein), including the 16,000 
participant STEP trial of HIV vaccination described above105 which used a pox vector and 
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recombinant protein boost. The immunological basis for increased immune responses in 
prime boost combinations is incompletely understood. A component of this phenomenon 
is attributable to the fact that secondary T cell responses are typically greater and longer-
lasting than primary responses due to the increased proliferative capacity of memory T 
cells. This does not explain, however, the additional benefit to the immune response 
conferred by use of different vaccination modalities for priming and recall. DNA is 
consistently more efficient as the prime, perhaps ensuring the immune response is 
focused on a single encoded antigen and not the polyclonal expansion of T cells with 
specificities against multiple vector components which may have to compete for survival 
signals and antigen exposure106.  
 
1.2 Lentiviral vectors for vaccination 
 
1.2.1 Lentivirus attenuation and vector design 
 
Lentiviruses are single-strand RNA(+) viruses of the Retroviridae family. This includes 
human, simian, equine and feline immunodeficiency viruses (HIV, SIV, EIV and FIV) but the 
first is the most commonly adapted for vectored delivery of genes in humans. The life 
cycle of HIV-1 and lentiviral vectors are compared in Figures 1-1 and 1-2. The HIV genome 
has been engineered to remove its replication capacity whilst preserving the ability to 
transfer and integrate into the host genome. This was achieved by separating trans-acting 
elements, encoding enzymatic, envelope, accessory and structural proteins, from cis-
acting elements required for vector RNA synthesis, reverse transcription, integration and 
packaging.  
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❶ The tRNA (rose) which hybridises to the PB site provides a hydroxyl group for initiation 
of reverse transcription by reverse transcriptase (RT) in a 3’ to 5’ direction. While a ssDNA 
strand is produced, the RNAse H function of RT degrades the 5’ end of the ssRNA. ❷ The 
DNA-tRNA hybrid hybridises with the R region at the 3’ end continuing first strand 
synthesis. The PP site is resistant to RNAse activity and forms the primer to initiate the 
second strand synthesis. ❸ Both the PP site and the tRNA are degraded during 5’ to 3’ 
second strand synthesis. ❹ 1st and 2nd strands hybridise at their PB sites at 5’ and 3’ ends 
respectively. ❺ The DNA polymerase function of RT completes both strands. Each is now 
flanked by U3-R-U5 sequences, or long terminal repeats (LTRs).  
Figure 1-1. HIV life cycle and stages of reverse transcription (inset). Ss single stranded, ds 
double stranded, gag group antigens (encodes capsid, matrix, nucleocapsid and p6 
proteins), pol enzymes, env envelope proteins, PP polypurine tract, PB primer binding site, 
U3 3’ unique sequence, U5 5’ unique sequence, tRNA transfer RNA, RNAse H ribonuclease 
H, RT reverse transcriptase. 
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Figure 1-2. Lentiviral vector transduction. VSV-G attaches and fuses to the membrane 
through an unknown receptor. Because gag, pol, rev and other essential viral elements are 
deleted from the expression vector replications does not occur. A mutated U3 is copied 
across to the 5’ position during reverse transcription, abrogating the promoter function of 
the 5’ LTR and preventing transcription of the whole vector genome which would permit 
uptake into wild-type virions in a subject infected with HIV. Abbreviations are described in 
Figure 1-1. 
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By transiently co-transfecting producer cells with these elements on separate expression 
plasmids the risk of generating replication competent lentiviral vectors is greatly reduced 
since it would require at least three recombination events between the separated 
elements. Secondly, the removal of HIV pathogenicity factors (Vpr, Vif, Vpu, Nef and Tat) 
which are dispensable for delivery and integration of the transgene further enhanced LV 
safety. Thirdly, the transcriptional elements in the long terminal repeats (LTR) that flank 
the HIV genome have been modified to generate self-inactivating (SIN) vectors. This was 
achieved by deletion of transcriptional activation regions of the 3’ U3 region of the long-
terminal repeat (ΔU3). This deletion is copied to the 5’ LTR of the proviral DNA during 
reverse transcription (Figure 1-2) where, following integration, the deletion prevents 
transcription of the full length vector into RNA for viral particle incorporation. This reduces 
the likelihood of generating a replication competent LV by recombination events, avoids 
transcriptional interference between the 5’ LTR and internal vector promoters and also 
abrogates the risk of uptake of an engineered vector by wild-type HIV infection of the host 
cell107. Finally, separation of the rev element (necessary for viral packaging) onto a 
separate plasmid has been instituted as a further safety measure in 3rd generation LV.  
LV are thus produced by transient transfection of producer 293T cells, a kidney fibroblast 
cell line, with up to 4 plasmids as described in Figure 1-3: 
1. Transfer Vector plasmid 
2. Envelope plasmid. Many glycoproteins are used to pseudotype LV. VSV-G is a 
commonly used option since it ensures high titres, is robust enough to 
withstand ultracentrifugation during concentration and has a wide target cell 
tropism (although the receptor for VSV-G is unknown). 
3. Packaging plasmid  
4. Rev plasmid (3rd generation LV only) 
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Figure 1-3 Lentiviral vector production. LV are produced by co-transfection of 293T cells 
with plasmids encoding packaging, transfer and envelope proteins. RRE rev response 
element, PRM promoter, WPRE woodchuck hepatitis virus posttranscriptional regulatory 
element, cPPT central polypurine tract, Ψ packaging sequence. 
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1.2.2 Lentiviral vectors as vaccines for cancer and infection 
 
There are multiple examples of LV vaccines tested for tumour immunotherapy in animal 
models but the application of LV vaccines for prophylactic T cell mediated immunity 
against infection is in its infancy. Most attention in this area has focused on the potential 
of LV vaccine in T cell-mediated prevention against HIV, with the assumption that vector 
tropism and the combination of anti-vector and anti-transgene responses will together 
generate a memory response ideally tailored against wild-type virus. 
Experiments in anti-tumour and infection vaccination using LV, summarised in Table 1-2 
and Table 1-3, have consistently demonstrated humoral and T cell responses with 
meaningful functional correlates of therapy or protection. These studies, together with a 
significant recent expansion in the use of LV for gene therapy, have elucidated numerous 
attributes of LV that contribute to the generation of potent T cell responses by the 
mechanisms previously described.  
 
1.2.3 Tropism for immune and non-immune cells 
 
LV transduce human and mouse DC with high efficiency and this is often linked to the 
natural tropism of HIV for dendritic cells and macrophages. There is now extensive 
evidence of HIV adaptation to infection of DC as a means of onward transmission to CD4+ 
T cells (reviewed in112). However, the parent virus attributes that favour this tropism are, 
for the most part, removed from the attenuated vector. For example, the HIV envelope 
protein gp120 interacts with DC-SIGN (DC) or the mannose binding protein binding 
(macrophages) and is also thought to be critical for down-modulating autophagy of HIV by 
DC through activation of mTOR113.  
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Table 1-2. Lentiviral vectors as vaccines for tumour immunotherapy in mouse models 
Disease/Model Reference Modifications 
Characterisation of immune 
response 
Functional assays 
Melanoma 
114
 None CD8+ and CD4++ response against 
Melan-A 
In vivo cytotoxicity assay 
 
 
115
 None CD8+ T cell response against NY-
ESO-1 
 
Elimination of in vivo cytotoxicity assay targets; response 
improved by boosting 
 
 
116
 Hsp70 co-
expressed 
CD8+ T cell response against Trp2 
 
Decreased growth of small established B16 or G-26 
tumours  
 
 
117
 None CD8+ T cell response against 
Melan-A 
 
Ex vivo and in vivo cytotoxicity assays 
Secondary response to challenge with peptide 
 
118
 MHC II promoter 
for APC specificity 
CD8+ T cell response against TRP-2 
 
Increase in survival following tumour challenge with B16 
cells using CMV promoter but not with MHC-II promoter 
 
119
 None CD8+ and CD4+ T cell and 
antibody response against NY-
ESO-1 
 
No T cell function assessment  
 
120
 DC-specific 
promoter 
CD8+ and CD4+ T cell response 
against NY-ESO-1 
 
No T cell function assessment  
 
121
 None CD8+ T cell response against TRP-1 
 
Elimination of targets in in vivo cytotoxicity assay 
Protection against B16 tumour challenge 
Inhibition of growth of established B16 tumours 
 
     
OVA-expressing 
tumours  
122
 None CD8+ and CD4+ T cell response 
against OVA 
Elimination of targets in in vivo cytotoxicity assay 
Inhibition of growth of established EG.7 tumours 
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Disease/Model Reference Modifications 
Characterisation of immune 
response 
Functional assays 
     
 
123
 None CD8+ T cell response against OVA Elimination of targets in in vivo cytotoxicity assay 
Protection against B16-OVA tumour challenge 
 
124
 None CD8+ and CD4+ T cell and 
antibody response against OVA 
Complete protection against EG.7 tumour challenge 
 
125
 vFLIP co-expressed CD8+ and CD4+ T cell and 
antibody response against OVA 
Complete protection against EG.7 tumour challenge 
 
126
 vFLIP, MKK6 co-
expressed 
 
CD8+ T cell response against OVA 
 
 
Partial regression and increased survival of mice bearing 
EG.7 tumours. 
 
127
 MKK6, JNK1 
activator co-
expressed 
CD8+ T cell responses against OVA Increased survival of mice bearing EG.7 tumours. 
 
CEA expressing 
tumours 
128
  CD8+ and CD4+ T cell and 
antibody response against CEA 
 
Temporary regression of carcinoembryonic antigen (CEA)-
expressing tumours 
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Table 1-3. Lentiviral vectors as vaccines for infection 
Disease/Model Reference Modifications 
Characterisation of immune 
response 
Outcome 
HPV 
129
 E7 fused to 
calreticulin to 
enhance MHC I 
presentation 
CD8+ T cell and antibody response 
against E7 
No functional T cell assessment 
West Nile Virus 
130
 None Antibody response againt WNV E-
glycoprotein 
 
Protective, sterilizing humoral immunity against WNV 
 
Influenza 
131
 Non-integrating LV CD8+ T cell response against 
Matrix-1 protein 
 
No functional T cell assessment or infectious challenge 
 
HSV-1 and HSV -2 
132
 (FIV vector) CD8+ T cell response and 
Antibody response against HSV 
glycoprotein B 
Increased survival to both HSV-1 and HSV-2 challenge 
HIV 
133
 Multiple HIV 
epitopes encoded 
Multispecific CD8+ and CD4+ 
response against multiple 
encoded HIV epitopes 
In vivo cytotoxicity assay 
 
134
 Codon-optimisied 
gp120. Integrase 
deficient vector 
CD8++ T cell response and 
sntibody response against gp120 
In vivo cytotoxicity assay 
 
135
 Codon-optimised 
gp120 
CD4+ and CD8+ T cell response No functional T cell assessment  
 
 
110
 Prime-boost with 
Adhu5 vector 
CD4+ and CD8+ + T cell response 
against Gag, Pol and Rev 
No functional T cell assessment 
SIV 
136
 Prime-boost with 
LV with non-cross 
reactive VSV-G 
pseutoypes 
CD8++ and CD4++ T cell response 
against SIV GAG  
Partial protection against intra-rectal SIV challenge in 
primates 
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Despite the removal of these parent virus adaptations to DC infection, transduction of 
human and mouse DC by VSV-G pseudotyped LV is retained with efficiencies ranging 
from 35-90% 137–140,123,141,142. Importantly, LV-transduced DC remain viable, present 
antigen, respond to maturation stimuli and are capable of secreting cytokines such as 
IL-12143. In direct comparison with adenovectors, LV have been shown to be 2-10 times 
more effective in transducing mouse and human DC144. Importantly, DC transduction 
has been demonstrated in vivo in murine models and is integral to CD8+ T cell 
responses. Skin-derived DC are transduced by subcutaneous vaccination of mice with 
LV and subsequently readily identified in draining lymph nodes. Adoptive transfer of 
these in vivo transduced DC from lymph nodes into recipient mice elicit potent CD8+ T 
cell responses to encoded antigen145. Intravenous injection of LV also transduces high 
numbers of proliferation-capable DC precursors and macrophages146.  
 
Although human DC transduction by VSV-G pseudotyped LV has been demonstrated in 
vitro, it occurs at efficiencies much lower than that observed in mice. This may be in 
part due to reduced DC tropism of VSV-G compared with native HIV envelope gp120 
and can be addressed by use of alternative pseudotyping with envelopes which 
interact with DC-SIGN such as Sindbis virus envelope54 or the haemagluttinin and 
fusion proteins of measles virus147. However, LV transduction of human DC is further 
restricted by sterile alpha motif domain and HD domain containing protein (SAMHD1) 
which inhibits the replication of LV in human dendritic cells by hydrolyzing the cellular 
deoxynucleotide triphosphates (dNTPs) below the level required for reverse 
transcription148. Lentiviral vectors that incorporate the simian immunodeficiency virus 
(SIV) accessory protein Vpx, which degrades SAMHD1 by initiating its ubiquitination, 
have very recently been shown to transduce human DC with much higher efficiency 
than current HIV-1 derived vectors149.  
As with other viral vectors, the relative efficiency of transduction of APC and non-APCs 
may influence the resultant T cell response by encouraging stimulatory and regulatory 
responses respectively. Like AAV, LV transduce hepatocytes with high efficiency which 
are capable of inducing T cell tolerance to presented antigen. LV transgene expression 
can be de-targeted from DC by use of a hepatocyte-specific promoter and addition of 
3’ microRNA targets which limit expression in haematopoetic cell lineages.  This 
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induces prolonged expression of encoded antigen together with transgene product-
specific T cell deletion or exhaustion150. Whilst this is an advantage for gene therapy, it 
is undesirable in vaccination which may conversely benefit from better means of 
targeting APC and de-targeting non-immune cells. Pseudotyping LV with a single chain 
antibody targeting MHC-II has recently achieved this, demonstrating highly specific 
transduction of MHC-II expressing cells after intravenous LV administration151.  
 
1.2.4 The innate immune response to lentiviral vector components 
 
One of the reasons LV have come to the fore in gene therapy in recent years is their 
low immunogenicity, avoiding strong PRR stimulation and thus minimizing anti-
transgene CD8+ T cell immune responses. This would appear to make LV a poor choice 
as a T cell vaccine since the presentation of antigen in the absence of co-stimulation by 
APCs risks T cell deletion or anergy rather than activation. However, LV do instigate at 
least transient DC activation by stimulation of TLR7 and then TLR3 stimulation as 
delivered ssRNA is reverse transcribed152, although this may occur predominantly at 
high MOI in vitro153. This, together with efficient transduction and endogenous antigen 
production and processing seems to consistently ensure strong CD8+ T cell responses 
to LV encoding antigen alone. 
 
The ability of LV to incorporate large or multiple inserts means that additional 
immunostimulatory signals such as DC maturation signals or specific co-stimulatory 
molecules can be readily delivered to APCs in order to enhance T cell activation. 
Examples of such signals used to date in LV vaccines include CD40L154, heat-shock 
protein 70 (hsp70)155 and myD88 or TRIF-1156. This group has previously demonstrated 
that transduction of DC with LV expressing activators of signaling pathways involved in 
maturation can dramatically enhance co-stimulatory molecule expression and cytokine 
secretion thereby enhancing T cell responses against co-encoded antigen. One 
particularly promising approach has been NFкB pathway activation by viral flice-like 
inhibitor protein (vFLIP) from Kaposi’s sarcoma herpes virus (KHSV)157. Transduction of 
bone-marrow derived dendritic cells from mice with LV expressing vFLIP led to marked 
up-regulation of CD80, CD86, CD40 and intercellular adhesion molecule 1 (ICAM-1) and 
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increased TNFα and IL-12 secretion to levels comparable to lipopolsaccharide (LPS) 
stimulation. When vFLIP was co-expressed with OVA, antigen specific CD8+T cell 
responses were enhanced 10-fold and vFLIP-OVA vaccinated mice demonstrated 
improved tumour-free survival in an OVA-expressing tumour model. Stimulation of the 
p38 mitogen-activated protein kinase (MAPK) pathway by an LV encoded MAPK Kinase 
6 (MKK6) mutant that constitutively phosphorylates p38 also results in DC co-
stimulatory molecule up-regulation (although no increase in pro-inflammatory 
cytokines) and enhanced T cell responses against co-encoded antigen158.  
 
An alternative strategy to enhance DC activation by LV vaccines is to down regulate 
pathways that inhibit DC activation. LV encoding shRNA against A20, an inhibitor of 
NFкB activation, can enhance NFкB signaling and DC activation, resulting in A20 
resulting in co-stimulatory molecule and pro-inflammatory responses159. Specific 
inhibition of co-inhibitory signals may also enhance T cell responses to LV-transduced 
DC. Transduction of DC with LV co-encoding shRNA against PDL-1 and OVA resulted in 
generation of OVA-specific hyper-activated CD8+ T cells without antigen-mediated T 
cell receptor down regulation160.  
 
1.2.5 Level and persistence of antigen expression 
 
Since the LV genome is integrated into the target genome it is both more stable than 
episomal DNA and also propagated with subsequent cell divisions, ensuring high-level, 
persistent antigen expression. Other modifications have been made to LV since their 
inception to further improve transgene expression. For example, the addition of a cPPT 
enhances transport of the vector into the host cell nucleus after transduction161. 
Inclusion of the WPRE increases transgene expression (as it does in many vectors by an 
unknown mechanism). This ensures both high quantity and duration of antigen 
expression which, as discussed above, is critical for optimizing T cell memory and 
protection. Our group has recently examined the ramifications of long-term antigen 
expression induced by intravenous administration of LV. This route of administration 
transduces high numbers of proliferation-capable DC precursors which ensures antigen 
presentation for up to 2 months. Long-term expression of OVA was slightly lower than 
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green fluorescent protein (GFP) which may reflect the higher immunogenicity of this 
antigen. Nevertheless, OT-1 CD8+ T cells (specific for an  OVA epitope) underwent 
proliferation when adoptively transferred up to 3 months after recipient mouse 
vaccination, and in vivo cytotoxic killing of OVA peptide-pulsed splenocytes was 
preserved at this time point, allaying the concern that persistent antigen expression by 
LV may induce tolerance162. It is unclear whether or not the prolonged antigen 
presentation following LV vaccination sustains persistence of T cell memory, although 
there is some evidence that T cell memory populations are longer-lasting than those 
induced by vaccinia vectors in which antigen presentation is transient123.  
 
1.2.6 Anti-vector immunity 
 
Immune responses directed against LV envelope glycoproteins can inhibit effective re-
use of the vector. However, although neutralising antibodies against VSV-G have been 
demonstrated in mice following VSV-G pseudotyped LV vaccination, these have not 
been shown to block transduction after subsequent LV administration. Repeated 
subcutaneous vaccination with VSV-G pseudotyped LV in mice induces minimal anti-
vector neutralising antibody163 and in vitro, DC can be readily transduced additively 
with consistent efficiency164. There is some evidence that VSV-G activates human 
complement which can then inhibit vector fusion with target cells, a problem that can 
be circumvented by PEGylation of VSV-G pseudotyped LV165.  
 
1.2.7 Prime-boost vaccination regimens 
 
 The inclusion of LV in vaccination regimens with other modalities is a relatively un-
tested area. A second homologous vaccination of macaques primed with an HIV-1 
derived LV expressing SIV GAG induced secondary T cell responses of greater 
magnitude and longer persistence than seen in the primary response after single 
vaccination, and this corresponded to greater protection against SIV challenge. 
Notably, this study used LV pseudotyped with different VSV-G serotypes to avoid the 
theoretical risk of anti-vector immunity described above166. Others have demonstrated 
that heterologous vaccine regimens incorporating an LV expressing GAG, Pol and Rev 
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(VRX1023) and Adhu5 encoding GAG and Pol (VRC5409) significantly improved the 
percentage of polyfunctional HIV-specific CD4+ and CD8+ T cells compared with dual 
vaccination of either vaccine, with Adhu5 prime-LV boost being the most effective 
strategy167. 
 
1.3 Comparing vaccine modalities for T cell responses against infection 
 
Quantifying the T cell response to vaccination typically involves one or more of the 
following surrogate measures: 
 
a) Enzyme-linked immunospot assay (ELIspot) of number of IFNγ-secreting 
splenocytes (in mouse experiments) or peripheral blood mononuclear cells 
(PBMCs, in human experiments) following peptide re-stimulation in vitro.  
b) Intracelluar cytokine staining of T cells from splenocytes/PBMC for IFNγ, IL-2 
and TNF as corollaries of functionality after stimulation in vitro with relevant 
peptide. 
c) Tetramer or pentamer staining for numbers of antigen-specific CD8+(and 
increasingly CD4) T cells. 
d) 3H-thymidine and Carboxyfluorescein Succinimidyl Ester (CFSE) proliferation 
assays 
e) Killing/cytotoxicity assays 
 
Despite routine measurement of T cell number or function, there are no defined 
thresholds that need to be achieved for vaccine efficacy, nor are these readily 
predicted. These parameters are also subject to non-standardised experimental 
variations which confound comparison between studies. Live infectious challenge, for 
example, would seem an appropriate benchmark for vaccine efficacy. However, 
influenza challenge of mice, for example, only results in a predictable clinical sequelae 
(such as weight loss or survival) if virus strain and challenge dose are standardised. In 
the absence of an agreed standard challenge strain or dose there is considerable 
variation in the “robustness” of challenge. Inoculation dose and replication efficiency 
(V(0) and πα respectively in Figure 1-5, page 70) affect peak viral titres in different 
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ways. Increasing the inoculation dose will not increase peak viral titres but will shift it  
to an earlier time point, whereas increasing replication efficiency (by using a mouse-
adapted strain versus a non-adapted strain, for example) will enhance peak viral titres 
but will not change its timing168. The measured impact of a memory T cell response 
following vaccination will be highly sensitive to both these variations. Other factors 
that contribute to variation between studies include the species of mouse used 
(BALB/c and C57BL/6 mice, for example, have varying susceptibilities to identical 
influenza strains) and the route of administration (intratracheal administration delivers 
a greater inoculation dose to the alveoli than intranasal). 
 
Perhaps the greatest variable that confounds comparisons of immunogenicity between 
candidate T cell vaccines is that the T cell response is dynamic, and there is no agreed 
time-point after vaccination at which to apply the above measures of efficacy. There 
are three distinct phases to primary T cell responses: expansion, contraction and 
memory. Expansion follows interaction between the T cell receptor (TCR) on naïve T 
cells and its cognate MHC-peptide complex on the surface of professional antigen-
presenting cells with APCs in lymphoid tissue, providing there are sufficient co-
stimulatory and cytokine signals to meet the threshold for T cell activation. Following 
an expansion phase and antigen clearance, a contraction phase begins driven by rapid 
effector T cell apoptosis. This population does not dwindle completely and plateaus at 
a level (usually several-fold lower than the peak of expansion) that can be maintained 
for considerable lengths of time. These memory T cells have altered trafficking 
properties, are less susceptible to apoptosis and can respond rapidly to future antigen 
encounter without the need for co-stimulatory signals. Conventionally, responses to T 
cell vaccines are usually measured after the expansion and contraction phases (during 
which T cell number changes rapidly at different time points) and during the memory 
phase, but there is significant debate as to when this begins. Indeed it is impossible to 
determine without dynamic monitoring of a response to a specific vaccine. The delay 
between vaccination and immunological assessment (or infectious challenge) is usually 
a compromise between the point at which the contraction phase has finished and the 
practical constraint of completing series of experiments within a limited period of 
available time.  
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These variables thus confound the comparison of different modalities of vaccination in 
terms of their efficacy in generating T cell responses. This problem is compounded by a 
paucity of studies comparing two or more vaccination modalities in the same 
experimental system. Some 30 years into T cell vaccine development it is therefore 
impossible to state with confidence which of the modalities for vaccination discussed 
above (or in which combination) generate the greatest degree of T cell mediated 
protection in any given disease model. 
 
A more fruitful approach may be to consider the requirements of an ideal T cell 
vaccine for controlling a given disease and tailor a chosen vaccine modality 
accordingly. Lentiviral vectors have some specific advantages in this regard. Their low 
inherent immunogencicity means that the immunological benefit of encoded 
adjuvants over and above the immunogenicity of the vector is more easily determined. 
Their, their high capacity for transgene incorporation means combinations of 
immunomodulating factors can be included and their ability to transduce non-dividing 
cells means a functionally wide range of cells can be harnessed for a desired 
immunological outcome. 
 
This thesis describes the testing of a lentiviral vector vaccine in a mouse model of 
influenza. This was chosen, in part, because influenza has a fast-changing antigenic 
profile that rapidly eludes antibody mediated protection and as such is a prime 
candidate for T cell vaccine strategies that target conserved epitopes. However, 
influenza is an acute, potentially lethal viral infection, which replicates rapidly and at a 
site distant from secondary lymphoid organs in which memory T cells reside. 
Furthermore, T cell responses in the lung are tightly regulated to protect the delicate 
architecture from the deleterious consequences of inflammation. These disease-
specific factors present robust challenges to a T cell vaccine and are considered in 
more detail in the next section. 
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1.4 Influenza virology and immunology 
 
In broad terms, those who search for a universal vaccine against influenza that can 
protect against multiple strains can be divided into two camps. Some groups have 
attempted to generate broadly cross-neutralizing antibodies against conserved B-cell 
epitopes on the surface of the influenza virion. Others have tried to generate potent T 
cell responses against influenza epitopes, principally towards internal components 
which are highly conserved.  
 
Both these approaches to universal vaccination have a long history, benefiting from 
and developing in parallel with significant advances in the understanding of influenza 
structure and life-cycle, in-host viral dynamics, the immune response to influenza (and 
other respiratory infections) and the development of effective vaccine modalities for 
generating more potent antibody and T cell responses.  
 
1.4.1 Influenza structure, life cycle and in-host viral dynamics 
 
A number of features of the influenza structure and life cycle are relevant to effective 
vaccine design. In principle, proteins that are exposed at the surface of the virion are 
amenable to antibody attachment for sterile immunity whereas those which are 
internal can only be targeted through T cell recognition of processed epitopes. This is 
an oversimplification, however, since generating antibody responses to internal 
components of the influenza virion has been shown to confer partial protection, by 
mechanisms that remain unclear169. An important distinction between external and 
internal proteins of the influenza virus is that many of the former are subject to wide-
ranging and dynamic sequence and structural variations between and within virus 
subtypes, whereas the latter tend to be more conserved due to functional constraints 
upon their essential role in viral assembly and therefore viability. This informs the 
selection of conserved T cell and antibody epitopes which might be targeted for cross-
strain protection through vaccination.  
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An understanding of the influenza life-cycle (Error! Not a valid bookmark self-
reference.) is integral to accurate modelling of the dynamics of influenza infection and 
the immune response. This has significant repercussions for vaccination measures 
designed to modify rather than prevent infection.  
 
Viral Structure and host cell entry 
Influenza A is an enveloped orthomyxovirus with a single-stranded, negative-sense 
RNA composed of 8 segments. These encode 11 viral components, namely HA, NA, NP, 
non-structural protein (NSP1), non-structural protein 2(NSP2), M1, Matrix 2(M2), 
polymerase acidic protein (PA) and polymerase basic proteins 1, 2 and F1 (PB1, PB2, 
F1). HA consists of two domains, HA1 and HA2, and associates into trimers which form 
spikes on the virion surface. The interaction of HA1 with sialic acid on the cells surface 
is specific to the type of linkage formed between sialic acids and the glycoproteins on 
the membrane surface170. The two predominant linkages are α(2,3) and α(2,6). Viruses 
capable of infecting humans recognise the α(2,6) linkage, whereas avian and equine 
influenza strains bind to the α(2,3) linkage. Swine express both linkage types on the 
epithelial surface making them an ideal mixing vessel for avian and human influenza 
strains. Interspecies variation in the phenotype and distribution of sialic acid receptors 
throughout the respiratory tract means both the route of administration (e.g. 
intratracheal versus intranasal) and strain of an influenza virus will influence its 
behaviour in a given species – a major consideration in the extrapolation of findings 
from animal influenza challenges to humans.  
Binding of HA2 to the sialic acid linkage triggers uptake into endosomes wherein the 
low pH exposes the HA2 fusion domain which inserts into the endosomal membrane 
and precipitates virus/endosomal membrane fusion. This process leads to a 
conformational change in the M2 ion channel, allowing acidification of the viral core 
and releasing viral ribonucleoproteins (NP, PA, PB1, and PB2) into the host cell 
cytoplasm171. This critical function of the M2 ion channel means it is structurally 
conserved between viral strains. Together with its partially external location, this 
makes it an attractive target for antibody based approaches to universal vaccination.  
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Viral replication and transcription  
 
Viral replication and transcription occur in the nucleus since they are dependent on 
many host factors abundant in nuclei. The viral ribonucleoproteins (vRNP) thus have 
nuclear localisation signals that ensure their trafficking into the nucleus via cellular 
nuclear import machinery172.  
Viral RNA dependent RNA polymerase (RdRp, a combination of PB1, PB2 and PA) 
initiates replication by RdRp after “self-priming” of the negative sense (-) RNA genome 
by hybridisation of 5’ and 3’ ends, which have partial inverse complementarity173. A 
key feature of viral replication is that is it highly error-prone due to the absence of an 
RNA proof-reading enzyme, leading to an error rate of approximately 1 in 10,000 
nucleotides. Given that this is the approximate length of the influenza RNA, most 
replication by RdRp will generate a mutant. This results in the rapid antigenic drift that 
causes much of the seasonal variation in influenza and presents a problem for 
vaccination that targets variable domains.  
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Figure 1-4. The influenza 
life cycle. 
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Transcription of viral mRNA from the (-) RNA is primed by 5’ methylated “caps” cleaved 
from cellular mRNAs by the endonuclease activity of PB2, a mechanism known as “cap-
snatching”174 which substantially inhibits host cell mRNA translation. Viral mRNA 
transcripts from segment 7 and 8 undergo splicing to encode 2 protein products each 
(M1, M2 and NSP1, NSP2 respectively) and this exploits cellular splicing machinery, 
again at the expense of host mRNA splicing175. NS1 binds to splicing proteins via 
associated U6 small nuclear RNAs causing them to relocate to the host cell nucleus 
depriving cytoplasm cellular mRNAs of splicing176. Through binding to both the 
cleavage and polyadenylation specificity factor (CPSF) and polyA binding protein II 
(PABPII), NS1 prevents the cleavage of cellular mRNA at the polyadenylation site in 
preparation for addition of the polyA polymerase177. NS1 inhibits nuclear export of 
cellular mRNAs through preventing their proper polyadenylation. Polyadenylation of 
viral mRNA, however, requires neither a classic polyadenylation signal nor PolyA 
polymerasse but it achieved through reiterative copying of 5-7 uracil residues close to 
the 5’ end by RdRp which “stutters” back and forth over this U-rich region178.  
In summary, in addition to inhibiting cellular mRNA splicing, the influenza virus inhibits 
5’ capping and polyadenylation of host mRNA, thus reducing its stability, nuclear 
export, excision of the 5’ proximal intron and translation initiation. Viral protein 
synthesis is promoted at the expense of the host cell, permitting fast, high quantity 
replication and producing approximately 200 virions per infected cell per day179. Whilst 
hijacking host cell translational machinery will also reduce the innate immune 
response to infection (such as type I interferon production) it also has profound 
cytopathic effects resulting in cell death, independently of a cytotoxic T cell response. 
Indeed, apoptosis rates are directly proportional to viral mRNA synthesis180. Depletion 
of susceptible target cells can be a major limiting factor in sustaining viral replication 
therefore influenza strains must evolve an optimal compromise between replicative 
vigour and prolongation of infection to ensure onward spread through viral shedding. 
This has implications for the “systems biology” modelling of influenza spread and 
estimating the population impact of measures such as anti-viral medications and T cell 
mediated protection, both of which limit the duration and severity of disease rather 
than confer sterile immunity.  
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Nuclear Export 
vRNPs associated with negative sense RNA are exported through nuclear pores by the 
chromosome region maintenance 1 protein (CRM-1) pathway. It is thought that NSP-2 
(otherwise known as nuclear export protein) interacts with CRM-1 and also the the N-
terminus of M1. In turn, M1 interacts with the RNA(-) associated ribonucleoproteins 
through its C-terminus. Through this “daisy-chain” of viral proteins the 
ribonucleoproteins are exported from the nucleus. Since the binding of NSP-2 to M1 
masks the latter’s nuclear import signal this ensures unidirectional transport of the 
vRNP-RNA complex into the cytoplasm for assembly and budding181. 
Viral Assembly and Budding 
Virions bud from the apical surface of infected cells after accumulation of the envelope 
proteins (HA, NA and M2) at this site and these are therefore the only viral proteins 
which have a surface-exposed component. HA, NA and M2 associate with lipid rafts in 
the membrane lipid bilayer and the cytoplasmic tail of M2 is thought to be critical in 
the association of other internal proteins at this site182. It remains uncertain whether 
genomic RNA is packaged stochastically into virions during assembly183 or if this occurs 
in a deterministic fashion184, but the identification of numerous packaging signals in a 
number of coding and non-coding regions of influenza RNA segments supports the 
latter hypothesis185. The segmental nature of the influenza RNA genome means that 
cells infected with virus of more than one strain may readily reassort to create 
daughter progeny with unique antigen profiles and pathogenicity characteristics. In 
broad terms, this risks a combination of HA and/or NA epitopes from a non-human 
strain - for which there is little or no cognate humoral immunity in the human 
population - with segments encoding internal viral components which are structurally 
well-adapted for human infection. Such antigen shifts have been responsible for at 
least two pandemics in the past century (H2N2 in 1957 and H3N2 in 1968). Population 
prevalence studies of influenza genotypes suggest at least 2-3 such reassortment 
viruses emerge per annum, with a preference for single segment reassortments of NA 
or HA186.  
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The M1 protein is crucial for viral budding and cooperates with several cellular factors 
to achieve this, including host cortical actin microfilaments187. The final stage of viral 
release is mediated by NA which cleaves the sialic acid residues (bound to membrane 
glyocoproteins and glycolipids) which attach to HA preventing viral separation from 
the host membrane188. Sialic acid binding to HA is crucial to viral entry and its cleavage 
during viral budding by NA may play a role in limiting viral superinfection of host cells.  
 
1.4.2 The dynamics of influenza propagation and the primary immune response 
 
The primary immune response to influenza 
The innate immune response to influenza infection is initiated by the release of pro-
inflammatory cytokines by antigen presenting cells and infected epithelial cells. 
Infected macrophages secrete macrophage inflammatory protein 1α (MIP-1α), MIP-1β, 
RANTES (regulated on activation, normal T cell expressed and secreted), monocyte 
chemoattractant protein-1 (MCP-1), MCP-3, MIP-3α and IP-10 whilst epithelial cells 
secrete RANTES, MACP-1 and IL-8189. These appear to have a crucial role in the 
recruitment of mononuclear cells of the adaptive immune response in both mice and 
humans and are considered in more detail in Section 4.3.4. Immediate control of viral 
replication, however, is provided by the production of type I interferons (IFNα/β) by 
both infected epithelial cells and macrophages190–192. This slows viral replication and 
renders epithelial cells more resistant to infection, delaying productive infection and 
allowing time for the adaptive immune system to respond. Mice bearing a disrupted 
IFNα/β receptor demonstrate accelerated viral growth kinetics after challenge with a 
non-lethal A/X31 (H3N2) strain and develop much higher compensatory peak antibody 
titres193.  
Both B cell and T cell adaptive immune responses are thought to determine the end of 
viral expansion and eventual clearance of influenza virus. Virus-specific antibodies 
appear at around day 5 after infection in mice with a peak in IgM titres between day 8-
10 and IgG at day 25194. Early antibody isotype depletion studies in mice established 
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that IgG and IgA, but not IgM are dispensable to antibody-mediated viral clearance 
during the primary response191. This is thought to occur by both reducing the 
attachment of virus to host cells (through anti-HA antibodies) and preventing budding 
virus from detaching from host cells (anti-NA antibodies)195.  
The primary CD8+ and CD4+ T cell response is also not detectable in the lung until 
around day 5 of infection. Suppression of the CD4+ T cell response in mouse models of 
influenza (through antibody-mediated CD4+ T cell depletion or use of MHC class II 
knock-out mice) only slightly delays clearance and has little impact on survival196,197. 
Removal of the CD8+ T cell response, on the other hand, significantly delays clearance 
and increases mortality, although some mice are able to clear infection if CD4+ T cell 
and B cells are intact198. If both CD4+ and CD8+ T cell responses are depleted, 
however, animals generally do not control infection despite substantial production of 
anti-influenza IgM driven by higher viral loads199. Similarly, animals depleted of both B 
cells and CD8+ T cells typically cannot control infection and do not survive200–202. Taken 
together, these studies suggest crucial roles for CD8+ T cell responses and IgM 
antibody responses to clear primary infection, but a lesser role for CD4+ T cell 
responses. 
 
Modelling influenza in-host dynamics 
Studies of lymphocyte depleted mice or knockout models have several limitations, not 
least that near-complete removal of one arm of the adaptive immune system will have 
unpredictable, non-physiological consequences for the remaining components. 
Furthermore, these studies provide qualitative rather than quantitative insights into 
the impact of the immune response. In recent years there has been a proliferation of 
experiments that combine high frequency quantitative sampling of virus load and 
immune parameters together with mathematical modelling in order to gain insights in 
to the complex interaction and relative impact of the different components of the 
immune response upon influenza in-host dynamics. This has been facilitated by 
increasing computer processing power but also by experience and knowledge gained 
from modelling the in-host dynamics of other viral infections such as HIV. This 
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approach has also benefited from growing interest in anti-viral measures that do not 
rely upon antibody mediated sterile immunity, such as the increasing use of anti-viral 
drugs and emergent clinical trials of T cell based vaccines and from growing 
understanding of influenza virus pathogenicity factors. Justification of such approaches 
relies upon their impact on disease duration and severity in the individual, which in 
turn will impact on infectivity and spread throughout a population.  
To date, such models have generated disparate conclusions. For example, one analysis 
of viral load data from infected human volunteers has shown that it is possible to 
describe the infection dynamics without inclusion of the immune response as a 
modifying factor203,204. This study suggests the interesting conclusion that infection 
might be limited by exhaustion of available primary epithelial target cells rather than 
immunomodulation. However, this would require complete desquamation of the 
upper respiratory tract (URT) which, although observed in ferrets exposed to an 
epidemic strain in a 1930s study205, is not observed in humans with seasonal flu. It also 
fails to explain the well-established phenomenon that immunocompromised patients 
shed influenza for prolonged periods206207,. One problem with modelling the human 
response to influenza is that it is limited to use of mild strains, analysis of peripheral 
blood rather than lung immune responses and the use of non-invasive measures of 
viral load (such as in expectorated mucus) which are subject to greater variation than 
whole-lung measurement in the mouse. Mice do not provide a model of infection 
relevant to URT infection in humans, partly because it is difficult to specifically 
administer virus to the URT without distal aspiration and partly because sialic acid 
residues that interact with human strain are mostly expressed in distal respiratory 
epithelium.  
The ferret provides a more accurate model, since the distribution and subtype of sialic 
acid receptors for human and avian influenza viruses is very similar to that found in 
humans199 and restricted inoculation of the URT is technically straightforward. This 
model has recently been used to compare the spatiotemporal dynamics of three 
current influenza strains of varying pathogenicity and anatomical tropism in some 
detail: avian H5N1, seasonal H3N2 and pandemic H1N1. In ferrets, seasonal H3N2 is 
quickly cleared from the URT after peaking at day 1 post-infection, whereas avian 
H5N1 infects the alveoli and peaks at day 3208. However, quantification of the immune 
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response in this study was crude, limited by the relative scarcity of antibodies and 
reagents for analysis of cellular immune responses in the ferret compared with the 
mouse.  
Mice do provide a relevant model of flu strains that infect the lower respiratory tract in 
humans (such as H5N1 avian influenza or severe pandemic 1918 Spanish influenza). To 
date, much of the modelling analysis of influenza propagation and its modulation by 
immune responses is based upon data from two studies of experimental infection of 
BALB/c mice from over 20209 and 30210 years ago. The former study data are of viral 
loads in wild-type and nude mice (which lack T cells and have a severely impaired B-cell 
response). The latter dataset reports viral load, type 1 IFN levels and antibody titres 
and tracks infection both in immunocompetent mice and IgM-, IgG- and IgA-depleted 
mice. One recent analysis of these data found that both the type I IFN response (as a 
surrogate of the innate immune response) and antibody response need to be taken 
into account to adequately explain observed patterns of viral propagation and 
clearance211. 
A more complete attempt to model virus propagation and the adaptive immune 
response was described recently, using higher resolution sampling (up to 12-hourly) of 
mice infected with H3N2 (A/X31) influenza, with detailed analyses of the 
contemporaneous CD4+ T cell, CD8+ T cell, and isotype-specific antibody responses212. 
Viral titres peaked between days 2 and 3, with complete clearance by day 11. As in 
previous studies, virus-specific CD8+ T cells were not detectable before day 5 and 
peaked between days 9 and 11. Virus-specific IgM levels also peaked at this time-point, 
returning to baseline after 20 days, whilst IgG levels peaked at day 25, decaying slowly 
over the next 60 days.  
A series of differential equations incorporating these measured parameters together 
with a number of calculated parameters (such as number of uninfected epithelial cells 
at day 0) and fixed assumed constants (for example, rate of virus production per 
infected cell) were combined with estimated parameters (e.g. the rate at which CD8+ T 
cells kill infected cells or IgM antibody neutralizes free virus) and then tested to 
generate a model that best fits the observed data. The interrelationship between these 
measured, calculated, assumed and estimated parameters is shown in Figure 1-5.  
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The model of best fit reveals a number of interesting insights: 
 
- Peak viral load is target cell limited. There is an early and rapid drop in 
the number of cells susceptible to infection which cannot be accounted 
for by exhaustion of available cells, or by the adaptive immune 
response. This is most likely due to the effects of IFNα/β on increasing 
epithelial cell resilience to infection. This early pre-adaptive phase of 
virus control corresponds to plateauing of viral loads at around day 2 to 
3 (when adaptive responses are negligible). 
 
- Peak viral titres occur earlier but are not increased if viral infectivity or 
inoculum dose is enhanced. Increasing replication rate, however, 
dramatically increases peak viral load.   
 
- Viral titres start to drop with the arrival of CD8+ T cells and the 
appearance of IgM antibody in the adaptive phase. By removing CD8+ T 
cells and/or antibody responses from the model and determining how 
this impairs the fit (submodel analysis), the degree to which these 
contribute to viral clearance can be estimated. In the best fit model, 
these appear to make equivalent contributions to viral clearance. 
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Figure 1-5 Modelling in-host influenza dynamics. 
 
 
 
 
 
  
71 
 
Modelling the impact of T cell vaccines against influenza 
 
Similar models have been used to attempt to describe the impact of pre-existing T cells 
in the lung at the point of challenge upon viral dynamics, as might occur after previous 
exposure to a heterosubtypic influenza strain (as discussed below). As one may 
assume, these models predict more rapid viral clearance and lower peak titres if CD8+ 
T cells are present in the lung at the onset of infection. Surprisingly, however, any 
starting number of CD8+ T cells less than 105 seems to be insufficient to have any 
impact on the peak viral load or clearance time213. The killing rate of infected cells has 
to be very high to impact upon the rapidly rising viral loads seen in the first few days of 
infection, when the type I IFN response has yet to impact upon target cell susceptibility 
to infection. This is a crucial, if often overlooked, factor in estimating the likely impact 
of generating systemic T cell immunity against influenza as a vaccination strategy. 
Whilst the presence of systemic T cell memory, for example, may bring forward the 
time at which peak CD8+ T cell numbers are achieved in the lung by 2-3 days, this may 
have negligible impact on peak viral titres and therefore the disease severity of a highly 
pathogenic strain.  
However, since these models are based on quantitative measurements of the primary 
T cell response they do not account for the improved ability of memory influenza-
specific T cells in the secondary response to expand and kill upon reencounter with 
antigen214, and should therefore be interpreted with caution. More importantly, such 
models focus on viral load and clearance without addressing key parameters of clinical 
severity or duration of disease which can also be readily quantified (weight loss, 
respiratory rate, mortality). This is crucial since the clinical severity of influenza 
infection is a complex, composite function of not only viral titres and their cytopathic 
effect but also immune-mediated injury. Establishing the relative contribution of these 
two factors to lung injury in humans is further confounded by their interdependence. 
The CD8+ T cell response, for example, is driven by antigen load, yet this direction of 
influence is notably absent from current schemata of virus-immune system interaction 
models (Figure 1-5). T cells also have a direct role in tissue injury independently of viral 
load. The clearest demonstration of this is the observation of deleterious effects on 
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respiratory parenchyma in the absence of replicating virus when inducible, alveolar-
restricted expression of an antigen is followed by transfer of antigen-specific T cells215.  
Therefore, in order to determine the clinical impact of vaccines that generate T cell 
responses against influenza, we require more quantitative data regarding the dynamics 
of the secondary T cell response and more qualitative information about how virus and 
immune response interact to generate clinicopathological sequelae.  
 
1.4.3 Heterosubtypic immunity and the T cell response to influenza 
 
T cells and heterosubtypic immunity 
 
It has been known since the late 1970s that T cells are capable of conferring cross-
strain protection against influenza. Mice immunised intraperitoneally with a single 
strain of influenza A would generate potent populations of splenic T cells capable of 
killing target cells in vitro that were infected with other influenza A strains216,217. This 
was the first convincing mechanism to explain the phenomenon of heterosubtypic 
immunity against influenza A that had been observed more than 10 years earlier218, 
wherein mice exposed to one influenza A strain were found to be partially immune to 
exposure to a another. A number of subsequent studies demonstrated that 
intravenous adoptive transfer of NP-specific CD8+ T cells could confer heterosubtypic 
immunity to mice219–221 and further evidence followed of a reduction in heterosubtypic 
immunity following CD8+ (and to a lesser extent CD4+ ) T cell depletion222.  
 
It has proved harder to demonstrate a role for T cells in retrospective studies of 
protection from influenza epidemics in humans due to unknown prior exposure history 
and variation in non-adaptive susceptibility factors. In 1983 McMichael et al 
demonstrated through experimental infection of human subjects that viral shedding 
was reduced in the presence of cytotoxic T cell memory from prior infection, despite 
the absence of specific antibodies223. A number of subsequent epidemiological studies 
in the 1980s showed cross protection conferred by one influenza subtype against 
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another during sequential or overlapping epidemics224 or periods of mixed 
outbreaks225. Memory T cell responses against epitopes from M1, NP and PB2 in 
humans following exposure to seasonal influenza strains were also identified later in 
this decade226. Since then, over 5000 experimentally-determined strain- and HLA- 
specific T cell epitopes have identified and are now available in publically accessible 
databases227.  
 
Indirect evidence of the importance of CD8+ T cell mediated cross-protective immunity 
in humans emerged more recently with the observation that mutation in the  
immunodominant T cell epitopes of influenza NP (normally highly conserved) can 
confer a selective advantage. Voeten et al describe the emergence of a mutation 
(R384G) that disrupts MHC I presentation of the HLA-B27 restricted influenza A NP383-
391 epitope in a 1993 H3N2 strain and quickly superseded strains lacking the mutation 
which disappeared in subsequent epidemics228. This pattern of emerging T cell escape 
influenza variants has since been demonstrated in HLA-B*3501 and HLA-B*08 
restricted CTL epitopes229,230. Following the recent SOH1N1 pandemic, it was proposed 
that the mild phenotype may have been in part due to cross-protective CD8+ T cell 
responses generated by seasonal influenza exposure against the highly conserved HLA-
A2 restricted M158-66 epitope shared by SOH1N1
231. Natural immunity from seasonal 
influenza infection, but not seasonal influenza vaccination which generates poor T cell 
responses, may also generate cross-protective CD8+ T cell responses against H5N1 
avian influenza A232. Importantly, these studies consistently demonstrate that 
heterosubtypic immunity from natural infection is not only partial, but starts to wane 
after an as yet ill-defined time point ranging from 3-9 months233. In mice this 
phenomenon has been defined more precisely with the demonstration that cross-
protection from primary influenza infection starts to wane after 15 weeks234235. 
 
Although CD4+ T cells have an essential role in establishing long-lasting protective 
antibody responses236, the depletion of naïve CD4+ T cells in mice has little or no 
impact on the primary response to influenza. Furthermore, memory CD4+ T cells after 
primary infection wane considerably faster than CD8+ T cells and before 
heterosubtypic immunity declines237 and early mouse depletion studies of CD4+ T cells 
after primary infection appears to have significantly less impact on heterosubtypic 
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protection than CD8+ memory depletion234. Historically, therefore, there has been less 
interest their role in heterosubtypic immunity compared with CD8+ T cells. However, 
more recent studies have pointed towards a significant role for CD4+ T cell memory in 
heterosubtypic protection of mice and humans. Using TcR Tg mice in which CD4+ T 
cells recognise class II restricted HA epitopes, McKinstry et al generated memory CD4+ 
T cell population by influenza infection and then transferred these to unprimed 
mice238. This successfully protected mice from lethal influenza challenge, (although 
others have contended that the transfer of lower, “physiological” numbers of CD4+ T 
cells results in minimal protection239). Protection in recipients of TcR Tg CD4+ memory 
T cells is impaired in the absence of functional B cells and CD8+ T cells, suggesting 
memory CD4+ T cells confer heterosubtypic immunity through supporting the primary 
antibody and CD8+ T cell response. However, CD4+ T cells do suppress initial viral titres 
when transferred into severe combined immunodeficiency (SCID) mice (lacking B and T 
cells) before infectious challenge by an IFNγ-dependent mechanism, suggesting they 
are capable of contributing to viral control directly. Titres were only temporarily 
suppressed, however, and death was delayed rather than prevented. In this study, a 
perforin-dependent mechanism of selection of CD4+ epitope-specific viral escape 
mutants was also observed, raising the possibility of cytotoxic CD4+ T cells playing a 
role in viral control. This finding appears to corroborate a previous study by the same 
group showing early, antibody-independent control of viral titres by adoptively 
transferred CD4+ memory T cells in a perforin-dependent manner240. Such CD4+ 
secondary effector functions are only seen in lung populations (splenic CD4+ memory T 
cells remain predominantly cytokine-secreting and non-cytotoxic, for example) which 
presents a problem for human studies which are mostly limited to analysis of 
peripheral blood T cell populations. Nevertheless, Wilkinson et al recently 
demonstrated that in healthy volunteers challenged with mild H3N2 or H1N1 strains, 
symptoms were less severe and viral shedding lower in the presence of pre-existing 
CD4+ T cells specific to pools of NP and M1 peptides found in the challenge strains. 
Furthermore, circulating CD4+ T memory T cells isolated during infection showed 
evidence of cytotoxicity against peptide pulsed target cells in a chromium release 
assay.  
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Antibody responses and heterosubtypic immunity  
 
Antibody responses may also have a role in heterosubtypic immunity. Dominant 
antibody responses emerge to the highly immunogenic haemagluttinin (HA) and 
neurominadase (NA) surface glycoproteins which protect completely against 
subsequent infection with the same strain. However, the tolerance for high mutation 
rates in this region without loss of function (attachment and fusion) mean there is 
typically little cross-neutralisation between anti-HA and anti-NA across subtypes or 
between drift variants within subtypes. Such subtypes are phylogenetically categorised 
based on their amino acid sequence. HA, for example, has 16 subtypes belonging to 
two broadly similar structural conformations. Despite this structural variation, there 
has been at least one report of anti-HA mediated cross protection in humans241 and it 
has been shown that vaccination of pregnant mice resulted in cross-strain protection 
of their offspring against 3 different subtypes242, dependent upon serum virus-specific 
neutralizing antibodies in both mother and neonates. There have since been rare 
reports of antibody clones isolated from humans capable of cross-neutralising two 
different HA subtypes. The first of these in 1993 identified an antibody clone 
(designated C179) that cross-reacted with both HA1 and HA2. Subsequent sequence 
analysis of these subtypes identified the stem region of the HA molecule as the likely 
binding site243. In 2008 an antibody designated CR6261 was isolated from a healthy, 
vaccinated volunteer which showed cross-neutralising activity against multiple HA 
types including several HA5 types (from avian H5N1) to which the individual had not 
previously been exposed244. Importantly, these antibodies were neutralizing both in 
vitro and in vivo, rescuing mice when given up to 5 days after lethal challenge with 
either H1N1 or H5N1 influenza. This pivotal nature of this study became evident with 
the subsequent elucidation of the epitope target of CR6261 - a portion of the HA stem 
highly conserved within the two major groups of the 16 HA subtypes.  
 
Several studies have since identified similar monoclonal antibodies in individuals that 
recognize this region, including the important observation that broadly cross-
neutralising (BCN) anti-HA stem antibodies dominated the B-cell response in nine 
individuals infected with the 2009 pandemic SOH1N1245246. One study has isolated a 
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monoclonal antibody by high-throughput screening of human plasma cells (using a 
novel single-cell culture method) from individuals recently vaccinated with the 
seasonal influenza vaccine which cross-neutralises group 1 and 2 HA subtypes and 
confers protection against influenza in mice and ferrets by passive transfer247. It has 
also been shown that BCN antibodies specific to the HA stem region are readily 
generated in mice and non-human primates, particularly by DNA/viral vector prime-
boost combinations248. The recent multiple successes in identifying anti-HA stalk 
antibody clones from phage libraries may be explained by the increased sensitivity of 
detecting these by novel high-throughput techniques and use of trimeric recombinant 
HA for capture249. 
However, despite demonstration of neutralization activity in vitro and in vivo, BCN 
antibodies consistently fail to confer sterile immunity against influenza, even at high 
doses. In all the above-mentioned studies using vaccination to generate BCN 
neutralising anti-HA stalk Ab or using passive transfer of cross-reactive anti-HA stem 
mAb, mice suffer weight loss after inoculation (albeit less severe than controls). This is 
at odds with a mechanism of action that blocks viral fusion with target cells and 
confers sterile immunity. It is conceivable that the inhibition of the HA hinge 
mechanism in the HA stem region which prevents fusion is less efficient than antibody-
mediated blockade of the receptor-binding region of the HA head. Indeed, 
neutralization assays against pseudtoyped virons reveal the doses of mAb required to 
achieve 100% neutralization are several orders of magnitude greater than seen in a 
typical neutralization assay employing mAb directed at the HA receptor binding region. 
This lower neutralisation efficiency may be compounded by the fact that titres of these 
antibodies are typically low, either in response to infection or vaccination. Taken 
together, these may explain why the apparent ease with which BCN antibodies are 
generated by seasonal vaccination or infection does not translate into subsequent 
protection. 
Finding a means to enhance the titres of these antibodies to protective levels through 
vaccination is currently the focus of much effort. The low titres seen after infection or 
seasonal influenza vaccination may be a consequence of the immunodominant B-cell 
response to the HA receptor binding head which is more exposed than the HA stalk 
region249. Attempts to generate an immunodominant B-cell response against the HA 
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stalk through vaccination with a recombinant truncated “headless” HA have generated 
cross-neutralizing antibodies but have not conclusively shown these bind to the HA 
stem region. Vaccination did confer improved survival in mice but, as in previous 
experiments, did not confer sterile immunity250. DNA/adenovector prime boost 
combinations appear to enhance titres of cross-neutralizing anti-HA stem antibodies, 
but again these fall short of conferring sterile immunity against heterosubtypic 
challenge.  
The current efforts to develop anti-HA stem BCN for universal protection may benefit 
from insights gained from previous attempts to develop antibody responses against 
conserved B-cell epitopes on the virion surface. Much attention has previously focused 
on the M2 glycoprotein as a potential trigger for antibody-mediated heterosubtypic 
immunity since it has an ectodomain exposed on the surface of the influenza virion 
(M2e) and is highly conserved. However, generation of anti-M2e antibodies by 
vaccination has been impeded by poor B cell responses to M2e peptide (unless fused 
to a more immunogenic antigen) and antibody titres in humans and animals are very 
low after influenza A infection251252. Treanor et al was the first to show that passive 
transfer of an anti-M2e monoclonal antibody accelerated influenza clearance following 
sublethal challenge253. There have been subsequent successful attempts to enhance 
anti-M2e antibody generation in mice with consistent demonstration of enhanced 
protection against lethal influenza challenge254–258. In human trials, Sanofi Pasteur 
Biologics Co reported after a Phase I trial that a recombinant vaccine consisting of M2e 
fused with hepatitis B core (HBc) – designated ACAM-FLU-A – was safe, well-tolerated 
and generated high titres of anti-M2e antibodies. This formulation was also shown to 
confer 70% protection in ferrets against lethal H5N1 (Vietnam 2004). However, the 
results have yet to be formally published some 4 years after these announcements.  
There are significant parallels with the recent investigation of anti-HA stem BCN 
antibodies. Anti-M2e antibodies were been reported to demonstrate neutralizing 
activity in vitro, for example slowing the infection rate of cultured Madin-Derby canine 
kidney (MDCK) cells259, and yet in all in vivo experiments immunity was non-sterilising, 
with shortened duration and severity of disease but no prevention. As with the target 
of anti-HA stem BCN, this may be because the M2e ectodomain is less accessible to 
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antibody shielded by the more extensive ectodomains of HA and NA, making virus 
neutralization inefficient.  
Recent experiments have shed light on the protective mechanism of action of anti-
M2e antibodies. M2e is expressed abundantly on the surface of infected cells in a 
manner accessible to antibody, and it has been proposed that this may mediate 
cytotoxic killing by natural killer (NK) cells engaging with the Fc domain of bound 
antibody260, although others have found that depletion of NK cells has a limited impact 
on the protection conferred by anti-M2e antibody261. Complement mediated killing of 
infected cells opsonised by anti-M2e antibody also appears to be minimal. However, 
the depletion of alveolar macrophages appears to completely abrogate the protection 
conferred by anti-M2e antibodies against influenza infection, suggesting that 
enhanced phagocytosis of virions (or infected cells) by innate immune cells may play a 
crucial role in limiting the course of infection262. This may occur by a number of 
mechanisms, including reducing the pool of infectious virus, enhancing innate Type I 
IFN responses and increasing T cell responses through enhanced cross presentation of 
phagocytosed antigen. The dependence of the protectiveness of anti-M2e antibodies 
upon innate cellular responses has been further confirmed by the observation that 
anti-M2e antibodies confer no benefit in Fc receptor knock-out mice262.  
Similar findings have been observed with the protective efficacy of antibodies against 
influenza NP, which is highly conserved (>90%) between all influenza A strains263. 
Mechanistically, antibody response against an internal virion target cannot be 
neutralising, and yet passive transfer of anti-NP antibodies has been consistently 
shown to mediate infection-permissive protection against influenza A264–266267,. Like 
anti-M2e mediated protection, this protection appears to be dependent upon Fc 
receptor expression by innate immune cells, as demonstrated by its attenuation in FcR 
deficient mice. Furthermore, the absence of CD8+ T cells removes any survival benefit 
conferred by anti-NP antibodies, supporting the notion that the non-neutralising 
antibodies enhance viral clearance by boosting innate and cellular adaptive 
repsonses268.  
It is noteworthy that the role of FcR or T cell dependent mechanisms have yet to be 
investigated in the context of BCN antibodies directed against the HA stem, yet the 
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pattern of infection-permissive protection strongly suggests they may enhance 
immunity by a similar mechanism to anti M2e or anti-NP antibodies.  
 
The T cell response to influenza and lung injury 
 
T cell effector mechanisms appear to have different roles in viral clearance and lung 
injury raising the tantalizing prospect that specific manipulation of the immune 
response might enhance the former and minimise the latter. CD8+ T cells clear virally-
infected cells by Fas ligand (FasL) or perforin-dependent mechanisms yet there is little 
evidence that this cytotoxic effector function drives parenchymal damage. This is also 
the case in experimental RSV infection wherein FasL and perforin seem dispensable for 
histopathological change269. CD8+ T cell derived inteferon γ (IFNγ ) and tumour 
necrosis factor α (TNFα) appear to play a prominent role in lung injury but the 
clearance of influenza is only marginally impaired in their absence11,12. TNFα is a key 
mediator of lung injury in influenza infection and one study has shown CD8+ T cell 
derived TNFα to be the principal driver of inflammation in a model of inducible 
alveolar antigen expression. In this model, immunopathology is initiated by TNFα-
dependent stimulation of chemokine secretion by epithelial cells and subsequent 
inflammatory cell recruitment, rather than by TNFα-induced cell death. IFNγ has a less 
clear role in lung injury, with some studies reporting that milder injury occurs with 
transfer of IFNγ deficient CD8+ T cells to a host expressing transgenic antigen in distal 
airways. Others, however, have reported enhanced injury in live influenza infection in 
the presence of IFNγ-deficient T cells. Taken together, these studies suggest whilst 
IFNγ is capable of inducing inflammatory damage, an effective IFNγ response 
ultimately mitigates associated inflammation and immunopathology by the rapid 
control of viral replication and inhibition of alternative immune cell recruitment such 
as eosinophils270. 
 
The degree to which different T cell subset responses can negatively influence the 
clinical outcome of influenza is highly relevant to vaccine design. This is underlined by 
the RSV vaccine trails in the 1960s mentioned above, in which increased morbidity and 
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mortality was observed in vaccinated subjects following infection. Vaccination had 
primed excessive CD4+ TH2 responses and eosinophilic influx on secondary challenge7. 
This was later attributed to a portion of the RSV attachment G-protein that induced 
potent CD4+TH2 responses; following its removal, vaccination could generate T cell 
mediated protection without eosinophilia. Deleterious consequences of CD4+ TH-2 
responses in lung injury have been consistently demonstrated in mouse models. 
Intravenous adoptive transfer of influenza-specific CD4+ TH-1 T cells promotes viral 
clearance upon influenza challenge of mice, whilst TH-2 transfer enhanced lung 
pathology without accelerating viral clearance271. Similarly, IL-4- and IL-10-secreting 
CD4+ T cell responses potentiate lung injury and airway hypersensitivity in influenza 
infection of mice without enhancing viral clearance or protection272. In humans, high 
numbers of circulating virus-specific CD4+ T specific to NP and M1 during early 
influenza infection are associated with subsequent severity. Also, strong and early 
CD4+ TH-17 responses have been associated with a more severe illness in hospitalized 
patients during the recent SO H1N1 pandemic105. This has also been demonstrated in 
knockout mouse models, wherein IL-17 has been shown to be essential for lung injury, 
weight loss and neutrophil infiltration but dispensable for viral clearance273,274.  
 
1.4.4 Memory T cell responses to influenza  
 
Memory T cells are typically divided into central and effector subsets based on their 
homing properties275–277. Central memory T cells express CD62L and CCR7 which 
directs their recirculation through lymphoid organs and do not have instant effector 
function on encounter with antigen278 but rather expand rapidly and differentiate to 
supply the effector T cell population. These effector T cells express low CD62L and 
CCR7 and are found in non-lymphoid tissues where they respond rapidly to antigen 
encounter with cytotoxicity or cytokine secretion.  
 
Not long after these distinct subsets were characterised, there were attempts to 
determine their relative contribution to secondary responses in the lung. It has been 
known since the 1970s that during the secondary response to a heterologous strain, 
memory cytotoxic T cells appear in appreciable numbers in the lung much earlier after 
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exposure than in naïve mice279.The availability of tetramers for labelling of antigen-
specific T cells in the late 1990s permitted more precise tracking of influenza-specific 
CD8+memory T cells and their subsets during primary and secondary influenza 
infection280. This led to two unexpected findings. The first was that the anatomical 
head-start afforded by cognate T cell immunity was considerable, with large numbers 
of antigen-specific CD8+T cells appearing in the lung around 3 days sooner in mice 
previously exposed to a heterologous subtype versus naïve counterparts. The second 
finding challenged the classical paradigm of central memory T cells residing in 
secondary lymphoid organs (spleen and draining lymph nodes) until being recalled and 
expanded at the site of infection where they differentiate into effector T cells. Instead, 
very large numbers of CD8+ memory T cells were found to reside in the lung 
parenchyma. Their distribution within the lung was not only within bronchus 
associated lymphoid tissue (BALT) or nasal-associated lymphoid tissue (NALT) but also 
in inducible regions of lymphoid aggregates arising in the perivascular or interstitial 
areas281. Some estimate as many as 40000 antigen specific T cells can be recovered 1 
month after influenza infection of in mice within the airways themselves, an area 
previously regarded as hostile to T cells due to the presence of surfactant and 
proximity of the external environment282,283. Importantly, CD8+T cells in both the 
airways and parenchyma have an effector phenotype and are able to respond more 
rapidly to secondary infection than their splenic or lymphoid tissue counterparts, 
consistent with their higher expression of activation markers (CD62LLO, CD25+, CD69+). 
Those T cells with the highest activated proportion (70-80%) were retrieved from the 
airways by broncho-alveolar lavage (BAL), with a progressive decline in this proportion 
observed through lung parenchymal T cells (50%), mediastinal lymph nodes (20%), and 
spleen (15%)284. Comparatively little is known about antigen-specific CD4+memory T 
cells in the airways although these have also been reported to persist in the lung 
airways after infection285 albeit at much lower frequencies than CD8+ T cells.  
 
These observations have coincided with the revelation that the differences in 
expandability and function between central and effector memory were not as distinct 
as first described237,286. Non-proliferating effector T cells in the lung airways may have 
a key role in early responses to heterologous influenza challenge287 since they are able 
to respond to very low viral loads with rapid cytokine secretion but, curiously, minimal 
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cytolytic potential288. The latter may be attributable to lower expression of leukocyte 
function-associated antigen-1 (LFA-1), an integrin key to T cell-target cell adhesion. 
Interestingly, the proliferative capacity of airway memory T cells is recovered by their 
extraction in BAL suggesting alveolar macrophages or surfactant may actively suppress 
this function. Importantly, effector memory cells in the lung parenchyma have been 
shown to retain their ability to proliferate in response to influenza infection289290. 
These cells have high lymphocyte function-associated antigen 1 (LFA-1) expression, 
cytokine secretion and cytolytic activity. Central memory phenotype CD8+ T cells also 
reside within the lung parenchyma either in loose lymphoid aggregates or in more 
organized BALT and nasal associated lymphoid tissue (NALT) regions. These structures 
lack afferent lymphatics and instead are in direct contact with the lung epithelium 
allowing them to respond rapidly to infection.  
 
Following the discovery of large, lung-resident populations of T cells after influenza 
infection it was shown that both spleen or mediastinal lymph nodes can be removed 
without detriment to the size, speed or efficacy of the response to subsequent 
heterosubtypic challenge291–293. Also, if T cell immunity was generated by 
intraperitoneal or intravenous inoculation of influenza, significant lung-based memory 
T cell populations failed to develop and heterosubtypic protection was much lower 
than that seen with intrapulmonary infection294. Furthermore, adoptive transfer of 
memory T cells by intranasal routes establishes more effective heterosubtypic 
influenza protection than intravenous transfer288. These experiments suggested mixed 
splenic or lymph node central/effector populations are, at least in the short term, 
redundant for effective T cell secondary responses within the lung whilst airway and 
lung-parenchymal memory T cells act as the principal agents of heterosubtypic 
immunity by controlling viral replication soon after inoculation. 
 
During the secondary response, lung- and airway-based T cells are subsequently 
supported by an further influx of effector memory T cells recruited from the 
circulation, peaking in number around day 6295. These cells are non-proliferating and 
their recruitment is not an antigen-specific phenomenon, since intranasal 
administration of TLR agonists will also induce their ingress296. As a consequence, the 
fraction of antigen-specific effector memory T cells in this wave of recruitment is very 
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similar to the proportion of antigen-specific T cells residing in the secondary lymphoid 
organ and circulation. Since the pool of available effector memory T cells in secondary 
lymphoid organs declines with time after the primary infection, the maximum 
achievable peak of this accelerated influx may reduce with time and provide another 
explanation for why heterosubtypic immunity wanes. A third (and final) phase of the 
recall response involves arrival of T-memory cells that have been proliferating in 
response to antigen presentation in the local lymph nodes and spleen. These begin to 
arrive in the airways at day 4 and peak around day 7 (and can be distinguished from 
previous, non-replicating waves by their incorporation of intravenously administered 
BrdU). This wave is analogous to the primary naïve response but occurs more rapidly 
since T-memory cells in the lung parenchyma can proliferate more rapidly in response 
to antigen presentation by epithelial and non-APCs  and without the requirement for 
co-stimulation. 
 
 
Lung-based T cell persistence 
 
The persistence of compartmentalised populations of T cells with different capabilities 
after primary influenza infection raises the question of how these populations are 
maintained. Within secondary lymphoid organs it is well established that memory T 
cell populations are kept at steady-state by homeostatic proliferation under the 
control of IL-7 and IL-15, which replaces cells at a similar rate to which they are lost297–
299. However, the inability of airway CD8+ T cell memory populations to proliferate 
suggests their numbers must be maintained by recruitment from lung parenchyma or 
circulating populations. This is supported by the observation that LFA-1 expression is 
uniformLy down-regulated within 48hrs of adoptive transfer of T cells to the airways 
and yet after primary infection in mice a steady proportion (10-40%) are found to be 
LFA-1 positive up to a year later, implying recent migration into the airway 
compartment. Experiments with Sendai virus in mice have shown that intra-tracheal 
biotinylated populations of airway T cells are progressively diluted by non-biotinylated 
cells with time in the absence of proliferation. Also, intravenously transferred labelled 
memory T cells will appear in the airways within 14 days in normal mice without an 
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infectious stimulus300.  
 
Pro-inflammatory signals from the innate immune system, epithelial and endothelial 
cells after infection in the lung may also play a role in sustaining airway and 
parenchymal T cell recruitment after infection is cleared. CD11c-expressing cells are 
maintained in the lung and display enhanced antigen presentation for several months 
after the resolution of influenza or RSV infection301,302. This may be the consequence of 
IFNγ secretion by γδ T cells recruited late in infection resolution303. Alveolar 
macrophages, which have a prominent immunoregulatory role in the steady-state304, 
are sustained in an activated state following infection by GM-CSF and thought to be 
secreted by both mesenchymal cells and memory T cells after infection305. This 
cytokine also recruits a new population of CD11bHI macrophages which may persist for 
many weeks within the airways306. Epithelial cells also demonstrate prolonged 
alterations after influenza infection, most notably up-regulated TLR3 expression and 
thus a lower threshold for secretion of IL-8, IL-6 and expression of ICAM-1307. There are 
thus multiple mechanisms of “innate imprinting” following infection that may last for 
the lifetime of these cells once activated. This not only enhances the readiness of the 
host for future heterologous infection but may also sustain non-specific recruitment of 
effector T cells long after infection has resolved308.  
 
The limitations of heterosubtypic immunity 
 
Were heterosubtypic immunity to provide complete and lasting cross protection, then 
influenza would quickly cease to circulate in the human and animal population. 
Instead, the numbers of airway and lung-based T cell memory cells starts to wane soon 
after influenza infection, whereas splenic memory T cell populations are preserved at 
high levels indefinitely280. In humans the half-life of anti-influenza CTL activity in 
peripheral blood is thought to be approximately 12 months309 and is undetectable 
three years after infection. Numbers start to fall at around 15 weeks after infection in 
mice. Airway T cells are not highly apoptotic and do not appear to re-enter the 
circulation. Therefore, assuming the rate of their mucociliary clearance remain 
constant, the decline in number can be attributed to reduced recruitment of effector T 
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cells from the lung parenchyma or circulation. Indeed, their decline in number is 
coincident with a dramatic shift from effector to central memory phenotype in 
antigen-specific T cells in secondary lymphoid organs310 which supports the notion that 
lung-based effector memory populations are sustained over the long-term by supply 
from secondary lymphoid organs. It also correlates with the slow decline in innate 
immune and epithelial cell activation in the lung after infection308. 
 
The lung is a fragile tissue adapted for gas exchange which perhaps cannot sustain the 
prolonged presence of mutually sustaining T cell and innate immune cell populations 
deleterious to lung architecture and function. Bronchiectasis and sarcoidosis are 
testament to the potential pathological consequences of chronic and sustained 
parenchymal T cell responses. The declining lung CD8+ T cell memory pool after 
infection may therefore be a an evolved compromise between ameliorating future 
heterosubtypic infection and the risks of long-term airway destruction that accompany 
sustained T cell infiltration.  
 
1.5 Formulating the ideal T cell vaccine against influenza 
 
Taking into account the mechanisms of T cell mediated heterosubtypic immunity and 
lung injury, the ideal characteristics of a T cell vaccine against influenza can be 
formulated as follows:  
 
1. T cell phenotype: Generates cytotoxic CD8+ T cells, TH-1 CD4+ T cells and 
avoids TH-2 CD4+ T cell responses to maximise viral clearance and minimise 
lung injury. 
2. T cell specificity: Generates multispecific T cells against conserved virion 
epitopes to provide cross-strain protection and minimise the risk of T cell 
escape.  
3. Anatomy: Generates a lung-based T cell memory population for early control of 
viral replication. 
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4. Longevity: Generates lasting central memory populations to supply sustained 
lung-resident effector memory T cell populations that are maintained for at 
least the duration of an influenza season. 
5. Clinically applicable: Generates protection rapidly with a simple, acceptable 
and safe vaccination regimen. 
 
No T cell vaccine for influenza has so far achieved the above criteria, although there 
has been substantial progress in each category. These advances are discussed in more 
detail in the introductions to the experiments described below, after a description of 
the molecular and immunological methods used.  
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2 Methods 
 
2.1 Molecular biology techniques 
 
2.1.1 Buffers and media  
 
These are described in Table 2-2. 
 
2.1.2 Polymerase chain reaction (PCR) 
 
PCR reaction mixtures used the GoTaq® Green Master Mix (Promega, Madison, WI) 
and other reagents shown below in Table 2-1. 
Table 2-1 PCR reaction mixtures (top) and cycle parameters (bottom). 
Reactive Stock concentration Volume 
GoTaq® Green Master Mix 2X 25 
Forward Primer 10 µM 2.5 
Reverse Primer 10 µM 2.5 
Water - 15 
DNA Template 20 ng/μL 5 
TOTAL  50 
25-30 cycles were run in a Hybraid thermal cycler, using the parameters shown below 
Phase Time Temperature 
Activation 10 minutes 95º C 
Denaturation 45 seconds 94º C 
Primer annealing 30 seconds 5º C below Tm of primers 
Extension 1 min/kb 72º C 
Final extension 10 min 72º C 
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Table 2-2 Composition of buffers and media  
Buffer/Media Composition pH 
Phosphate-buffered 
saline (PBS) 
137 mM NaCl, 2mM KCl, 10 mM sodium hydrogen 
phosphate (dibasic), 2 mM potassium hydrogen 
phosphate (dibasic), 
 
7.4 
Tris-EDTA buffer (TE) 10 mM Tris.Cl, 1mM EDTA, 
 
8.0 
EB buffer 10 mM Tris.Cl, pH 
 
8.5 
Tris-acetate EDTA 
buffer (TAE) 
40 mM Tris, 20 mM sodium acetate, 1 mM EDTA 
 
7.8 
Transformation 
buffer (TFB)-I 
30 mM potassium acetate, 100 mM rubidium 
chloride, 10 mM calcium chloride, 50 mM magnesium 
chloride, 15% glycerol, acetic acid to desired pH 
 
5.5 
TFB-II 10 mM MOPS, 75 mM calcium chloride, 10 mM 
rubidium chloride, 15% glycerol, KOH to desired pH 
 
6.5 
Luria Bertani agar LB broth plus bacto-agar 15 g/L 
 
7.5 
Luria Bertani broth 1% bacto-tryptone, 0.5% bacto-yeast extract, 10% 
NaCl, pH 7.0 
 
7.5 
6X gel loading buffer 0.25% bromophenol blue, 0.25% xylene cyanol FF, 
30% glycerol in water 
 
6.8 
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2.1.3 Restriction digestions and ligations 
 
Restriction digestions for DNA analysis were incubated for at least 1 hour at 37o C in a 
final volume of 10 µL comprising 1 µL of each restriction enzyme (Promega, Madison, 
WI or New England Biolabs, Ipswich, MA), 1 µL buffer 10X, 2 µL DNA, 5 µL water. For 
isolations of backbone or inserts for ligation, digestions were performed in a total 
volume of 30 µL including 10 µL DNA.  
 
Ligations were incubated overnight at 17º C in the presence of T4 DNA ligase and 
ligation buffer (New England Biolabs, Hitchin, UK) in a final volume of 10 µL (4 µL of 
each DNA fragment, 1 µL T4 DNA ligase, 1 µL buffer 10X). 
 
2.1.4 Agarose gel electrophoresis 
  
DNA was electrophoresed in 1% agarose gels (Invitrogen, Carlsbad, CA) with 5 µg/mL 
ethidium bromide (Dutscher Scientific, Essex, UK) with a 1-Kb Plus DNA size reference 
ladder (Invitrogen, Carlsbad, CA). For DNA purification, DNA fragments were excised 
from the gel and purified using a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions.  
2.1.5 Preparation and transformation of competent bacteria 
 
For transformation, 100 µL competent bacteria (prepared from XL1-Blue E. coli, 
Agilent, Santa Clara, CA, using the rubidium chloride buffers TBF-I and TBF-II) were 
thawed on ice and inoculated with 1 µg of plasmid DNA or 3 µL of ligation reaction. 
After incubation on ice for 20 minutes, the bacteria were heat-shocked for 2 minutes 
at 37º C and returned to ice for a further 2 minutes. Transformed cells (ampicillin 
resistant) were selected in LB agar and ampicillin plates overnight at 37º C.  
2.1.6 DNA purification and quantification 
  
Colonies were picked from LB agar plates and grown at 37º C overnight in 4 mL 
(minipreps), 200 mL (midipreps) or 400 mL (maxipreps) of LB broth with ampicillin (50 
µg/mL). Plasmid DNA was purified with QiaPrep Spin Miniprep, Midi and Maxi kits 
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(Qiagen) following the manufacturer’s instructions. DNA concentrations were 
determined using a Nanodrop 3300 spectrophotometer (Thermoscientific, Wilmington, 
DE). DNA sequences were verified using standard or customised primers at the 
University College London Sequencing service.  
 
2.1.7 Western Blotting 
 
Reagents and antibodies are shown in Table 2-3 and Table 2-4. Cells were lysed with 
1% Igepal (Sigma-Aldrich) solution and re-suspended in LaemmLi buffer before heating 
at 96 º C for 5 minutes. Protein concentrations were measured using a bicinchononic 
acid (BCA) colourimetric assay (Pierce BCA protein assay, ThermoScientific, Rockford, 
IL). After equilibration for concentration, proteins were separated by SDS-PAGE 
electrophoresis in a 4% polyacrylamide stacking gel followed by an 11% polyacrylamide 
separation gel, in SDS running buffer at 150 volts. Proteins were transferred onto 
Hybond ECL nitrocellulose membrane (Amersham GE Healthcare, Buckinghamshire, 
UK) using a semi-dry technique (Biorad, Hercules, CA) in transfer buffer at 300 mA for 
45 minutes. After incubating for 1hr in blocking buffer at room temperature, 
membranes were probed with primary antibody (anti-vFLIP 1:400 in blocking biffer, 
anti-NP, An108, Hytest, Turku, Finland 1:300) at 4 ºC overnight. After washing three 
times with PBS plus 0.1% Tween 20, anti-mouse (or anti-rat) horseradish-peroxidase 
(HRP)-conjugated antibody (DakoCytomation, Glostrup, Denmark) was added diluted 
1:3000 in blocking buffer. After three washes with PBS plus 0.1% Tween 20, blots were 
developed with ECL substrate reagents and Hyperfilm ECL (GE Healthcare, Hatfield, 
UK). 
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Table 2-3 Western blot buffers and gel reagents 
Buffer/gel Composition 
Laemmli buffer 2% sodium duodecylsulphate (SDS), 10% glycerol, 5% 
2-mercaptoethanol, 0.2 mg/mL bromophenol blue, 0.1 
M DTT 50 mM Tris (pH 6.8) 
11% polyacrylamide gel 11% acrylamide/bis, 125 mM Tris.HCl (pH 8.8), 10% 
SDS, 0.1% TEMED, 1% ammonium persulphate (APS) 
4% stacking gel 4% acrylamide/bis, 125 mM Tris.HCl (pH 6.8), 10% 
SDS, 0.1% TEMED, 1% APS 
Running buffer 25 mM Tris (pH 8.5), 200 mM glycine, 0.1% SDS 
Transfer buffer 100 mM Tris, 200 mM glycine, 20% methanol 
Blocking buffer 5% semi-skimmed milk, 0.1% Tween 20 in PBS 
 
Table 2-4 Primary antibodies used in western blots 
2.1.8 Nuclear RelA translocation assay 
 
To confirm that vFLIP expressed in LV activates NFkB in an IKK dependent manner, a 
quantitative confocal microscopy assay, previously developed in the Collins laboratory, 
was used312. 4×105 pre-B cells (see Cell Lines, below) in 2 mL of IMDM (Gibco) with 50 
M 2-mercaptoethanol were transduced with 10 ng RT vFLIP-GFP or Null-GFP to 
achieve 30-40 % transduction. The cells were washed on day 1, and on day 2 cells were 
resuspended in 200 μL Hank’s balanced salt solution (HBSS). 100 μL was applied to a 
poly-L-Lysine coated coverslip (N°1.5, VWR, Lutterworth, UK) and incubated for 15-
30min at 37 ºC. Non-adherent cells were removed and cells fixed with 4% 
paraformaldehyde (Sigma) and stored at 4 ºC before staining. Cells were permeabilised 
Target 
Concentration in 
blocking buffer 
Clone and Maufacturer 
Influenza A NP 1:400 An108, Hytest, Turku, Finland 
vFLIP 1:400 Made in Collins lab311 
HBc 1:200 14e11, Abcam, Cambridge, UK 
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by application of 50 μL 0f 0.2% Triton X in Tris-buffered saline (TBS)(Sigma) for 10 
minutes. After washing in TBS, cells were blocked with TBS 10% goat serum (Sigma) 
0.1% azide for 30 minutes at room temperature. Anti-p65/RelA antibody (clone C-20, 
Santa Cruz Biotechnology) diluted 1:100 in TBS was applied to each coverslip in 50 μL 
and incubated at 4 ºC overnight. Coverslips were washed with TBS and secondary 
antibody (Alexa Fluor® 633-conjugated F(ab′)2 goat anti-rabbit IgG (Invitrogen)) 
applied at 4 μg/mL in 50 μL for 1 hour at room temperature. The next day, cells were 
re-suspended in 3 mL of medium. After washing, coverslips were mounted on glass 
slides (VWR) using mount solution with DAPI (Sigma) and dried for 3 hours.  
A Leica SP2 confocal microscope was used to capture fluorescent images. DAPI, GFP 
and Alexa Fluor AF633 fluorescence was captured using sequential acquisition to give 
separate image files for each frequency, using a pin hole of 1 Airy (114.5 μm), 400 Hz 
scan speed and four-frame averaging. Using photomultiplier tube gain and offset a 
subsaturating fluorescence intensity (based on DAPI signal) with an optimal 
signal:noise ratio was selected. ImageJ software (http://rsb.info.nih.gov/ij) was used to 
create image masks of GFP-, AF633- and DAPI- positive staining. To achieve this 3x3 
pixel radius median filter was applied, followed by automatic thresholding (using the 
IsoData algorithm) for conversion to a binary image. The DAPI staining mask was used 
to define the nuclear region, whilst subtraction of the of the DAPI mask from the 
AF633 image defined the cytoplasmic region. A GFP mask was used to identify 
transduced cells. Each of these staining masks was then applied to AF633 images to 
measure RelA subunit intensity in the nuclei and cytoplasm of transduced and 
untransduced cells within each high-power field. Quantitative fluorescence data were 
exported into Graphpad Prism 5 software for further analysis. Nuclear:cytoplasmic 
ratios of RelA subunit staining were then calculated by comparison of median values 
from total GFP-negative and GFP-positive cells. 
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2.2 Lentiviral vector cloning, production and titration 
2.2.1 Lentiviral transfer plasmids 
 
In these experiments the pDual promoter LV backbone, previously described in 
vaccination experiments by this group, was used162,313–315. This incorporates two 
inserts drive by the spleen focus-forming virus (SFFV) and ubiquitin (UBI) promoters. 
Early experiments confirmed weak expression of GFP from the UBI promoter in human 
DC as reported by others316. This was therefore replaced with the phosphoglycerate 
kinase promoter (PGK)317 for human in vitro experiments. Antigen was expressed from 
the ubiquitin promoter (mouse experiments) and PGK promoter (human experiments), 
whilst molecular adjuvants (vFLIP or 4-1BBL variants) were expressed from the SFFV 
promoter. In experiments where antigen-only expressing LV were required, molecular 
adjuvants at the first promoter were replaced by a 6 base-pair non-coding sequence 
(ACTAGT), designated “null”.  
 
cDNA sources: vFLIP was derived from pDual-vFLIP-iOVA, previously described by Dr 
Helen Rowe314. A pGMT plasmid encoding influenza nucleoprotein derived by reverse 
transcription from X31 virus (identical in sequence to NP from A/PR/8/34) was kindly 
provided by Dr Claire Bennett. In human experiments, adw strain Hbc was used as a 
control for non-antigen specific T cell responses (provided by Dr Mike Whelan (iQur 
Ltd)). 4-1BBL (human and mouse) cDNAs were sourced from Source Bioscience, 
Nottingham, UK. E coli expressing plasmids 4-1BBLH (IRCKp5014E0818Q) and 4-1BBLM 
(IRATp970d03124D) were supplied as stab cultures. cDNA were amplified using the 
primers shown below. 
 
Forward and reverse primers were used to amplify cDNA template plasmids with 
incorporated 5’ BamH1 and Kozak sequence (Forward primer) and 3’ Not1 (reverse 
primer) for insertion into pGMT and (following verification sequencing to exclude 
mutations) subsequent digestion and ligation into the LV backbone at the first 
insertion site. For insertion into the second site, PCR primers incorporating KpnI or 
MLuI (5’) and Xho1 (3’) were used.  
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The truncated version of 4-1BBL(mouse) was created using a forward primer 
containing (5’ to 3’) a BamH1 restriction site sequence, Kosack sequence, start codon 
and a 15bp sequence homologous to base pairs 234-251 of the mus musculus 4-1BBL 
cDNA. This region encodes for 5 amino acids proximal to the transmembrane region of 
4-1BBL. Reverse primers used were identical to those used to amplify 4-1BBL WT. 
 
In order to test the principle that LV transgene expression could be selective silenced 
in AM, a transfer vector was constructed in which a marker transgene cDNA (4-1BBL) 
was continuous with 4 repeats of a target sequence for the haematopoetic-specific 
microRNA, miR-142-3p as previously described318. A template plasmid containing this 
sequence was kindly provided by Dr David Escors (created using overlapping 
oligonucleotides as described by Annoni et al150) and amplified by PCR using primers 
incorporating Not1 (forward) and SBf1) (reverse) in order to digest and insert the 
sequence after the first transgene in the dual promoter backbone. 
 
Sequences of PCR primers used are shown in Table 2-5. 
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Table 2-5. Sequences of oligonucleotides used for PCR amplification of target 
sequences 
Name Sequence 
BamH1-vFLIP-Fw GGATCCGCCACCATGGCCACTTACGAGG 
Not1-vFLIP-RV GCGGCCGCCTATGGTGTATGGCGATAGT 
Kpn1-NP-Fw TGGTACCGCCACCATGGCGTCCCAAGGC 
Mlu1-NP-Fw ACGCGTGCCACCATGGCGTCCCAAGGCA 
Xho1-NP-Rv  CTCGAGTTAATTGTCGTACTCCTCTGCATTG 
EcoR1-PGK-Fw GAATTCCCACGGGGTTGGGGTTGCGCCT 
Mlu1-PGK-Rv ACGCGTCCTGGGGAGAGAGGTCGGTGATTCG 
BamH1-4-1BBLTc-Fw GGATCCGCCACCATGCGCCACCCAAAGCTC 
BamH1-4-1BBLm-Fw GGATCCGCCACCATGGACCAGCACACAC 
Not1-4-1BBLm-Rv GCGGCCGCTCATTCCCATGGGTTGTCGG 
BamH1-4-1BBLH-Fw GGATCCGCCACCATGGAATACGCCTCTG 
Not1-4-1BBLH-Rv GCGGCCGCTTATTCCGACCTCGGTGAAG 
Mlu1-HBc-Fw ACGCGTGCCACCATGGACATTGACCCTT 
Xho1-HBc-Rv CTCGAGCTAACATTGAGATTCCCGAGAT 
Kpn1-GFP-Fw GGTACCACCGGTCGCCACCATGGTGAGCAA 
Xho1-GFP-Rv CTCGAGTTTACTTGTACAGCTCGTCCAT 
Sma1-m1423p-Fw CCCGGGGGCCGCCGACTCCATAAAGT 
Sbf1-m1423p-Rv CCTGCAGGTCGACTCTAGTGTAGTGTTT 
2.2.2 Lentiviral vector production 
 
LV were produced by a 3 plasmid transient transfection of 293T cells using a a transfer 
vector, an HIV-1 derived packaging plasmid (p8.91) and a plasmid encoding the 
vesicular stomatitis virus glycoprotein (VSV-G) (pMD.G), as described previously124 and 
in the introduction. p8.91 and pMD.G were produced by Plasmid Factory (Bielefeld, 
Germany).  
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107 293T cells were plated in 14 cm plates to reach 80-90% confluence the following 
day. Fugene 6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany) was 
used to enhance transfection using the following mix (per plate): 
 
Reagent Quantity 
p8.91   2.5 µg 
pMD.G  2.5 µg 
Transfer plasmid 37.5 µg 
Optimem (Gibco) 500 µL 
Fugene 6 45 µL 
 
The transfection mix was added dropwise to each plate and the medium changed 9 
hours later. The supernatants were collected at 48 and 72 hours and passed through a 
45 µm filter and stored at 4 C until concentration by centrifugation. 
 
LV particles were concentrated 200-fold in 35 mL ultracentrifugation tubes (Beckmann-
coulter) by two rounds of ultracentrifugation (115 000 x g for 2 hours at 4   ºC) in a 
Sorvall ultracentrifuge. UC tubes were filled with a 5 mL 20% sucrose cushion overlaid 
with 30 mL supernatant. Viral pellets were re-suspended in HBSS 10% glycerol and 
frozen at -80º C until use.  
 
2.2.3 LV titration 
 
FACS titration 
 
FACS titration measures numbers of transcriptionally active, integrated transgene 
cassettes and thus encompasses efficiency of transduction as well as gene expression. 
It is thus sensitive to cell-specific factors such as the availability of transcription factors 
for a chosen promoter.  
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To titrate GFP-encoding LV, 2 x 105 293T cells were transduced with 25 µL of serial 1:5 
dilutions of LV stock in 12-well plates. After 3 days, the percentage of GFP-expressing 
cells was determined by FACS. Infectious units per mL were determined from a sample 
in the non-saturated (linear) portion of the saturation curve as follows:  
 
Viral titre (IU/mL) = 2 x 105 cells x % transduction x (dilution factor / 25 µL) x 1000 
 
Reverse transcriptase quantification 
Quantification of RT activity in viral stocks gives an indirect measure of number of viral 
particles, but does not determine the number of functional infectious particles (since 
“empty” particles lacking RNA may be RT active).  
RT activity was measured using a Reverse Transcriptase Assay colorimetric kit (Roche), 
according to the manufacturer’s instructions. Concentrated virus was diluted 1:20-
1:100 and incubated for 3 h for the RT reaction.  
 
2.3 Tissue Culture 
 
2.3.1 Cell lines 
 
293T cells are a hypotriploid immortalised line derived from human embryonic kidney 
cells. They are readily transfected (and transduced by LV) and demonstrate high 
expression of transgenes319 making them ideal for both LV packaging and as target 
cells to test LV transgene expression. 293T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco, Paisley, UK), with 10% Foetal Calf Serum (FCS) 
(Serotec, Oxford, UK), 100 U/mL penicillin, 100 µg/mL streptomycin (Gibco) and 2 mM 
L-glutamine (Gibco). Cells were passaged 1:4 using trypsin/EDTA (Gibco) every 3 days. 
 
MDCK cells were used for titration of influenza virus (see below). These were cultured 
in DMEM with 10% FCS and passaged 1:4 using trypsin/EDTA every 3 days.  
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Pre-B cells were used for the relA translocation assay. These were cultured in Roswell 
Park Memorial Institute (RPMI) Medium (Gibco) with 10% FCS and passaged 1:8 every 
3 days. An IKKγ-deficient mouse pre-B cell line, 1.3E2, derived from wild-type (WT) 
70Z/3 cells, together with 1.3E2 cells reconstituted with WT IKKγ were kindly provided 
by Dr Akira Shiamzu, as described previously320.  
 
2.3.2 Mouse bone marrow-derived dendritic cells 
 
  
Bone marrow-derived DC were extracted using a method modified from Talmor et 
al321. The bone marrow of BALB/c mice was flushed from the femur and tibia with 
Hank’s buffered salt solution (HBSS, Gibco) supplemented with 1% FCS using a 25G 
needle and 5 mL syringe. Red blood cells were lysed with re-suspension in red cell lysis 
buffer ((Sigma) for 5 minutes before washing twice in HBSS 1% FCS an then re-
suspending at 5-7.5 x 105 cells/mL in RPMI supplemented with 10% FCS, 2 mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µM 2-mercaptoethanol 
(Gibco) and 50 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Peprotech, Rocky Hill, NJ). On day 4 non-adherent DC were harvested for use in 
transduction experiments and then cultured in the same media thereafter. 10 ng/RT of 
LV typically gave 50% transduction of 500,000 murine DC as measured by FACS 
expression of GFP.  
 
2.3.3 Human monocyte-derived dendritic cells 
 
60 mL of blood from healthy volunteers were diluted 1:2 in RPMI and peripheral blood 
mononuclear cells (PBMC) isolated by density gradient centrifugation using Ficoll 
Paque PLUS (GE Heatlhcare Life Sciences, Buckinghamshire, UK). CD14+ cells were 
isolated by positive selection using a magnetic-activated cell sorting system (MACS) 
according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). 60 mL of 
whole blood typically yielded 10 million CD14+ cells which were cultured at a density 
of 1x106 cells/mL in an upright flask in X-vivo 15 Media (Lonza, Walkersville, MD) 
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supplemented with 1% human AB serum, (human GM-CSF (Peprotech) and human IL-4 
(Peprotech) both at 50 ng/mL.  
 
2.3.4 Isolation of CD14- human peripheral blood mononuclear cells (PBMC) 
 
Human PBMC were isolated from whole blood by centrifugation over Ficoll (GE 
Healthcare) as described above. PBMC were frozen at 1x107 cells/mL in FCS 10% DMSO 
(Sigma) and stored at -80 ºC until use.  
 
2.4 Mouse Vaccination and Influenza challenge  
Female BALB/c mice, 6-8 weeks old, were purchased from the UK branch of Charles 
River Laboratories (Wilmington, MA) and bred in pathogen-free conditions in an 
animal house facility at the Windeyer building, University College London (and 
Kathleen Lonsdale building after June 2011).  
 
2.4.1 Vaccination 
 
A dose of 50 ng RT was given for subcutaneous vaccination (given into the 
hindquarter). This dose was chosen after early titration experiments established a fall 
in IFNγ+ CD8+ T cell responses against NP by ELIspot below 25 ng RT. 
Intranasal vaccination was performed under ketamine and xylazine anaesthesia (20 
mg/Kg and 2 mg/Kg respectively) by inoculation of 20 μL of viral suspension into each 
nostril. A dose of 200 ng RT per mouse was used, derived from previously published 
data using the same VSV-G pseudotyped LV in mouse models of intranasal LV delivery 
for gene therapy322. 20 μL into each nostril ensured aspiration into distal lung and 
transient tachypnoea lasting 10 minutes.  
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2.4.2 Influenza strains and challenge 
Intranasal challenges with influenza virus were performed in the same way as 
intranasal vaccination. Following challenge, mice were weighed daily from day 3 
onwards. Mice were sacrificed if weight loss exceeded 25% under the terms of the 
corresponding Home Office license. Influenza strains used were mouse-adapted 
A/PR/8/34 (a gift from Dr Mike Whelan, iQur Ltd) and A/Eng/195/09 an H1N1 strain 
from the recent SO H1N1 pandemic that was isolated from a subject with mild 
influenza symptoms (a gift from Prof Wendy Barclay, Imperial). LD50 titration was 
determined by infecting groups of 7 mice with incremental doses of PR8 from 100 – 
10,000 PFU per mouse. A lethal dose of 2xLD50 corresponded to 2500 PFU per mouse 
by plaque assay. A 0.8 xLD50 dose was given to unvaccinated mice in experiments 
investigating the primary T cell response to ensure survival of some mice for the 15 day 
duration of the experiment. A/Eng/195/09 is non-lethal in mice even at high doses. 
A/Eng/195/09 challenges used 5x104 PFU per mouse which was the minimum dose 
that resulted in 10% weight loss in control mice.  
 
2.4.3 Plaque assay  
 
Influenza virus in stocks and lung lysates were titrated by plaque assay (reagents 
shown in Table 2-6). MDCK cells were seeded in 12-well plates to form a confluent 
monolayer and incubated overnight. After washing cells in PBS, virus stock/lung lysate 
was added after serial 10-fold dilutions. Plates were incubated at 33  ºC for 1 hour. 
17.5 mL of Flu overlay (per 12-well plate, see reagent list) was warmed to 37  ºC. 2% 
plaque agarose melted in a 55 ºC water bath and 7.5 mL added to Flu Overlay together 
with 50 μL Trypsin. The inoculum was removed from each well and 1 mL overlay 
added. After agarose had set, plates were inverted and incubated for 3 days to allow 
plaques to form. Plaques were counted after removal of agarose and addition of 
crystal violet stain for 10 minutes.  
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Table 2-6 Reagents for influenza plaque assay 
Buffer/gel Composition/Manufacturer 
Flu Overlay 100 ml 10x MEM (GIBCO), 28 mL 7.5 % BSA (fraction 
V, GIBCO), 10 mL L-Glutamine , 20 mL 7.5 NaHCO2 , 
10 ml 1M HEPES, 5ml 1% dextran, 10 mL 
Penicillin/Streptomycin, 517 mL H20 
 
Trypsin 1 mg/mL (Worhtington, Reading, UK) 
2% Agarose 6g Agarose (Oxoid, Basingstoke, UK) in 200 mL H20 
Crystal violet stain 40ml 1% Crystal violet in water (Sigma) , 80ml 
ethanol, 
300ml H20 
2.5 Immunoanalysis 
 
2.5.1 Cell retrieval  
 
Splenocytes 
Splenocytes were dissected from exsanguinated mice and mashed through 70 μM pore 
strainers (VWR) in 2 mL of HBSS 1% FCS. Splenocytes were washed in HBSS 1% FCS and 
re-suspended in red-cell lysis buffer. Following two further washes splenocytes were 
counted and then either stained and analysed by FACS or stimulated overnight with 
peptide for analysis by ELISpot or intracellular cytokine staining the following day. 
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Lymph nodes 
Lymph nodes were dissected from the inguinal region of exsanguinated mice and 
mashed through 70 μM pore strainers (VWR) in 2mL of HBSS 1% FCS. Following two 
washes cells were counted and analysed by FACS or stimulated overnight with peptide 
for analysis by Elispot or intracellular cytokine staining the following day.  
 
Broncho-alveolar lavage 
Mice were dissected and the trachea exposed. Broncho-alveolar lavage (BAL) was 
performed by instillation and retrieval of 2 mL of HBSS through a 16G Venflon® 
catheter (BD) into the transected trachea. Samples were centrifuged and supernatants 
stored for cytokine analysis. Cells were washed in HBSS and re-suspended in 200 μL 
FACS buffer for staining or media for culture. 
 
Total lung 
Lungs were exsanguinated by cardiac puncture and lymph nodes dissected away after 
removal. After weighing, lungs were mashed through 70 μM pore strainers (VWR) into 
2 mL of HBSS supplemented with 1% FCS. Cell suspensions were layered onto 1.5 mL 
Histopaque® 1083 (Sigma) in 15 mL v-bottomed centrifuge tubes (BD Falcon) and 
centrifuged at 800g in a Sorvall RT legend centrifuge at room temperature with no 
brake. The buffy coat was aspirated and washed twice in media-free RPMI before re-
suspending in RPMI 10% FCS for culture or in PBS for immediate FACS staining.  
 
Blood 
Blood was obtained by cardiac puncture (into heparinised tubes) from mice under non-
recovery anaesthesia. Samples were diluted to a total volume of 2 mL with serum-free 
RPMI and separated over 1.5 mL Histopaque 1083 (Sigma) and processed there forth in 
the same manner as lung samples.  
 
103 
 
 
2.5.2 Enzyme-linked immunospot assay  
 
Enzyme-linked immunospot assay (ELISpot) plates (Millipore, Billerica, MA) were 
covered at 4  ºC overnight with 5 μg/mL of purified anti-IFNγ (BD Pharmingen, San 
Diego, CA). The following day, plates were washed and blocked for 2 hours with RPMI 
medium supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin and 100 
µg/mL streptomycin. Splenocytes were re-suspended in RPMI and 1 x 106 added per 
well. The plate was incubated for 20 hours at 37 ºC, in the presence of class I or class II 
peptide (see Table 2-8).Cells were lysed with water and plates washed with PBS. Plate-
bound IFNγ was determined with serial labelling with 0.5 mg/mL biotinylated anti-IFNγ 
antibody (BD Pharmingen), 1:10000 streptavidin-conjugated alkaline phosphatase 
(Caltag, Burlington CA) and then an Alkaline Phosphatase Conjugate Substrate Kit 
(BioRad, Hercules, CA). An AID ELISPOT counter and software was used to count spots. 
 
2.5.3 Antibody labelling for FACS 
 
All stains were performed in round-bottomed 96-well plates (Helena Biosciences, 
Gateshead, UK). Primary antibody panels used are shown in Table 2-7. If applicable, 
cells were first incubated with 5 μL NP147-155 pentamer-PE in 30 μL PBS (ProImmune, 
Oxford, UK) for 15 minutes at room temperature. Cells were then washed by addition 
of 200 μL PBS per well and centrifugation at 400g for 5 minutes. All subsequent 
staining steps were performed in the presence of a blocking antibody mix consisting of 
rabbit serum, goat serum and rat anti-Fc antibodies. All primary antibodies were 
diluted in PBS (containing blocking mix at a 1:50 dilution) at the specified 
concentration and 50 μL added per well before incubation for 1 hour at 4º C. After 
washing twice with PBS, secondary antibody was added (if applicable) and cells re-
incubated. Otherwise cells were permeabilised using FoxP3 fixation/permeabilisation 
solution (eBioscience, Hatfield, UK) for 20 minutes. Subsequent antibody labelling of 
internal targets was performed in permeabilisation buffer (eBioscience) supplemented 
with Blocking solution at a dilution of 1:50. Permeabilised cells were incubated with 
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antibody for 1 hour before washing and re-suspending in permeabilisation buffer prior 
to analysis.  
All samples were analysed on a BD FACS Calibur (before 2009) or BD LSR 2 or BD 
Fortessa (post-2009), using Cellquest or FACSDiva software respectively. FACS gating 
strategies are shown in Figure 2-1.  
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Figure 2-1 FACS gating strategies. (A) 
Analysis of human PBMC following 10-
day expansion with autologous LV-
transduced DC and overnight NP 
peptide stimulation. Example shows 
IFNγ staining after expansion with DC 
transduced with vFLIP-NP (see Figure 
9C) (B) Gating of LV-transduced BALB/c 
DC by GFP positivity (see Figure 3A) (C) 
Quantification of CD19-, CD8+, NP147-155 
pentamer+ T cells in lung homogenate 
(See Figure 4) in (i) SC-IN vFLIP-NP 
immunised mouse (ii) unimmunised 
control (iii) splenocytes gated in the 
same way stained with NP147-155 
pentamer and (iv) irrelevant OVA 
pentamer (D) Intracellular cytokine 
staining in T cells from lung 
homogenate. Example shown is IFNγ 
staining of CD8 T cells from lung 
homogenate day 6 post lethal influenza 
challenge in vFLIP-NP SCx2 immunised 
mice after overnight NP peptide re-
stimulation (i) and unstimulated (ii). 
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Table 2-7 FACS antibody panels 
Panel  Anti-Mouse Antibody Clone Company Dilution 
Pentamer 
quantification 
with homing 
phenotype 
Ex
tr
ac
el
lu
la
r 
CD19-AlexaFluor®700 1D3 eBioscience 1:200 
NP147-155 Pentamer F098 Proimmune 
5 
μL/well 
CD8-APC  53-6.7 
 
eBioscience 1:200 
CD62L-eFluor® 450 MEL-14 eBioscience 1:200 
CD127-FITC A7R34 eBioscience 1:200 
Pentamer 
cytotoxicity/ 
proliferation 
Ex
tr
ac
el
lu
la
r 
NP147-155 Pentamer F098 Proimmune 1:6 
Fixable viability dye- 
eFluor® 780 
65-0865-18 eBioscience 1:1000 
CD3-PERCP-Cy5.5 17A2 Biolegend 1:200 
CD4-v500 RM4-5 BD 1:100 
CD8-v450 53-6.7 ebioscience 1:150 
In
tr
ac
el
lu
la
r 
GzmB-APC GB11  Invitrogen 1:75 
Ki67-FITC 20Raj1 ebioscience 1:50 
FOXP3- 
AlexaFluor®700 
FJK-16s  eBioscience 1:500 
T cell post-re-
stimulation  
 
 
 
 
 
Ex
tr
ac
el
lu
la
r 
Fixable viability dye- 
eFluor® 780 
65-0865-18 eBioscience 1:1000 
CD3-PERCP-Cy5.5 
17A2 
 
Biolegend 1:200 
CD4-v500 
RM4-5 
 
BD 1:100 
CD8-v450 53-6.7 ebioscience 1:150 
In
tr
ac
el
lu
la
r 
GzmB-APC 
 
GB11  Invitrogen 1:75 
IFNγ-FITC XMG1.2 eBioscience 1:75 
TNFα-PE MP6-XT22 BD 1:75 
IL-2-PE-Cy7 JES6-5H4 eBioscience 1:75 
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DC Activation 
(sample split 
for 6 separate 
stains) 
Ex
tr
ac
el
lu
la
r 
CD11c-APC  N418 eBioscience 1:300 
CD80-PE 1610A1 eBioscience 1:200 
CD86-PE PO3.1 eBioscience 1:200 
ICAM1-PE YN1/1.7.4 eBioscience 1:200 
CD40-PE 1C10 eBioscience 1:200 
MHCII-PE NIMR-4 eBioscience 1:200 
PDL1-PE MIH5 eBioscience 1:200 
DC 4-1BB and 
4-1BBL 
Ex
tr
ac
el
lu
la
r 
CD11c-APC  N418 eBioscience 1:300 
4-1BB-PE 17-B5 eBioscience 1:250 
4-1BBL-Biotin + 
streptavidin-
eFluor450 
TKS-1 eBioscience 1:250 
Alveolar 
macrophage 
Ex
tr
ac
el
lu
la
r 
CD11c-APC  N418 eBioscience 1:300 
F4/80-eFluor450 BM8 eBioscience 1:200 
CD86-PE 
 
PO3.1 eBioscience 1:200 
CD80-Biotin + 
streptavidin-
eFluor605NC 
1610A1 eBioscience 1:200 
 
Panel  Anti-Human Antibody Clone Company Dilution 
T Cell re-
stimulation 
Ex
tr
ac
el
lu
la
r 
Live/Dead fixable stain 
Pacific Blue 
L34957* Invitrogen 1:1000 
CD4-APCCy7 OKT-4 eBioscience 1:200 
CD3-PeCy7 
 
UCHT1 eBioscience 1:300 
CD8-AlexaFluor700 OKT-8 eBioscience 1:200 
In
tr
ac
el
lu
la
r 
TNFα-PE  
MP6-
XT22  
 
eBioscience 1:50 
IFNγ-APC 4S.B3 eBioscience 1:80 
IL2-FITC 
MQ1-
7H12 
eBiosceince 1:70 
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Table 2-8 Peptides used for T cell re-stimulation  
HLA restriction Restriction Sequence 
NP147-155 H2-K
d class I TYQRTRALV 
NP55-78 H2-K
d class II RLIQNSLTIERMVLSAFDERRNKY 
NP 265-274 HLA-A3 class I ILRGSVAHK 
HBc18-27 (control) HLA-A2 class I FLPSDFFPSV 
 
2.5.4 Cytometric Bead Array 
 
In order to measure cytokines in cell culture supernatant, BAL or lung lysate cytometric 
bead arrays (BD) were used according to the manufacturer’s instructions. These kits 
use antibodies against specific cytokines bound to two groups of differently-sized 
beads. Each group contains beads of 5 separate fluorescence intensities, each specific 
for a cytokine. Analyte bound to a bead is detected by a second antibody (PE-
conjugated) and the PE signal is proportionate to the amount of bound analyte. A 
standard curve is generated with provided cytokines of known concentration. All 
samples were analysed in 96 well plates in a BD FACSArray™ bioanalyser. Cytokine 
panels are shown in Table 2-9 below. 
Table 2-9. Cytometric bead array panels 
Panel Cytokine (mouse) 
 
TH-1/TH-2/TH-17 
 
IL-1alpha, IL-2, IL-5 
IL-6, IL-10, TNFα 
IFNγ, IL-17, GM-CSF 
IL-4 
 
T cell chemoattractant 
 
RANTES, MIP-1α 
MIP-1β, IP-10 
MCP-1, MCP-3 
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2.5.5 AM depletion  
 
Depletion of AM was attempted (see results page 162) with clodronate liposomes 
(ordered from clodronateliposomes.org). 40 μL of 5 mg/mL liposome suspension 
(clodronate or PBS control) was administered intranasally to anaesthetised mice as 
described above. The procedure was repeated 2 days later. 4 days after the second 
administration, mice were euthanized and BAL performed. AM were stained and 
quantified by FACS as described above.  
Depletion of AM was also attempted by intranasal administration of diphtheria toxin to 
CD11c-diptheria toxin receptor (DTR) transgenic mice as described by van Rijt et al323. 
CD11c-DTR BL/6 transgenic mice were a kind gift from Dr Claire Bennett. The mice 
express the diphtheria toxin receptor driven by the CD11c promoter, resulting in 
expression in dendritic cells and alveolar macrophages. This permits selective killing of 
these cell types with in vivo administration of diphtheria toxin. 100 ng DT (in 40 μL) 
was administered to anaesthetised mice intranasally. AM numbers were assessed by 
sacrifice and BAL 4 days later.  
 
2.5.6 Adoptive transfer of AM 
 
AMs were transduced in vivo by intranasal administration of LV at 200 ng RT per 
mouse. 2 days later, mice were sacrificed and 2x2 mL BAL performed on each mouse. 
Cells were pooled within vaccination groups, washed and re-suspended in HBSS, and 
transferred intranasally into recipients. 1.5 donor mice were used per recipient. 40 μL 
was left aside from each group for FACS quantification of the total number of AM 
transferred after staining for F4/80 and CD11c. 2 weeks after adoptive transfer mice 
were either sacrificed for analysis (n=3) or challenged with lethal A/PR/8/24 influenza 
(n=5). In initial experiments attempted purification of AM by adherence substantially 
reduced the numbers that could be harvested for transfer. However, the high 
specificity of AM transduction (>99%) by intranasal LV permitted transfer all cells from 
the BAL without sorting or purification. Sufficient AM could be harvested from 5 mice 
to transfer between 10,000-13000 F4/80+CD11c+ cells to each of 3 recipient mice.  
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2.5.7 Human PBMC re-stimulation with autologous LV-transduced monocyte-
derived DC 
 
Human CD14+ cells were isolated from peripheral blood mononuclear cells (PBMCs) 
and cultured as described above. On day 4, non-adherent cells were harvested and 
transduced with LV at 22 ng RT per 100,000 DC in the presence of protamine 10 μg/mL 
at a concentration of 1x106 cells/mL. Control DC were matured with IFNγ 100 IU/mL 
and LPS 100 ng/mL and pulsed with either HLA-matched NP class-I peptide or hepatitis 
B core peptide. Cells were incubated for 3 days in 96-well plates before washing and 
re-suspension in media with addition of thawed CD14- autologous PBMCs. DC and 
PBMC were co-cultured for 10 days, replenishing 50% of the media at day 5. Prior to 
FACS analysis, cells were re-stimulated overnight with the appropriate HLA-matched 
NP peptide in the presence of Brefeldin A 1 μg/mL. PBMC were stained according to 
the antibody panels shown in Table 2-7. 
 
2.6 Statistical analyses  
All data were analysed using the GraphPad Prism v5.0 statistical software package. 
Statistical tests applied to each data set are indicated in the relevant figure legend.  
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3 Systemic vaccination against influenza with lentiviral vectors  
 
3.1 Introduction 
 
3.1.1 DC activation for improved T cell responses to vaccination 
 
DC are potent antigen presenting cells - as few as 300 antigen-pulsed DC are required 
to generate proliferative responses in several million T cells324. Exploiting this ability to 
stimulate T cell responses against infection and cancer has been a major focus of 
immunotherapy research for several decades. A key early finding in such work was that 
for effective T cell priming, DC had to both present antigen and also undergo 
activation. Activated DC express the co-stimulatory molecules and cytokine signals 
necessary to prime effective T –cell responses (the 3 signal hypothesis). Current 
opinion is that the pattern of co-stimulatory molecules and cytokine production is 
determined by the dominant pathway of DC activation, which in turn is directed by the 
pattern of PRR stimulation by PAMPs or DAMPs. However, there is growing recognition 
of the role of antigen presenting cells in peripheral tolerance; silencing T cell clones 
with self-reactivity that have escaped deletion in the thymus in order to avoid 
autoimmunity. Like immunogenicity, immunotolerance is difficult to generate with 
antigen alone. DC play a central role under steady- state condition in presenting self-
antigens and maintaining tolerance325,326, and can be harnessed to enhance the 
deletion or anergy of T cells specific to a chosen antigen327. DC can also be exploited to 
enhance T regulatory (CD25+Foxp3+) responses and actively suppress autimmunity328. 
Effective vaccines must minimise forms of DC activation that generate co-inhibitory 
signals and thus tolerance, anergy or deletion, since these may impair the immune 
response to subsequent infectious challenge. Suppressing a tolerogenic response 
entirely may be undesirable however, since this is an essential part of resolution of 
inflammation and limitation of collateral tissue damage.  
Stimulating PRRs with synthetic or naturally occurring PAMPS in order to enhance DC 
co-stimulatory molecule expression and therefore T cell responses is a fundamental 
tenet of vaccine and adjuvant design. Viral and gene based vectors provide 
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opportunities to activate DC at multiple levels of signalling between PRR stimulation 
and up-regulation of co-stimulatory molecule expression (Figure 3-1). These range 
from co-encoding antigen with a chosen single co-stimulatory molecule, to direct 
activation of signalling pathways involved in pathways of activation that lead to 
desirable patterns of co-stimulatory molecule expression. The principle advantage of 
DNA or viral vector based vaccines – the endogenous production of antigen and 
efficient class I processing – can thus be supplemented with signals which activate DC 
in a manner that ultimately gives rise to a desirable effector or memory T cell profile.  
Previous work in this laboratory has explored these concepts using lentiviral vectors to 
deliver both antigen and DC-modifying signals with the purpose of manipulating the 
resultant T cell response. Other groups have also shown that LV expressing DC 
activators can enhance T cell responses to antigen. LV expressing GM-CSF and IL-4 
have been used to drive monocyte differentiation into DC and improve autologous 
human CD8+ T cells responses against pulsed antigens329, whilst LV expressing CD40L 
and OX40L have been used to induce self-maturation of DC ex vivo330,331. LV expressing 
HSP 70, which activates TLR 2 and 4 in DC, fused to melanoma antigen (tyrosinase-
related protein-2, TRP2), delivered subcutaneously generated an IFNγ-producing CD8+ 
T cell response associated with anti-tumour immunity in a subcutaneous B16 
melanoma model in mice332.  
One key advantage of using lentiviral vectors in this role is their low intrinsic 
immunogenicity minimises vector-mediated DC activation and permits discrimination 
of the effects of the encoded activator. The integrating nature of LV also permits 
examination of the long-term consequences of persistent expression of the activator 
and antigen by APCs.  
 
3.1.2 Activation of DC can be immunogenic or tolerogenic 
 
Transduction of DC with LV expressing activators or dominant negative inhibitors of 
the signalling pathways (Figure 3-1) can result in diverse patterns of DC activation and 
similarly varied T cell responses to co-encoded antigen. Two major signalling pathways, 
the MAPK and NFκB pathways have been consistently implicated in DC activation. A 
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number of PRRs, both intracellular and membrane-bound, initiate signals which feed 
into these final common pathways. The cytoplasmic tails of TLRs, for example, recruit 
two Toll/IL-1 receptor (TIR) domain containing adaptor molecules after ligand 
engagement: myeloid differentiation factor 88 (Myd88) and TIR domain-containing 
adaptor-inducing IFN-β (TRIF). These form an essential framework to which protein 
kinases and ubiquitin kinases bind and activate MAPK and NFкB pathways333.  
MAPKs can be divided into three groups: the p38 stress-activated protein kinases 
(p38), c-Jun protein kinase (JNK) and extracellular signal regulated kinases (ERK). 
Activation of MAPKs through phosphorylation requires a three-stage kinase cascade 
beginning at the membrane (or endosome membrane) level. Different patterns of 
membrane TLR stimulation combined with other signalling receptors (such as the TNF-
receptor family) will result in differential stimulation of the three final MAPK pathways. 
For example, ERK is activated by TLR recruitment of TNF-receptor associated factor 
(TRAF) 6 and TRAF3 together with tumour progression locus 2 (Tpl2)334. ERK activation 
decreases co-stimulatory molecule expression and increases secretion of 
immunosuppressive cytokines such as TGF-β335 and IL-10336. P38 phosphorylation by 
MAPKKs, MKK3 and MKK6 is dependent upon transforming growth factor B-activated 
kinase (TAK-1) rather than Tpl2 recruitment to the TRAF6/Myd88 complex. This leads 
to DC maturation and expression of co-stimulatory molecules such as CD80, CD86, 
CD83 and CD40337. Similarly, JNK is activated by TLR signals via MKK3, MKK4 and MKK7 
and results in pro-inflammatory cytokine secretion although its role in DC maturation 
is less well-characterised338. 
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Figure 3-1 Pattern recognition receptor signaling pathways in DC and resulting 
patterns of co-stimulatory molecule and cytokine expression. TLR Toll-like receptor, 
LPS lipopolysaccharide, Rac1 Ras-related C3 botulinum toxin substrate 1, PI3K 
Phosphatidylinositide 3-kinases, IKK inhibitor of nuclear factor kappa-B kinase, NFкB 
nuclear factor kappa-B, TAK1 Mitogen-activated protein kinase kinase kinase 7, MKK 
mitogen-activated protein kinase kinase, MyD88 Myeloid differentiation primary 
response gene (88), IRAK Interleukin-1 receptor-associated kinase, TRAF TNF-receptor 
associated factor, TRAM TRIF-related adaptor molecule, TRIF TIR-domain-containing 
adapter-inducing interferon-β, TBK1 TANK-binding kinase-1, ERK extracellular signal-
regulated kinase, JNK c-Jun N-terminal kinase, STAT1 Signal Transducers and Activators 
of Transcription 1, IRF interferon regulatory transcription factor, JAK Janus kinase, PDL-
1 programmed cell death ligand-1, IFN interferon, MIP macrophage inflammatory 
protein, MIG monokine induced by gamma interferon, IP-10 Interferon gamma-
induced protein 10, ITAC Interferon-inducible T cell alpha chemoattractant, RANTES 
Regulated on Activation, Normal T cell Expressed and Secreted. 
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NFкB is a transcription factor activated in DC by several pro-inflammatory stimuli 
including TLR ligands and cytokines. NFкB responsive elements are found in a wide 
range of promoters upstream of genes involved in inflammation339. There are two 
main pathways of activation: classical and alternative. The former is activated through 
TNF-receptor family signalling, TLRs and intracellular PRRs such as melanoma 
differentiation associated factor (MDA) 5, retinoic acid inducible gene (RIG) 1 and 
protein kinase R (PKR)340. These activate the main regulator of NFkB signalling, 
inhibitors of Kappa-B (IκB) Kinase (IKK). This is composed of two catalytic subunits IKKα 
and IKKβ, and a third regulatory subunit IKKγ, also known as NFkB essential modulator 
(NEMO). The NFκB transcription factor consists of homo- and hetero-dimeric 
complexes of 5 subunits: p65/RelA, RelB, c-REl, p50 and p52. The Rel domains bind 
IκBs in the cytoplasm, preventing translocation of the transcription dimers to the 
nucleus. IкBs are phosphorylated by IKK, leading to their degradation by ubiquitination 
and allowing translocation of the p50-RelA heterodimers to the nucleus where they act 
upon NFкB responsive elements in promoters. In the alternative pathway of activation, 
IKKα phosphorylates the NFкB subunit precursor p100, leading to release of the p52 
fragment which translocates to the nucleus as a heterodimer with RelB. This is initiated 
by a number of upstream signalling pathways originating from receptors to 
lymphotoxin-β, CD40L and receptor activator of NFкB ligand (RANKL), which release 
inhibitory ankyrin repeats in the c-terminus of p100341.  
 
By overexpressing or using constitutively activated or dominant negative mutants of 
signalling components of these pathways it is possible to determine their role in 
generating immunogenic or tolerogenic effector function in dendritic cells. This group 
has previously activated the p38, ERK and JNK MAPK pathways using a constitutively 
activated MKK6 (MEKK6), MEK-1 and MKK7-JNK fusion protein respectively. These 
activators typically contain acidic amino acids such as glutamate and aspartate in place 
of the serine/threonine residues in their phosphorylation dependent activation loop. 
Activation of p38 MAPK through transduction with LV expressing a constitutively active 
MKK6 resulted in partial maturation of DC comparable to LPS, a prototypic TLR-4 
stimulator. Specifically, co-stimulatory molecules CD80, CD40 and ICAM-1 were up-
regulated but there was no increase in “3rd signal” cytokines such as IL-12342. Co-
116 
 
expression of an OVA transgene resulted in enhanced T cell responses to the antigen 
and regression of tumours in an OVA-producing tumour mouse model. By contrast, 
activation of JNK produced minimal up-regulation of co-stimulatory molecules and did 
not enhance T cell responses. Activation of ERK in DC, using a dominant negative MEK-
1, resulted in an increase in TGF-β expression and no increase in co-stimulatory 
molecule expression. CD8+ T cell responses to co-encoded antigen (OVA) were 
reduced and a T regulatory population was generated by vaccination which expanded 
substantially on re-exposure to antigen335.  
The targeted activation of NFкB has been used by other groups to enhance DC 
activation and T cell responses. Andreakos et al overexpressed NFкB inducing kinase 
(NIK) in DC using adenoviral vector transduction, resulting in increased CD80, CD86, IL-
12, IL-15 and IL-18 expression. This enhanced T cell responses to co-encoded GFP, both 
in vitro and in vivo343. Others have shown that chromosome 1 open reading frame 190 
(C1orf190) activates the classical NFкB pathway when overexpressed in monocyte 
derived human DC by transfection, resulting in secretion of pro-inflammatory 
cytokines including IL-12p70 and IL-6344. 
An alternative strategy of NFкB activation is to silence its negative regulators leading to 
sustained activation. Small interfering RNA (siRNA)-mediated silencing of A20, a 
negative regulator of NFKB, prevents this molecule from deactivating (by ubiquitin 
editing) components of the TNFR and TLR signalling pathways345. Delivery of siRNA 
using transfection or lentiviral vectors simulated persistent TLR activation of NFкB and 
results in up-regulation of CD80, CD86, CD40, IL-6 and TNFα346. This strategy can be 
used to generate superior anti-tumour CTL and CD4+ T cell responses. However, A20 
silencing also leads to IL-10 up-regulation and potential immunosuppression, and 
inhibition of both A20 and IL-10 was required to stimulate effective melan-A-specific 
CD8+ T cell responses in a mouse melanoma model347.  
The NFкB pathway can be manipulated using non-endogenous viral proteins. We and 
others have previously shown that vFLIP from KSHV is a potent activator of NFκB348–351. 
vFLIP binds to NEMO (IKKγ) inducing a conformational change that leads to IKK 
activation and NFkB activation via the classical pathway350,352. Others have reported 
that vFLIP over-expression also results in up-regulation of p100/NF-kappa B2 
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expression resulting in p52 subunit processing and NFкB activation via the alternative 
pathway353.  
Activation of the NFкB pathway by vFLIP appears to be highly specific. Microarray 
analysis of both endothelial cells and primary effusion lymphoma cell lines (in which 
vFLIP is constitutively expressed) reveal a consistent pattern of up-regulation of only 
those genes with NFкB responsive promoter elements354,355. Since activation occurs far 
downstream in the classical pathway and is independent of NFкB activation by 
cytokine signalling pathways356, TRAF6, TAK1 or linear ubiquitination associated 
complex (LUBAC)357, constitutive expression of vFLIP will result in sustained and 
specific NFкB activation without interference from other signals. Some regulatory 
feedback does occur however from NFкB mediated up-regulation of A20 which in turn 
inhibits IKK activation358. 
Lentiviral vectors expressing vFLIP activate transduced DC and increase expression of 
CD80, CD86, CD40, ICAM-1, TNFα and IL-12 secretion359. Co-expression of vFLIP and 
OVA in a lentiviral vaccine resulted in up to 10-fold greater CD8+ T cell responses than 
observed with LV expressing OVA alone. LV expressing vFLIP-OVA immunised mice 
showed prolonged survival in a OVA-expressing tumour challenge model and a single 
immunisation with vFLIP-OVA reduced parasite counts after subsequent challenge with 
an OVA-expressing leishmaniasis donovani strain124. Expression of vFLIP in a non-
integrating LV vaccine has also been shown to enhance T cell responses against co-
encoded antigen126.  
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3.2 Aims 
 
The varying effects of p38, JNK, ERK and NFкB activation upon DC activation are 
summarised in Figure 3-1. Of these, only NFкB activation appears to increase both co-
stimulatory molecule expression and secretion of pro-inflammatory cytokines. This 
pattern of co-stimulation should favour the generation of effective cytotoxic CD8+ T 
cell responses and TH-1 skewed CD4+ T helper cell responses that are thought to be 
essential in anti-influenza responses.  
 
In the experiments described in this chapter we aimed to test the efficacy of lentiviral 
vectors in generating antigen–specific CD8+ and CD4+ T cell responses against encoded 
Influenza A NP (from A/PR/8/34) as a means of generating cross-strain protective 
immunity against influenza A in mice. We also wished to determine if the vFLIP would 
enhance DC activation and T cell responses in mice, and whether this corresponded to 
enhanced protection against lethal influenza challenge using a model of BALB/c mouse 
infection with A/PR/8/34.  
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3.3 Results 
 
3.3.1 Influenza NP and vFLIP are expressed in 293 T cells and BALB/c DC following 
LV transduction 
 
LV constructs are shown in Figure 3-2A. All mouse vaccination experiments were 
performed with dual promoter lentiviral constructs using spleen forming virus (SFFV) 
promoter driving insert 1 and ubiquitin (UBI) promoter driving insert 2.  
Figure 3-2B shows that transduction of human 293T cells in vitro with varying doses of 
LV expressing influenza NP gave rise to readily detectable 64 kD protein on western 
blot two days later. vFLIP expression was also readily detected in 293T cells after 
transduction. This was also the case in BALB/c bone marrow derived DC confirming 
adequate functioning of the SFFV and ubiquitin promoters in both cell types.  
To demonstrate IKK-dependent NFкB activation by LV expressing vFLIP, WT pre-B cells 
and IKK knock-out pre-B cells (1.3E2) were transduced with lentiviral vectors 
expressing vFLIP-GFP or Null-GFP. RelA nuclear localization was measured using a 
quantitative confocal microscopy assay (see methods page 91). Image analysis was 
used to separate GFP+ and GFP− cells and measurement of nuclear/cytoplasmic ratio 
of RelA staining in individual cells was used as an estimate of RelA nuclear 
translocation356. This showed RelA nuclear translocation in vFLIP transduced WT but 
not IKK KO pre-B cells or pre-B cells transduced with GFP alone (Figure 3-2D).  
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Figure 3-2 (A) Lentiviral vector constructs. (B) Western blot showing dose-dependent 
expression of influenza NP in 293T cells. (C) Confocal assay of nuclear RelA location in 
Pre-B cells transduced with vFLIP-GFP. Arrows indicate GFP+ transduced cells. Left 
panel shows GFP signal. Right panel shows RelA distribution staining. (D) Analysis of 
RelA staining in nuclear:cytoplasmic region ratios (see methods page 91). 70Z/3 are 
wild-type pre-B cells. 1.3 E2 cells are IKKγ knock-out pre-B cells. Green shapes indicate 
GFP-transduced cells. Cells were transduced at an MOI of approximately 0.5 with 
vFLIP-GFP (circles) or Null-GFP (triangles). Data from one experimental set are shown. 
Mean values for nuclear:cytoplasmic RelA ratios from three independent repeats were 
compared with a Students T test (significance level indicated above brackets). A 
significant increase in nuclear:cytoplasmic RelA ratios was seen in vFLIP-transduced, 
IKKγ+ cells only. 
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3.3.2 Co-stimulatory molecule expression in BALB/c DC is increased by vFLIP 
 
We aimed to corroborate the results of Rowe et al in BALB/c DC using a panel of six 
markers of DC activation (CD80, CD86, CD40, ICAM-1, PDL-1, MHC II). A minimum of 6 
independent experiments using BM derived DC poled from 2 mice was used on each 
occasion to reach a quantitative estimate of the fold increase induced in each marker. 
Transduction of BALB/c DC with LV expressing vFLIP-GFP resulted in significant up-
regulation of co-stimulatory molecules, programmed cell death ligand-1 (PDL-1) and 
MHC II compared with un-transduced DC (Figure 3-3). In nearly all cases (with the 
exception of PDL-1) up-regulation induced by vFLIP was not significantly different from 
that induced by LPS. Transduction with LV expressing GFP alone resulted in 
significantly less co-stimulatory molecule up-regulation.  
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Where expression was bimodal (CD86, CD40, ICAM-1, MHC II), % of positive DC were compared with untransduced populations. Significance levels 
are indicated by stars over where the factor of increase was significantly greater than 1 (i.e. no increase). No significant difference in co-stimulatory 
molecule expression was observed between LPS matured DC and vFLIP-GFP transduced populations. The data shown is from 6 independent repeats 
using BM-derived DC pooled from 2 mice on each occasion. 
Figure 3-3 (A) Gating 
strategy of BM-derived 
DC analysed on day 4 
after transduction with 
vFLIP-GFP or Null-GFP. 
LPS treated or 
untransduced DC were 
gated on CD11c alone. 
(B) Fold increase of 
expression (note 
exponential scale) of co-
stimulatory (and PDL-1) 
molecules on DC after 
transduction or LPS 
treatment. The fold 
increase in expression 
was calculated from the 
MFI of 
transduced/treated DC 
divided by that of 
untransduced DC in the 
same experimental set.  
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3.3.3 vFLIP enhances functional CD8+ and TH-1 CD4+ T cell responses to influenza 
NP in BALB/c mice  
 
A dose of 50 ng RT was given for subcutaneous (SC) vaccination following titration 
experiments which established a fall in CD8+ T cell responses below 25ng RT by ELIspot 
(data not shown). CD4+ and CD8+ T cell responses to SC vaccination were measured 14 
days later by IFNγ ELIspot or intracellular cytokine staining for IFNγ and TNFα following 
overnight incubation with class II restricted (NP57-78) or class I (NP147-155) peptide 
respectively. Figure 3-4B shows significantly greater numbers of IFNγ+ CD8+ T cells 
generated by vaccination with vFLIP-NP compared with Null-NP, as measured by both 
ELISpot and intracellular cytokine staining.  
NP-specific CD8+ T cells were quantified by pentamer without overnight re-
stimulation. This revealed a trend towards greater numbers of NP-specific CD8+ T cells 
in the vFLIP-NP versus Null-NP group, but this did not reach significance (Figure 3-4C). 
No differences were found in IL-7R expression or CD62L (data not shown). Pentamer 
positive CD8+ T cells were also stained for granzyme B (GzmB) and Ki67 after re-
stimulation, which indicated greater on-going proliferation and cytotoxic potential in 
NP-specific CD8+ T cells 14 days after vaccination (Figure 3-4C).  
Homologous dual vaccination 14 days apart resulted in neither increased numbers of 
pentamer positive CD8+ T cells nor IFNγ positive splenocytes on re-stimulation in vitro. 
However, a greater proportion of effector memory CD62LLO T cells was observed in the 
spleen 2 weeks after final vaccination with dual vaccination with vFLIP compared with 
a single dose (Figure 3-5). A significant difference in CD62L expression between dual 
and single Null-NP vaccinated mice was not observed.  
Although numbers of IFNγ+ or TNFα + CD4+ T cells were lower than CD8+ T cells after 
vaccination, a significant difference was observed between vaccination with vFLIP-NP 
and Null-NP (Figure 3-6A). A small population of GzmB + CD4+ T cells was identified in 
mice vaccinated with vFLIP-NP but not Null-NP. To determine the TH-1 versus TH-2 
response of mice to vaccination, splenocytes were harvested at day 14 and incubated 
in media for a further 4 days with the class II restricted NP57-78 peptide. Supernatants 
were then analysed by cytokine bead array. Splenocytes from mice vaccinated with 
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vFLIP-NP and re-stimulated with NP57-78 peptide produced comparable quantities of 
TNFα and IFNγ to splenocytes from unvaccinated mice stimulated with ConA (Figure 
3-6B). The IFNγ:IL-4 ratio in vFLIP-NP supernatants was also significantly greater than 
in Null-NP after vaccination (mean 3.564 versus 1.04, p=0.02) indicating a skewing of 
the T-helper response towards a TH-1 phenotype with vFLIP. Dual vaccination 14 days 
apart showed similar results in CD4+ T cell responses 14 days after the last vaccination 
(not shown). 
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Figure 3-4 CD8+ T cell responses after vaccination with LV according to the schedule 
shown in (A). (B) IFNγ ELISpot and intrancellular staining for IFNγ and GzmB after re-
stimulation overnight with NP147-155 class I restricted peptide. Unstimulated populations 
are superimposed with clear bars. (C) NP pentamer+ CD8+ T cells analysed for GzmB 
and Ki67 expression.  
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Figure 3-5 (A) NP147-155 pentamer percentages of total CD8+ T cells after single and dual 
vaccination with vFLIP-NP or Null-NP according to the schedule in (C). (B) % CD62LLO 
(effector phenotype) NP pentamer+ CD8+ T cells after single or dual LV vaccination.  
A 
B C 
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Figure 3-6 CD4+ T cell responses after LV vaccination. (A) ELISpot and IFNγ and GzmB 
expression analysis by FACS after overnight re-stimulation with class II restricted NP 
peptide. Unstimulated populations are superimposed with clear bars. (B) 
Concentrations of IFNγ and TNFα in supernatant of splenocytes re-stimulated with 
class II restricted peptide for 4 days as described in the methods.   
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3.3.4 LV encoding NP confer protection against lethal A/PR/8/34 challenge. 
 
To determine whether the superior CD8+ and CD4+ T cell responses induced by vFLIP-
NP versus Null-NP conferred greater protection against live influenza challenge, groups 
of mice (minimum n=16) were vaccinated with either single subcutaneous injections of 
50 ng RT of LV or two vaccinations two weeks apart. Mice were challenged 2 weeks 
later with an intranasal 2xLD50 dose of mouse-adapted A/PR/8/34 (corresponding to 
2500 PFU) and weights and clinical sign scores recorded from day 3 onwards. Mice 
losing more than 25% of weight were deemed irrecoverable and euthanized under the 
terms of our Home Office animal license. Monitoring finished when all surviving mice 
had regained baseline weight.  
Mice vaccinated with vFLIP-NP demonstrated significantly greater survival than mice 
vaccinated with Null-NP (81.2% vs. 12.5% for dual vaccination regimens, p<0.001, 
53.8% vs. 11.11% for single vaccination, p=0.009, Mantel-Cox test). Dual vaccination 
with vFLIP-NP appeared to confer superior protection although this did not reach 
significance. All unvaccinated mice had died or fallen below 75% baseline weight by 
day 9.  
Despite the survival benefit of vFLIP-NP vaccination weight loss was still considerable, 
with a mean maximum weight loss of 17% at day 6. Mice also developed clear signs of 
infection including tachypnoea, piloerection and hunched posture. Clinical signs of 
infection resolved rapidly after day 6, with mice also recovering weight at around 1 g 
per day. 
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Figure 3-7 Survival and weight loss in surviving mice following single (A) or dual (B) 
vaccination with vFLIP-NP or Null-NP. All mice were challenged with a lethal dose of 
A/PR/8/34 and weights monitored from day 3. Mice losing more than 25% of baseline 
rate were deemed irrecoverable and sacrificed. Both Mantel-Cox tests and Gehan-
Breslow-Wilcoxon Test produced similar p-values for observed differences in survival. 
B A 
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3.4 Summary  
 
LV expressing vFLIP activate NFкB in an IKK-dependent manner and activate DC to an 
equivalent degree as LPS. LV expressing NP are capable of generating CD8+ and CD4+ T 
cells against the encoded antigen after SC administration. Numbers of antigen-specific 
CD8+ T cells were not increased by co-expression of vFLIP, but numbers of functional 
CD8+ T cells, as measured by IFNγ secretion or GzmB expression after re-stimulation 
were significantly increased. vFLIP also skewed the CD4+ T cell response towards a TH-
1 phenotype. These differences corresponded to greater protection against lethal 
challenge with A/PR/8/34 in vFLIP-NP versus Null-NP vaccinated mice. Vaccinated and 
unvaccinated mice were clinically indistinguishable until day 5-6 when vaccinated 
survivors began to rapidly recover weight.  
 
3.5 Discussion 
 
LV have been previously shown to induce cellular immunity against numerous antigen 
targets (Table 1-3, page 51). LV vaccines shave been effective in generating antibody 
responses against West Nile Virus envelope protein130 and HIV gp120108 and cellular 
responses against HIV360, SIV361 GAG and a leishmaniasis strain expressing OVA359. One 
study has demonstrated reduction in SIV titres following challenge of macaques with 
SIV, following vaccination with LV expressing SIV GAG, when used in a homologous 
prime-boost regimen362.  
Prior to this study, however, the ability of an LV vaccine to generate protective T cell 
responses against an acute viral infection had not been tested. A/PR/8/34 is a mouse-
adapted influenza strain with high pathogenicity which provides a robust test of T cell 
mediated protection. vFLIP-NP vaccination compares favourably with previously 
described means of generating T cell mediated protection against this strain of 
influenza in mice as summarised in Table 3-1 below. Notwithstanding the factors 
described in the introduction that make inter-experimental comparisons difficult in 
this field, an analysis restricted to studies using NP as a target antigen, BALB/c mice 
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and a A/PR/8/34 challenge reveals that the degree of survival correlates negatively 
with challenge dose by LD50 (Figure 3-8). It is unclear whether this is a linear or 
negative exponential correlation, but all experiments using a challenge greater than 5x 
LD50 reported very low or no survival. This underlies an important limitation in 
protection mediated by systemic T cell vaccines, in that it can be readily overwhelmed 
by high challenge doses. Another consistent finding is despite the highly variable 
degrees of weight loss observed in these studies, the time point at which the nadir of 
weight is reached is remarkably constant at 6.7 ± 0.8 days (μ ± 95% CI). Therefore, 
irrespective of the size of the T cell response generated by vaccination, there appears to 
be at least a 5-day window after infection wherein systemic T cell immunity has little 
bearing on the development of clinical disease.  
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Figure 3-8 Summary of survival rates and timing of nadir of weight loss in vaccination 
experiments described in Table 3-1 that use influenza NP as a target antigen and 
A/PR/8/34 challenge. The green circle indicates survival and timing of maximal weight 
loss after vFLIP-NP SC vaccination. 
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Table 3-1. Summary of mouse vaccination experiments using DNA or viral vectors expressing influenza NP 
Reference Antigen Vaccine 
modality 
Mouse 
species 
Challenge virus/ 
Dose 
Survival Minimum 
weight 
loss 
Nadir of 
weight 
loss 
(day)  
Main findings 
 
Fu et al 1997363 NP 
NPmut 
DNA BALB/c A/HK/68 
(H3N2)/10xLD50  
100%  
 
Not 
measured 
N/A DNA immunisation with mutated 
dominant NP epitopes still capable of 
inducing protective CD8 immunity.  
Fu et al 1999364 NP DNA (varying 
doses) 
BALB/c H3N2 A/HK/68 1xLD70 
H1N1 A/PR/8/34/ 1 
xLD70 
100% 20% 7 Protection and T cell response is dose-
dependent 
Ulmer et al 
1998365 
NP DNA BALB/c H3N2 (A/HK/68) 
1xLD50 
100% 20% 6 Protection reduced to 50% with CD8+ T 
cell depletion 
Robinson et al 
1997366 
NP DNA BALB/c H1N1 
PR/8/34 
10xLD50 
0%  Not 
measured 
N/A High challenge dose of high 
pathogenicity virus results in no 
detectable protection 
Chen et al 
1999
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NP DNA BALB/c 
B10 
C3H 
H1N1 
PR/8/34 
40xLD50 
 
BALB/c 10% 
B10 0% 
C3h 15% 
26.7 (day 
7) 
26.4(day 
7) 
25.2(day 
7) 
N/A NP-DNA fails to confer protection in 
context of a high challenge dose of 
mouse-adapted influenza 
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Chen et al 
1998368 
 
NP DNA BALB/c H1N1 
PR/8/34 
40xLD50 
 
0% N/A N/A NP-DNA fails to confer protection in 
context of a high challenge dose of 
mouse-adapted influenza 
Saha et al 
2006369 
 
NP fused 
with HSV 
VP22 
DNA BALB/c A/Udron/72 
5xLD50 
NP 20% 
NP-VP22 80% 
 
25% 
11% 
6 
7 
Tegument protein VP22 enhances T cell 
response against NP and protection. 
CD8+ depletion impairs protection. 
Roy et al 
2007370 
 
NP AdC7 (chimp 
adenovector) 
AdHu5 (human 
adenovector) 
BALB/c H5N1(Vietnam/1203/04 
or Hong Kong/483/97) 
100x LD50 H1N1 
PR/8/3410xLD50 
PR8 90-100% 
Viet04 50-80% 
HK97 20-30% 
Not 
assessed 
N/A Chimp and human adenoviral vectors 
expressing NP give comparable 
protection against lethal challenge 
Tsuji et al 
1998
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NP epitopes Recombinant 
Sindbis virus 
BALB/c H1N1 A/WJN/33 Not assessed Not 
assessed 
N/A Recombinant Sindbis virus generates 
CD8+ T cell responses against 
incorporated NP epitopes 
Laddy et al 
2008372 
NP DNA with 
electoporation 
 H1N1 PR/8/34 
10xLD50 
 
H1N1 -90% 
 
25% 7 Also demonstrated protection in ferrets 
Bender et al 
1998373 
NP DNA BALB/c H3N2 A/HK/68 
103 TCID50 
67% 24% 10 Similar CTL responses in young and aged 
mice but significantly less protection in 
the latter, attributed to non-CTL factors.  
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Ulmer et al 
1994374 
NP DNA BALB/c 
 
“lethal doses” 80% Not 
assessed 
N/A Demonstrates dose dependent CTL 
responses and protection.  
Epstein et al 
2002375 
NP and M1 DNA BALB/c 
 
H5N1 1997 HK/156 
HK/483 HK/485 and 
HK/486 
10-100x MID50 
100% to 100 
MID50 of 
intermediate 
virulence HK/156 
0% to 100 MID50 
of high virulence 
HK/483 
50% to 10xMID50 
HK/483 
14.2% 
HK/156 
6 Demonstrates the sensitivity of T cell 
mediated protection to the dose and 
virulence of the challenge strain.  
Bot et al 
1998376 
NP DNA BALB/c H1N1 
PR/8/34 
1xLD100 
H3N2 A/HK/68 
1.5x105 TCID50 
Adults: 85% PR8, 
10% HK68 
Neonates: 30% 
PR8, 0% HK68 
Not 
assessed 
N/A T cell responses and protection 
attenuated in newborn mice compared 
with adults 
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Epstein et al 
2005 377 
NP DNA prime +/- 
Adenovector 
boost 
BALB/c H5N1 HK/483/97 
10xMID50 
H1N1 
PR/8/34 
200xLD50 
NP DNA 100% 
against HK483 
0% against PR8 
NP DNA + NP Ad5 
70% against PR8 
NP 
DNA:25% 
 
NP 
DNA/Ad5 
:10%  
 
 
NP DNA: 
7 
 
 
NP 
DNA/Ad5: 
4 
DNA Prime Ad5 boost induces greater 
CD8 T cell responses than DNA alone, 
increases survival, shortens disease and 
lessens severity.  
Altstein et al 
2006
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NP Vaccinia virus BALB/c H3N2/5xLD50 or 1XLD50 100% 1 x LD50 
80% 5xLD50 
Not 
assessed 
N/A A co-encoded rapid proteolysis signal 
increases MHC expression and 
improved T cell responses 
Moraes et al 
2011379 
NP Adv5 +/- 4-1BBL C57BL/6 H1N1 
PR/8/34 
1xLD50 
 
Adv5 4-1BBL NP: 
80% 
Adv5 NP: 50% 
Adv5 4-
1BBL NP 
18% 
Adv5 NP: 
28% 
Adv5 4-
1BBL NP 
:7 
Adv5 NP: 
8 
4-1BBL co-expressed with NP in an 
adenovector enhances T cell responses, 
protection and their longevity 
compared with NP alone 
MacLeod et al 
2011380 
NP Protein +/- Alum 
and/or 
monophosphoryl 
lipid A 
BALB/c H1N1 
PR/8/34 
150 PFU 
Sub-lethal 
challenge in 
controls 
5% with 
Alum + 
MPL 
15% with 
NP alone 
8 Commonly used adjuvants can enhance 
T cell responses to NP recombinant 
protein for improved protection against 
sub-lethal challenge 
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Jimenex et al 
2007381 
 
NP Liposomal DNA 
delivery 
BALB/c H1N1 
PR/8/34 
1xLD90 
NP alone 20% 
protection 
30% 7 Protection improved with inclusion of 
M2 
James et al 
2007
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NP and/or 
M1/M2 
DNA +/- DNA 
encoding α/β 
interferons 
BALB/c H1N1 
PR/8/34 
101.5TCID50 
Sub-lethal 
challenge in 
controls 
10% 5 Co-delivery of DNA encoding α/β 
interferons reduced viral titres and 
weight loss 
Degano et al 
1999383 
NP DNA +/- MVA BALB/c H1N1 
PR/8/34 
100 HA units (approx. 
1xLD50) 
DNA-NP+MVA-
NP: 90-100% 
MVA-N: 0% 
9-12%  N/A MVA-NP alone did not protect. MVA-NP 
boosted DNA-NP superior to DNA-NP 
alone (similar survival but less weight 
loss) 
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This is most likely a consequence of the location of memory T cells rather than their 
quantity or functionality. Both effector memory T cells and central memory T cells 
contribute to the secondary response to influenza but do so in temporally distinct 
phases (as discussed in the introduction to the thesis) with lung-resident and recruited 
effector memory T cells (TEM) forming an early functional but non-proliferative 
response, followed by a rapid expansion of antigen specific T cells between days 4 and 
7 resulting from recruitment of TEM that have differentiated from proliferating central 
memory T cells (TCM) in secondary lymphoid tissues. This latter phase occurs sooner in 
the secondary response due to the more rapid dynamics of TCM proliferation in 
response to antigen presentation in lymphoid tissue compared with the primary 
response. Woodland et al showed that If secondary T cell responses to influenza in 
mice are tested by heterosubtypic challenge 8 months after the primary infection, then 
substantial T cell recruitment to the airway does not occur until between day 5 and 7 
post-infection (Figure 3-9) (versus day 7-10 in the primary response)384. Since tissue 
resident antigen-specific T cells have waned 8 months after primary infection, this 
scenario is analogous to T cell immunity generated by systemic vaccination 
(intramuscular, subcutaneous or peritoneal), following which antigen–specific mucosal 
T cell populations are known to be no more enriched than in the general circulation385. 
The substantial recruitment of secondary effector T cells to the airway between day 5-
7 corresponds to the consistent time-point at which recovery is observed in mice 
systemically vaccinated against NP.  
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Figure 3-9 Primary and secondary T cell responses to heterosubtypic strains in the 
airway. Adapted from data in Woodland et al384. 
  
140 
 
It may therefore be inferred that protection is determined not only by the quantity and 
functionality of the T cell response, but also by its timing and anatomy. Increasing the 
numbers of circulating T cells after vaccination may be one means of improving 
protection. Homologous prime-boost vaccination with LV has been shown to increase 
TEM cell responses against encoded OVA
386, Melan-A387, HIV-1 poly-epitope388 and HIV-
1 gag389, exploiting the low anti-vector antibody responses induced by VSV-G 
pseudotyped LV which permit effective transduction with subsequent doses362. We 
found in this study that numbers of NP-specific CD8+ T cells were not increased by dual 
compared with single vaccination. However, we did observe an increase in the 
proportion of CD62LO effector phenotype NP-specific T cells with dual vaccination. 
Given that effector T cells are recruited to the lung and airway during influenza 
infection during the first few days of infection, this may explain the trend towards 
superior survival seen with dual versus single vFLIP-NP vaccination.  
In the context of anti-tumour immunity or protection against slowly replicating 
infections, timing and location of memory T cells may be less crucial than in acute viral 
infection. Nevertheless, development of T cell vaccines for HIV, which replicates 
substantially slower than influenza, has pointed towards the benefits of priming TEM 
that will persist at mucosal sites of infection390. In influenza, an effector T cell 
population at the site of infection prior to challenge may have a dramatic impact on 
viral propagation, since the impact of the killing rate of infected cells on the production 
of infectious virions is inversely proportional to the number of infected cells (which is 
at its lowest after the first round of infection). However, the factors that determine the 
development and persistence of tissue-resident TEM cell population in the lung and 
airway are incompletely understood. The observation that these are established by 
pulmonary infection with influenza but not infection by other routes (such as 
intravenous or intraperitoneal) would imply that mucosal vaccination would be the 
best means of establishing mucosal T cell populations391. In terms of T cell function, 
the development of mucosal T cell vaccines for TB, RSV (lung) and HIV (gastrointestinal 
and vaginal) have been based on the empirical assumption that mucosal priming will 
generate T cell memory cells functional adapted to combat mucosal infection.  
In the following chapter the potential of LV to induce mucosal T cell populations for 
protection against influenza is investigated.   
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4 Mucosal vaccination with lentiviral vectors 
 
4.1 Introduction  
 
4.1.1 Immune homeostasis in the lung 
 
In addition to distinguishing self from non-self, a fundamental role of the immune 
system is to distinguish potentially harmful from non-harmful antigen. This is 
particularly challenging at the mucosal surfaces where exposure to foreign antigen is 
varied and continuous. The lungs are the largest mucosal surface area of the body and 
disruption of its delicate architecture by inflammation has a high cost in impaired gas 
exchange.  
Minimising the antigen exposure levels to near-sterility (compared with the 
gastrointestinal mucosa, for example) partially addresses this problem and is achieved 
through a number of adaptations of the mucosal barrier, including the mucociliary 
clearance system and the secretion of soluble agents with anti-bacterial and anti-viral 
activity such as lysozyme, surfactant, α and β defensins, collectins and lactoferrin. This 
reduces the antigen load sampled by DC, which are absent from the airway lumen but 
can access surface antigen in small airways through transepithelial dendritic 
processes392. Alveolar macrophages, by contrast, constitute 95% of the cellular 
component of broncho-alveolar lavage (BAL) and occupy the mucinous layers of the 
airway lumen where they have much greater exposure to antigen. They are 
phagocytically active but markedly limited in their ability to stimulate primary T cell 
responses. This is due to a number of mechanisms including impaired expression of co-
stimulatory molecules393,394, reduced binding of antigen-specific T cells to AM 
presenting cognate antigen395 and active suppression of T cell responses through 
secretion of IL-10, nitric oxide and TGF-β under steady state conditions396,397. The latter 
may also supress the activation of local DC398, indirectly and directly limiting both the T 
cell and also B cells response. 
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The powerful suppressive effect of AM on pulmonary T cell responses is clearly 
demonstrated by their depletion. The cytotoxic drug clodronate is avidly taken up by 
AM when administered intranasally in liposomal form, resulting in their depletion 
within 48hrs which is sustained for up to one week, with minimal change in other cell 
populations399. Intra-tracheal administration of antigen induced virtually no T cell 
response in normal animals, but in AM-depleted mice a dramatic increase in T cell 
proliferative responses was observed400. Depletion of AM also enhanced DC activation 
and the ability to stimulate antigen-specific T cell responses398.  
AM are themselves regulated by inhibitory signals within the alveolar 
microenvironment. Surfactant protein A (SP-A) inhibits TLR2 and TLR4 signaling by 
AM401, blocks TLR-4 activation by LPS402 and inhibits AM phagocytic activity by 
activating the inhibitory receptor SIRPα403. TLR signalling pathways in AM are also 
inhibited downstream of the TAK1-TRAF6 complex by mucin-like glycoprotein 1 
expression on epithelial cells by an as yet unknown mechanism404. Epithelial cells also 
express CD200, the receptor for which is highly expressed on AM and mediates 
negative inhibition of the p38 MAPK pathway405. AM are also susceptible to 
immunoregulatory signals from TGF-β and IL-10 secreted by epithelial cells406,407.  
The threshold for activation of innate adaptive immune responses in the lung is thus 
very high. Cytopathic infection of epithelial cells is likely to be key in overcoming 
immunotolerance, since this not only initiates pro-inflammatory cytokine release that 
enhance TLR expression signalling on AM , but also the loss of epithelial barrier 
integrity exposes less regulated tissue-resident macrophages and DC to antigen. 
 
4.1.2 Vaccine vectors for mucosal T cell immunity 
 
Unsurprisingly, it follows that the vaccines vectors most efficient at generating primary 
T cell responses in the lung are those derived from pathogens for which this is a 
natural route of infection.  
Live attenuated Influenza strains would seem the obvious choice for the task of 
generating mucosal T cell responses against influenza. Intranasal LAIV are licensed for 
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clinical use in children and as discussed above confer protection predominantly 
through antibody response to HA and NA epitopes matched to circulating seasonal 
strains. However, they have been consistently shown to induce superior systemic T cell 
responses against internal virion components to that with trivalent inactivated 
vaccines in humans408–411. It is unknown whether LAIV infection generates directly 
protective mucosal influenza-specific CD8+ T cell populations, or whether CD4+ T cell 
help contributes significantly to the strain specific antibody-mediated protection 
conferred by LAIV. It is a reasonable assumption, however, that mucosal T cell 
responses to LAIV will be no greater or more lasting than those to influenza itself, and 
therefore similarly limited in the degree of heterosubtypic immunity they confer. 
Other viral vectors adapted for mucosal infection and which can be readily adapted to 
incorporate immunogenic signals may therefore show more promise in generating 
sustained mucosal T cell populations. 
Adenoviral vectors have a natural tropism for the respiratory tract and can cause 
upper and lower tract infection, typically in childhood412. Use of early generation 
adenoviral vectors for gene transfer to lung epithelium for the treatment of cystic 
fibrosis revealed strong cellular responses which hampered the longevity of transgene 
expression413414. This ability was later exploited in a mucosal adenoviral vaccine 
encoding the mycobacterium tuberculosis antigen Ag85 in order to generate lung-
based CD4+ and CD8+ T cell responses against TB, which reduced replication upon 
intranasal challenge415. Adenoviral vectors expressing RSV antigens provide an 
effective intranasal boost of cellular immunity primed by a recombinant salmonella 
typhimurium, conferring partial protection against live RSV challenge in vaccinated 
mice. More recently, intranasal vaccination of mice with adenoviral vectors expressing 
influenza NP generated up to 12.5% of NP-specific CD8+ T cells in the lung. This 
conferred 80% protection against lethal challenge, but survivors lost approximately 
25% of their bodyweight (by day 8) suggesting the pattern of clinical disease was not 
significantly different from that observed with systemic immunity. Incorporating the 
external virion target M2 generated an antibody response which enhanced protection 
to 100% and reduced weight loss in survivors to 10%416. The authors speculate that 
protection is predominantly mediated by CD8+ T cells rather than antibodies against 
the M2 component since the Ad NP-M2 vaccine is only marginally less efficacious in 
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IgA-deficient mice. However, their finding of high titres of anti-M2 IgG and the now 
well-established concept that IgG but not IgA is essential for influenza neutralization417 
brings this conclusion into question. 
Pox viral vectors, such as the attenuated Vaccinia strains that were used to eradicate 
smallpox, were shown to induce mucosal T cell responses after intranasal delivery over 
30 years ago418. MVA has since been used in numerous studies to generate mucosal T 
cell responses via gastrointestinal, vaginal and respiratory routes419. Intranasal MVA 
encoding HIV or SIV antigen have been shown to induce greater rectal and vaginal 
mucosal antigen-specific CD8+ T memory cell infiltration than when administered by 
IM or SC routes, suggesting a common mucosal immune system wherein T cells primed 
at one mucosal site will migrate favourably to all mucosal surfaces420,421.  
VSV vectors also have a natural tropism for infection via respiratory routes. Indeed, 
their ability to transgress the nasal mucosa has led to safety concerns that replicative 
vectors may infect neuronal tissue via the olfactory bulb422. Recombinant attenuated 
strains of VSV administered intranasally have been used to successfully generate 
cellular responses against HIV, SIV and CMV antigens detectable in the lung and other 
mucosal sites423,424. Attenuated recombinant VSV can raise effective mucosal antibody 
responses against HA when delivered intranasally in mice, and these provide robust 
protection against challenge with influenza strains expressing homologous HA425. 
However, while recombinant VSV expressing influenza NP was able to induce systemic 
NP-specific CD8+ T cell response when delivered intranasally, it did not induce mucosal 
NP-specific T cell populations, nor confer significant protection against lethal 
challenge426.  
Nanoparticle antigen delivery systems have shown considerable promise as mucosal 
vaccines. A diverse range of lipid based and polymeric nanocarriers have been shown 
to generate effective humoral and cellular responses to encapsulated antigen when 
delivered intransally427. These either have repetitive intrinsic structures providing 
carrier-mediated PRR stimulation of antigen presenting cells, or they provide a 
framework which presents associated antigen in a repetitive pattern to enhance PRR 
stimulation. Nanocarriers provide resistance to mucosal enzyme antigen degradation 
and their particulate formulation enhances APC uptake and cross presentation of 
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encapsidated antigen428. Intranasal liposomal formulations have successfully 
generated cellular responses against plague429 and anthrax430 antigens and liposomal 
encapsidation of DNA expressing TB antigens permits effective generation of TB 
specific cellular responses in the lung mucosal after intranasal administration, 431. 
Nambrini et al demonstrated that a fully degradable polypropylene sulphide (PPS) can 
be coupled to antigen with disulphide linkages which dissociate in a reductive 
environment, resulting in endosomal release of antigen and enhanced cross 
presentation432. This formulation coupled with OVA and CpG induced very high 
percentages (44%) of OVA-specific CD8+ T cells in the lungs of intranasally vaccinated 
mice. This protected mice against lethal challenge with an OVA-expressing 
recombinant A/PR/8/34, with mice losing an average of just 5% of baseline weight by 
day 7. Immune Targeting Systems (ITS) have developed a nanoparticle formulation of 
dilauroylphosphatidylcholine (DLPC) liposomes containing the adjuvants 
monophosphoryl lipid A (MPL) and trehalose 6,6′ dimycolate, encapsulating 6 
conserved segments of the PA, PB1,PB2, NP and M1 proteins. Administered 
intranasally, this induces lung-based responses of around 17% antigen-specific CD8+ T 
cells which conferred protection against influenza without weight loss. However, the 
challenge strain used was a non-mouse adapted A/HK/8/68 (considerably less 
pathogenic in mice than A/PR/8/34) and was given at a dose that failed to kill all 
unvaccinated mice. In this context, even the empty nanoparticle formulation without 
peptide was able to induce transient but robust protection, possibly by the mechanism 
of “innate imprinting” described above. Splenic T cell memory was not generated by 
intranasal vaccination and survival rates fell to 0% if mice were challenged 8 weeks 
after final vaccination, questioning the longevity of protection induced by this 
approach.  
Lentiviral vectors have been investigated for their ability to generate mucosal T cell 
responses by intranasal administration in order to generate HIV-specific T cells in rectal 
and vaginal mucosae. Intranasal administration of a chimeric simian-human 
immunodeficiency virus (attenuated by nef deletion) to macaques resulted in larger 
SHIV-specific CD8+ and CD4+ T cell populations in the rectal and vaginal mucosa than 
intravenous administration. This completely protected macaques from rectal SHIV 
challenge, but T cell responses at the respiratory mucosa were not examined433. 
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Hashimoto et al examined the potential for lentiviral vectors to generate respiratory 
mucosal T cells specific to the TB antigen MPT51 after intratracheal administration. 
This resulted in MPT51-specific CD8+ T cells in the lung at frequencies of only 2%, 
which conferred partial inhibition of growth of TB upon challenge but not protection. 
Perhaps because of this disappointing result, no other studies have since assessed the 
potential of intranasal LV for protection against respiratory pathogens.  
There has nevertheless been considerable interest in the potential of LV delivered 
intranasally for gene therapy in cystic fibrosis. Promising early results were achieved 
with 1st generation VSV-G pseudotyped LV encoding CFTR, which transduced 
respiratory epithelia in vitro albeit with poor efficiency434. Pseudotyping of LV with a 
filoviral envelope (Ebo-Z), however, achieved over 80% transduction of airway 
epithelium after intratracheal administration to immunocompetent mice435. This 
approach has been used to establish sustained expression of CFTR with functional 
reversal of the chloride ion transport deficit436. Some investigators have reported gene 
expression after intranasal LV delivery that persists for the lifetime of the mouse437. 
Sustained expression may be in part due to transduction of stem-cell like progenitors, 
but is also permitted by the consistent lack of T cell responses to the cystic fibrosis 
transmembrane conductance regulator (CFTR) transgene or other vector 
components438.  
The observed immunotolerance to intranasally delivered LV transgenes contrasts 
markedly with the T cell responses observed after subcutaneous administration. It is 
also surprising given the efficient transduction of alveolar macrophages (AM)  by LV 
observed in several of these studies. For example, Buckley et al examined the 
persistence of GFP expression in the airway epithelia of mice given intranasal LV as 
newborns or adults322. They reported transduction of only 1% of adult respiratory 
epithelia, but markedly high rates of transduction of AM, approaching 50%. Despite 
transduction of these APCs, persistent gene expression was observed at 390 days after 
administration. This tropism of lentiviral vectors for alveolar macrophages was later 
exploited by Malur et al for restoration of surfactant catabolism by AM in an alveolar 
proteinosis model. This group achieved 79% transduction of AM with a single 
intratracheal administration of LV439.  
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The tolerogenic responses to intrapulmonary administration of LV for gene therapy 
would suggest this is not an optimal vector for generating strong mucosal T cell 
responses for protection against influenza. Whilst this may be due to the highly 
efficient transduction of AM which have a central role in regulation of the adaptive 
immune response in the lung, this tropism may also present an opportunity for 
subversion of AM immunoregulation. 
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4.2 Aims 
 
 
In the experiments described in this chapter we aimed to test the efficacy of lentiviral 
vectors in generating NP–specific CD8+ and CD4+ T cell responses in the lung and 
airway following intranasal administration. We also wished to determine whether 
NFкB activation, known to be an important pathway in activation of AM as well as DC, 
may enhance mucosal T cell responses compared with LV expressing NP alone. 
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4.3 Results 
 
4.3.1 Intranasal LV fails to prime mucosal or systemic T cell responses against NP 
 
Intranasal administration of vFLIP-NP or Null-NP LV (200 ng RT) failed to induce 
discernible antigen-specific response in CD8+ T cells isolated from lung homogenate 2 
weeks later. Indeed, more antigen-specific CD8+ T cells were detected in lung in mice 
receiving a single VFLIP-NP subcutaneous vaccination than mice receiving a single 
VFLIP-NP intranasal vaccination (mean 4.157 vs. 0.92, P=0.0002). Splenic or circulating 
antigen-specific T cells were also not significantly greater than background after 
intranasal administration of LV, suggesting a failure of both mucosal and systemic T cell 
priming by the intranasal route (Figure 4-1).  
 
4.3.2 Intranasal LV recalls substantial NP-specific populations to the lung in mice 
that have previously been vaccinated subcutaneously 
 
The lack of priming observed with intranasal LV contrasted markedly to the T cell 
response in the lung induced by sequential subcutaneous priming and intranasal 
boosting (SC-IN). Following SC-IN vaccination with vFLIP-NP more than a third of CD8+ 
T cells in the lungs harvested 14 days after the last vaccination were NP-specific. 
Intranasal Null-NP after Null-NP subcutaneous vaccination generated significantly 
lower proportions of NP-specific CD8+ T cells, although levels were still considerably 
higher than seen after subcutaneous vFLIP-NP alone. Figure 4-2C compares the relative 
proportions of NP-specific CD8+ T cells isolated from homogenised lung 14 days after 
subcutaneous, intranasal or SC-IN vaccination. Whereas all mice were killed by lethal 
A/PR/8/34 challenge following intranasal vaccination with vFLIP-NP or Null-NP, 100% 
of mice survived when challenged 14 days after vFLIP-NP SC-IN vaccination. Strikingly, 
mice developed no outward sign of clinical disease and lost no weight. SC-IN Null-NP 
vaccination also conferred improved protection compared with SC vaccination with 
either vFLIP-NP or Null-NP, albeit with evident clinical disease and weight loss.  
  
  
150 
 
 
Figure 4-1 Intranasally-administered LV fail to prime detectable NP-specific T cell 
responses in lung, circulation or spleen. Populations were compared with a Student’s t-
test.  
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Figure 4-2 Response to 
subcutaneous, intranasal or SC 
followed by IN (SC-IN) 
immunisation. Mice were 
challenged with lethal 
A/PR/8/34 (PR8) or sacrificed for 
analysis 2 weeks after the final 
immunization of the regimen 
indicated on the x-axis. Top: 
Survival after lethal 2xLD50 
challenge (n=10-18 per group). 
Both Mantel-Cox tests and 
Gehan-Breslow-Wilcoxon Test 
produced similar p-values for 
observed differences in survival. 
Middle: Weight loss from 
baseline after lethal PR8 
challenge (n=10-18 per group). 
Average weights are taken from 
all survivors in the group at that 
time point. Bottom: Percentage 
of NP147-155 pentamer positive 
CD8+ T cells from lung 
homogenate (n=4-6 per group).  
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4.3.3 Intranasal LV transduce AM with high efficiency  
 
Influenza infection of AM is known to drive NFкB-dependent secretion of non-ELR 
CXC chemokines which preferentially attract mononuclear cells440. To compare 
activation of AM by influenza with NFкB activation by vFLIP, LV expressing vFLIP 
and GFP (vFLIP-GFP), or GFP alone (Null-GFP) or live PR8 influenza were 
administered intranasally to naïve BALB/c mice and bronchoalveolar lavage 
performed on day 4. FACS analyses of broncho-alveolar lavage (BAL) cells stained 
with anti-F4/80 and anti-CD11c are shown in Figure 4-3. These show efficient 
transduction (>75%) of F4/80HICD11cHI AM (histogram) with very high specificity 
(>99%, adjacent FACS plots). To investigate the possibility of transduction of 
parenchymal DC (which have interdigitating processes that access the lumen but 
would not be retrieved by BAL) we analysed total lung homogenate. Analysis of 
total lung cells by F4/80 and CD11c (Figure 4-4) revealed a similar profile to BAL, 
but with a greater number of interstitial or tissue macrophages (F4/80+ CD11c-) 
and DC (F4/80-, CD11c+). Again, AM were transduced with high specificity, with no 
detectable GFP+ DC, interstitial macrophages or “transitional” macrophages 
(F4/80+CD11cINT). 
 
4.3.4 NFкB activation by vFLIP leads to secretion of T cell chemoattractants but not 
up-regulation of co-stimulatory molecules. 
 
NFкB activation increases transcription of a number of chemokine genes with NFкB 
elements in their promoters. Among these IP-10 (interferon-inducible protein of 10kd), 
MIP1α (macrophage inflammatory protein 1 α), MIP1β, MCP-1 (monocyte chemotactic 
protein-1), MCP-3 and RANTES (regulated upon activation, normal T cell expressed and 
secreted) play an essential role in T cell recruitment in response to influenza (reviewed 
in 441). Intranasal administration of vFLIP-GFP, but not Null-GFP, resulted in greatly 
increased levels of these six chemokines in the BAL 4 days later (Figure 4-5). To 
determine whether these originated from transduced immune cells in the airway or 
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transduced epithelial cells, BAL cells were cultured for 4 days and then chemokines 
quantified in collected supernatants. FACS analysis of cultured cells confirmed more 
than 97% of the transduced (GFP+) population were AM (F4/80HICD11cHI). Again, high 
levels of these chemokines were found in the supernatants of adherent cells from the 
vFLIP-GFP recipient group. Intranasal Null-GFP failed to generate a detectable 
chemokine response in BAL or in the supernatant of cultured adherent cells despite 
equivalent levels of AM transduction. Therefore vFLIP expression in AM stimulates 
secretion of quantities of T cell chemoattractants comparable to those released during 
influenza infection. 
 
However, expression of CD80 or CD86 was not up-regulated in vFLIP-GFP transduced 
AM compared with Null-GFP or AM post influenza challenge. This is consistent with 
previous findings of impaired CD80 and CD86 expression in AM393,394. The ability of 
vFLIP transduced AM to secrete T cell chemoattractants upon NFкB activation but not 
up-regulate co-stimulatory molecules may account for both the proficiency of T cell 
recall and also failure of T cell priming by intranasal vFLIP-NP.  
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Figure 4-3 AM are transduced with high efficiency and specificity by LV. 200 ng (RT) of 
LV encoding vFLIP-GFP or Null-GFP (n=3 per group) were introduced intranasally. BAL 
was performed 4 days later and retrieved cells were stained for F4/80 and CD11c and 
analysed by FACS (top row). Circled areas indicate F4/80HICD11cHI AM populations in 
naïve, Null-GFP and vFLIP-GFP groups. Middle row shows gating of GFP+ cells for the 
bottom row plots. Histogram indicates transduction efficiency (>75%) as indicated by 
GFP signal in AM (F4/80HICD11cHI) populations. Adjacent FACS plots (bottom) indicate 
LV transduce only F4/80HICD11cHI cells. 
155 
 
 
Figure 4-4 Analysis of total lung homogenate by the same method as in Figure 4-3. An 
additional population of F4/80+CD11c- (tissue macrophages) can be seen in the top row 
panels. These are not transduced by intranasal LV (bottom panel).  
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Figure 4-5 vFLIP transduced AM produce quantities of T cell chemo-attractants comparable mice infected with influenza A/PR/8/34. 
Concentrations of MIP-1α, MIP-1β, RANTES, IP-10, MCP-1 and MCP-3 were measured in a single 2ml BAL (n=5, top row) at day 4 after 
intranasal LV or influenza infection. These were also measured in 2 mL supernatants of adherent cells from BAL after 4 days culture in vitro 
(bottom row). FACS analysis of cultured adherent cells showed >97% of transduced cells (GFP positive) were F4/80HICD11cHI. Transduced 
(GFP+) CD11cHI F4/80- DC were not detected by FACS before or after culture of BAL cells. ND= not detected. 
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4.3.5 Airway NP-specific CD8+ T cells generated by SC-IN vaccination are high in 
GzmB and Ki67 but cytokine responses are minimal  
 
Substantial numbers of T cells were found in the airway by BAL 14 days after SC-IN 
vaccination: more than 60-fold greater than those found in unvaccinated mice. 
Numbers of CD8+ T cells were significantly higher in the vFLIP-NP SC-IN group versus 
the Null-NP SC-IN group, and nearly a third of total CD8+ T cells expressed high levels 
of GzmB without re-stimulation, indicating on-going cytotoxic potential (Figure 4-6). 
Over half (51%) of the NP-pentamer positive CD8+ T cells showed high GzmB 
expression in the vFLIP-NP SC-IN group compared with 30% of the NP-specific CD8+ T 
cells in the Null-NP SC-IN group (p= 0.003) and <1% in unvaccinated mice. CD4+ T cells 
were also recruited in large numbers to the airway by SC-IN vaccination, but there 
were no significant differences in numbers between vFLIP-NP and Null-NP groups. In 
both vFLIP-NP SC-IN and Null-NP SC-IN groups Ki67 staining was high in CD8+ and CD4+ 
T cells, indicating on-going proliferation in these populations. This contrasts with the 
observations of Woodland et al of airway T cell populations seen 2 weeks after primary 
infection which are non-replicating. 
 
Re-stimulation of CD8+ and CD4+ T cells with class I and class II restricted NP peptides 
respectively elicited IFNγ, TNFα and IL-2 responses but these were seen in much lower 
percentages than GzmB staining (Figure 4-7). No significant differences in cytokine 
secretion were observed between vFLIP-NP and Null-NP SC-IN groups, with the 
exception of slightly higher IL-2 secretion seen upon restimualtion of CD8+ T cells in 
the vFLIP-NP group.  
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A 
Figure 4-6 (A) FACS plots 
showing GzmB and Ki67 
expression of total CD8+ T cells, 
NP -pentamer positive CD8+ T 
cells and total CD4+ T cells. (B) 
Histograms show quantitative 
comparisons in these 
populations between groups of 
mice (n=5) SC-IN immunised 
with vFLIP-NP compared with 
Null-NP. Combined bars (top) 
are superimposed.  
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Figure 4-7 Intracellular cytokine staining of lung homogenate CD8+ (top) and CD4+ 
(bottom) T cells after SC-IN immunization. Mice were immunised subcutaneously 
then intranasally 2 weeks apart and sacrificed for analysis 2 weeks later. 
Mononuclear cells from lung (homogenized after exsanguination and removal of 
lymph nodes) were re-stimulated overnight in vitro with either MHC class I or II 
restricted peptides in the presence of brefeldin A prior to intracellular cytokine 
staining.  
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4.3.6 Both vFLIP and NP are required in intranasal lentiviral immunisation to 
maximize T cell recall and antigen-specific expansion respectively 
 
We postulated that the major components of a recall response – chemotactic 
recruitment of memory cells and antigen-driven expansion – are principally instigated 
by transduction of AM with the components vFLIP and NP respectively, and therefore 
numbers of antigen-specific T cells would be diminished in either’s absence. To test this 
we gave an intranasal LV expressing either vFLIP (vFLIP-GFP) or NP (Null-NP) to mice 
that had been immunised with vFLIP-NP subcutaneously two weeks earlier. The vFLIP-
GFP intranasal recall increased total numbers of airway CD8+ T cells but the proportion 
of antigen-specific NP-positive CD8+ T cells remained similar to that seen in the 
circulation and spleen (Figure 4-8A). By contrast, Null-NP IN recall recruited less than 
half the number of total CD8+ T cells to the airway as vFLIP-GFP, but a greater 
proportion of these were NP-pentamer positive (18.4% vs. 5.2%, p=0.002). This is 
consistent with local antigen-driven expansion of NP-specific CD8+ T cells, corroborated 
by the finding of 6-fold higher numbers of Ki67+ CD8+NP147-155 pentamer+ T cells in the 
airways of Null-NP IN recipients versus the vFLIP-GFP IN recall group. Both vFLIP-GFP 
and Null-NP IN recalls after vFLIP-NP SC priming generated similar absolute number of 
antigen-specific T cells in the airways but approximately three-fold lower than that 
seen with vFLIP-NP SC-IN recall. Correspondingly survival and weight loss after lethal 
influenza challenge were inferior to the complete protection observed with vFLIP-NP 
SC-IN immunisation (Figure 4-8B). 
161 
 
 
  
Figure 4-8 (A)  Comparison of airway NP147-155 pentamer+ CD8+ T cell numbers 
after SC vFLIP-NP immunization followed by intranasal vFLIP-GFP or Null-NP. 
Bars are superimposed. Number of Ki67+Pentamer+ CD8+ T cells in each group 
is shown in the lower panel. (B) Survival and weight loss after challenge with 
2xLD50 A/PR/8/34. 
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4.3.7 Adoptive transfer of transduced AM elicits lung T cell recall and protection 
against influenza  
 
Whilst LV transduce AM with very high specificity amongst airway immune cells, they 
have also been reported to transduce approximately 10% of alveolar epithelial cells442. 
To determine whether AM alone are necessary to instigate T cell recall we attempted 
their depletion by clodronate liposomes443 or diphtheria toxin in CD11c-DTR transgenic 
mice444 prior to intranasal LV vaccination. However, both approaches were confounded 
by only partial AM depletion (58% and 60% depletion for clodronate and diphtheria 
toxin in the CD11c—DTR model respectively). Also, AM depletion resulted in infiltration 
of the airway by DC that would be susceptible to intranasal LV transduction and 
confound attempts to isolate AM as the agents of T cell recall. We also attempted to 
de-target expression of the transgene from AM by constructing an LV in which the 
transgene was followed 3’ by 4 repeats of a target sequence for the haematopoetic-
specific microRNA, miR-142-3p as previously described318. This leads to silencing of the 
transgene by microRNA binding to transgene mRNA which is then degraded. LV 
expressing 4-1BBL(h) as a surface marker, followed 3’ by miR-142-3p repeats were 
delivered intranasally to 3 mice and expression of 4-1BBL on AM analysed after BAL 4 
days later. The inclusion of MiR-142-3p did lead to a 50% reduction in expression of 4-
1BBL, but this was nevertheless still 40 times greater than background levels, indicating 
incomplete silencing.  
 
We therefore adoptively transferred AM transduced in vivo with intranasal LV into 
recipient mice that had been primed with SC vFLIP-NP two weeks previously (Figure 
4-9). This approach takes advantage of the >99% specificity of AM transduction in the 
transferred population (Figure 4-3B), removing the need for cell sorting which incurs 
substantial processing losses of this highly adherent population. Two weeks after 
intranasal adoptive transfer, recipient mouse lungs were harvested from 3 mice per 
group for analysis of total lung T cells. This revealed a very similar pattern of T cell 
recall as direct intranasal administration of LV (Figure 4-2C). Whilst absolute numbers 
of NP147-155 pentamer+ CD8+ T cells recalled by this means were 3-fold lower than 
achieved by direct intranasal LV, it is noteworthy that only 12,000 AM were 
A 
B 
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transferred, representing some 0.4% of the estimated total that would be transduced 
by direct IN LV administration445. Despite this, adoptive transfer of vFLIP-NP transduced 
donor AM induced a sufficient T cell recall response to confer 100% survival against 
lethal challenge with minimal weight loss (Figure 4-10).  
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Figure 4-9 Adoptive transfer of 
LV-transduced AM recalls large 
lung T cell populations. (A) 
Adoptive transfer schedule. (B) 
BAL cells from donor mice were 
washed and concentrated at 
12,000 AM (F/480+CD11c+) 
cells per recipient mouse 
(40μl). FACS plots show high 
specificity of AM 
(F/480+CD11c+) transduction 
in donor cells. NP147-155 
pentamer positive CD8+ T cells 
were undetectable in BAL from 
donor mice. (C) CD8+ T cell 
populations from total lung 
homogenate of recipient mice 
2 weeks after adoptive 
transfer. Comparative T-test p-
values are given in the inset 
table. Bars are superimposed.  
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Figure 4-10 Survival (top) and weight loss in survivors (bottom) of recipient mice 
challenged 2 weeks after adoptive transfer as shown in Figure 4-9. 
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4.4 Summary 
 
Intranasal LV fail to prime T cell responses to encoded antigen, but recall very large 
populations of antigen-specific T cells to the lung and airway in mice in which memory 
has been established by prior subcutaneous vaccination. SC-IN vaccination with vFLIP-
NP generates sufficient lung-based populations of NP-specific CD8+ T cells to protect 
against lethal A/PR/8/34 challenge without weight loss or signs of clinical disease. AM 
are transduced with >75% efficiency and >99% specificity in BAL populations. 
Transduction of AM with vFLIP induces secretion of T cell chemoattractants but not up-
regulation of co-stimulatory molecules. Examination of airway CD8+ T cells from SC-IN 
vaccinated mice reveal these are high in Ki67 and GzmB, indicating on-going 
proliferation and cytotoxic potential. vFLIP-NP SC-IN vaccination resulted in higher 
GzmB staining than Null-NP SC-IN vaccination, although both vFLIP-NP and Null-NP 
were broadly equivalent in generating cytokine responsive CD4+ and CD8+ T cells. Both 
vFLIP and NP are required to maximise recall and expansion of NP-specific CD8+ T cells 
in the airway. Adoptive transfer of transduced AM to subcutaneously primed mice 
recalls NP-specific T cells to the lung in a similar manner to directly administered 
intranasal LV.  
 
4.5 Discussion 
 
It is common in dendritic cell biology for activation to be measured in terms of 
expression of the 3 signals eponymously hypothesised to be required for T cell 
activation. States of macrophage activation are not so straightforwardly classified, 
partly because they exhibit significant phenotypic plasticity but also because they have 
essential functions beyond their immune effector role. For example, they have a key 
role as phagocytes, clearing the interstitial environment of effete or apoptosis cells and 
debris, with little or no release of immune mediators in the absence of “danger“ 
signals446. In the presence of these, for example upon phagocytosis of necrotic tissue 
containing HSPs, histones, DNA and nuclear proteins, macrophages can undergo 
substantial phenotypic changes and become efficient immune effector cells 
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coordinating an adaptive T cell response. However, they can also shift to regulatory or 
“alternative” states, which are poorly understood.  
Mirroring the differentiation of T helper cells observed in the 1990s, there were 
parallel efforts to classify macrophages into either M1 or M2 phenotypes; the former 
designating classically activated macrophages and the latter “alternatively activated”. 
Early versions of this paradigm held that classical activation occurs under the influence 
of TH-1 cytokines (such as TNFα) or LPS and results in IL-12-secreting macrophages 
capable of stimulating CD8+ and TH-1 CD4+ T cell responses and secreting pro-
inflammatory cytokines such as IL-1 and IL-6. Alternative activation occurs under the 
influence of TH-2 cytokines such as IL-4 and IL-13, and results in an immunoregulatory 
phenotype of macrophage secreting IL-10 and supporting TH-2 skewed CD4+ T -cell 
responses447.  
NFкB signalling plays a central role in classical activation of macrophages, a final 
common pathway of both TNF α and LPS signalling. We therefore anticipated that 
NFкB stimulation may subvert the default immunoregulatory role of AM and generate 
classically activated APCs capable of T cell priming. However, intranasal vFLIP-NP failed 
to prime detectable T cell responses in the airway, lung, circulation or spleen 
suggesting NFкB activation alone is insufficient to generate AM capable of T –cell 
priming. Our finding of a lack of co-stimulatory molecule expression by AM despite 
NFкB activation suggests a fundamental limitation in T cell priming ability that occurs 
upon differentiation into AM from their interstitial or circulating monocyte 
progenitors. The signals and mechanisms governing this differentiation are poorly 
understood. AM exhibit high levels of CD11c, not seen in other macrophage types. This 
phenotype can be induced in non-pulmonary macrophages by transfer to the 
airway448, with high GM-CSF and surfactant protein D (SP-D) concentrations driving 
differentiation. Faulty GM-CSF signalling (either genetically determined or a 
consequence of auto-antibodies against the GM-CSF receptor) is the molecular 
mechanism underlying pulmonary alveolar proteinosis (PAP), wherein AM are 
incompletely differentiated and demonstrate numerous impairments in surfactant 
catabolism, phagocytosis and intracellular bacteria killing449. However, the 
immunostimulatory function of AM is further impaired, rather than enhanced, in PAP. 
168 
 
This suggests other GM-CSF independent pathways turn off the ability of macrophages 
to prime T cell responses upon differentiation into AM.  
Whilst poor at T cell priming, AM nevertheless play a key role as early detectors of 
danger signals and initiators of innate activation in the lung. This is particularly evident 
in influenza infection, wherein influenza-infected AM undergo rapid activation of NFкB 
(within 2 hours) and subsequently secrete chemokines. A striking pattern of AM 
chemokine secretion is observed, wherein secretion of neutrophil chemotactic 
substances are suppressed and secretion of mononuclear cell chemokines, such as 
RANTES, MCP-1, IP-10 and MIP-1α, are substantially increased450. The actions of these 
chemokines are not limited to T cells and also recruit dendritic cells into the airway, 
permitting competent priming of T cells in local bronchial associated lymphoid tissue 
and lymph nodes. In an activated state, AM can thus indirectly support T cell priming 
via DC recruitment to the airway.  
We therefore endeavoured to phenotype AM after LV transduction according to their 
profile of chemokine secretion. This revealed similarities between the profile of 
chemokine secretion by vFLIP-GFP transduced AM and that seen in A/PR/8/34 
infection. These T cell chemoattractants were also detectable in the supernatants of 
adherent cells after 4 days in culture. Analysis of these adherent cells before and after 
culture confirmed >99% specificity for transduction of F/480+CD11c+ cells, suggesting 
transduced AM rather than any transduced epithelial cells are the principal source of 
these chemokines. By contrast, influenza-infected adherent cells from BAL failed to 
produce significant quantities of chemokines during ex-vivo culture. This may indicate 
that AM are not the principal source of these chemokines following influenza infection 
(alveolar epithelial cells can produce IP-10 in response to influenza infection, for 
example) but a more likely explanation is that chemokine production by AM after 
influenza infection is transient, falling off rapidly in the absence of replicating virus. 
Indeed, in vitro studies of AM stimulation with influenza suggest chemokine 
production peaks under 24hrs post-exposure451.  
Despite the rapid response to influenza infection observed in AM in vitro, in vivo there 
is a 48 hour delay after influenza infection before innate activation – as measured by 
accumulation of type-I interferons, MIP-3α, MCP-1, IL-6 and TNFα– is readily 
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detectable. This has been described as a “stealth phase”, attributed to influenza 
mediated inhibition of APC activation through NS-1452. It has also previously been 
proposed that pro-inflammatory signals from the innate immune system, epithelial 
and endothelial cells after infection in the lung may play a role in enhancing airway 
defense. CD11c-expressing cells are maintained in the lung and display enhanced 
antigen presentation for several months after influenza or RSV antigen is 
undetectable301,302. This may be the consequence of IFNγ secretion by γδ T cells 
recruited late in infection resolution303. AM are also sustained in an activated state 
following infection by high GM-CSF concentrations, thought to be secreted by both 
mesenchymal cells and memory T cells after infection305. This cytokine also recruits a 
new population of CD11bHI macrophages which may persist for many weeks within the 
airways306. These mechanisms of “innate imprinting” following infection appear to 
confer a degree of protection over subsequent infectious challenge independently of 
antigen-specific T cell responses. For example, prior administration of a modified heat-
labile toxin from E. Coli (LTK63) to the lung enhances immunity to respiratory syncytial 
virus, influenza and Cryptococcus neoformans453. It is therefore striking that in addition 
to failing to prime T cell responses, AM transduced with vFLIP also confer no 
independent protection against influenza challenge, despite the “head-start” in 
sustained innate activation this appears to confer. Our results would suggest if there 
is a “stealth phase” of influenza infection in which activation of infected AM is delayed, 
it does not seem to confer an obvious viral advantage since pre-activation of NFкB in 
AM with vFLIP fails to confer a survival benefit. 
 
DC are known to migrate into the airway and lung parenchyma during influenza 
infection shortly after an initial phase of DC migration in the opposite direction from 
lung to lymph nodes where the T cell response is initiated. The origin of these DC is 
unknown, but lung and airway-resident DC during influenza infection appear to be 
essential to the on-going local primary T cell response. In the lung parenchyma it is 
possible these DC establish BALT where naïve T cell-DC interactions are known to 
occur454. However, the majority of these lung-migrating DC are observed in the 
alveolar interstitium and airway, where they are thought to maintain and enhance T 
cell responses to influenza by increasing T cell migration to the site of infection, 
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inducing subsequent T cell proliferation and protecting T cells from apoptosis through 
on-going costimulation455. Figure 4-3 shows that vFLIP-GFP transduction recruits a 
population of DC into the airway (CD11CHIF4/80 LO) and a population of “transitional” 
macrophages with CD11c expression somewhere between that of interstitial 
macrophages and AM. We envisaged that these would accelerate the process of 
influenza antigen uptake and presentation after migration to lymph nodes and through 
cross-presentation sustain and enhance the subsequent primary T cell response, 
shortening the duration of infection. However, intranasal vaccination with vFLIP-NP 
alone not only fails to prime an NP-specific T cell response but also does not appear to 
accelerate the primary response to subsequent infection, conferring no benefit upon 
survival or weight loss. Indeed, it is possible that the monocyte chemokine signal from 
vFLIP-activated AM in fact hinder retrograde migration of DC to local lymph nodes 
preventing efficient T cell priming.  
In contrast with the absence of NP-specific T cell response and protection seen with 
intranasal administration, SC-IN vaccination with vFLIP-NP induces large numbers of 
NP-specific CD8+ T cells, representing in excess of one third of the total found in total 
lung homogenate and protects against lethal influenza challenge without clinical 
disease. This compares favourably with previous attempts to generate mucosal T cell 
immunity against influenza as mentioned in the introduction, such as the ITS 
nanoparticle and NP-M2 adenovector vaccine which generate 17% and 12.5% of 
antigen-specific T cells in lung homogenate respectively. Neither of these formulations 
have generated protection without weight-loss in the context of a lethal challenge with 
a highly pathogenic strain.  
The efficacy of the vFLIP-NP SC-IN regimen in generating lung-resident T cells may be 
attributed to both the strong chemotactic signal generated by vFLIP activation of 
macrophages and the presence of NP driving antigen-dependent T cell proliferation. In 
either’s absence, the number of NP-specific T cells found in lung-homogenate, and 
corresponding protection, is diminished. However, the high degree of protection 
induced by vFLIP-NP may not only be a function of the higher numbers of lung-and 
airway-based NP-specific CD8+ T cells generated by this approach, but may also be due 
to their functional phenotype. We have identified GzmBHIKI67HI CD8+ T cells in the 
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airways 2 weeks after vFLIP-NP SC-IN vaccination, suggesting on-going cytotoxic 
activity and proliferation. Relatively small proportions of both CD4+ and CD8+ T cells in 
this compartment produce cytokines upon re-stimulation with their respective class II 
or I restricted NP peptides. This phenotype differs substantially from that observed in 
airway CD8+ T cells found in the airway following respiratory virus infection. These 
have been extensively characterised in a number of studies456–460 which have 
consistently shown these are unable to proliferate in response to infection and are 
non-cytolytic, yet they are capable of rapid cytokine secretion on reencounter of 
antigen which may contribute to heterosubtypic protection461,462. Indeed, cytokine-
secreting influenza-specific CD8+ T cells can be generated in very high numbers by 
repeated infection. Christensen et al used a similar systemic prime-intranasal boost 
strategy using intraperitoneal A/PR/8/34 infection followed by live intranasal X31 
challenge (an H3N2 subtype containing an identical NP as PR8)463. This generated in 
excess of 70% of NP-specific T cells in BAL, with similarly high frequencies of IFNγ 
secretion on re-stimulation. Upon a lethal H7N7 challenge, these accelerated viral 
clearance and conferred a survival benefit but did not prevent clinical disease. At the 
time of writing, Lambe et al have shown that systemic (intramuscular) prime with an 
adenovector expressing NP+M1 boosted with intranasal MVA expressing the same 
antigens resulted in high levels of IFN-γ secreting CD8+ T cells in mouse airways 
(around 25%)464. Curiously this conferred little benefit in terms of weight loss or 
survival upon A/PR/8/34 challenge compared with unvaccinated controls. Thus the 
presence of high numbers of NP-specific IFNγ-secreting CD8+ T cells may not confer 
equivalent protection to the GzmBHI IFN-γLO phenotype generated by SC-IN vFLIP-NP.  
A simple explanation for these observed phenotypic differences would be the 
persistence of antigen in in the airway of SC-IN vaccinated mice but not after influenza 
infection or MVA vaccination, since both GzmB expression and also proliferation in 
effector CD8+ T cells are antigen-dependent. Some studies have demonstrated 
detectable processed antigen presentation for up to two months after influenza virus 
clearance, but this is restricted to DC in draining lymph nodes465–467. Chemokine 
secretion and antigen presentation by influenza-infected airway AM is short-lived since 
in addition to NFкB activation, infection initiates apoptosis in AM leading to cell death 
within 20-30 hours468. LV-transduced AM, by contrast, have been shown to persist for 
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the lifespan of the adult mouse469. The longevity of T cell populations generated by SC-
IN LV vaccination is explored further in the next chapter.  
Whilst we have shown here that LV-transduced AM are sufficient for T cell recall to the 
lung by adoptive transfer to SC primed recipient mice, we have not demonstrated that 
they are necessary. Intranasal VSV-G pseudotyped LV also transduce a small (~10%) 
proportion of alveolar epithelial cells which may also be agents of T cell recall. 
Depleting AM to a degree that would demonstrate their necessity for T cell recall 
would be challenging, since we have shown here that transfer of just 0.4% of the 
estimated total AM number is sufficient to induce T cell recall in subcutaneously 
primed recipient mice. Thus depletion would have to be near total to reliably exclude a 
role for epithelial cells in T cell recall. We found only partial depletion (~60%) could be 
achieved using intranasal clodronate liposomes or administration of diphtheria toxin to 
CD11c-DTR mice (in which the diphtheria toxin receptor is driven by the CD11c 
promoter). In both cases DC were recruited to the airway, making them susceptible to 
transduction by intranasal LV and confounding the isolation of AM as the agents of T 
cell recall. Furthermore, both transduced and untransduced AM are depleted by this 
technique, altering the immunoregulatory environment by removing inactivated AM. 
An alternative approach is to use an LV for T cell recall that co-expresses the diphtheria 
toxin receptor. Our early data (not shown) with a DTR-GFP LV shows complete, 
selective depletion of transduced AM and preservation of untransduced AM (without a 
consequent influx of dendritic cells) following intranasal diphtheria toxin 
administration. However, significant further optimisation of the LV is required to 
ensure sufficient and consistent expression of all three transgenes (DTR, antigen, and 
NFкB activator) from an F4/80 or CD11c promoter.  
The ability to protect mice from a highly pathogenic strain at lethal doses, whilst 
preventing clinical disease, by targeting conserved T cell epitopes points towards 
significant potential for impact in the clinical domain. In this regard several key 
questions arise with regard to the safety, longevity and implementation of this 
approach in the context of cognate T cell memory as found in most of the adult human 
population. These are addressed in the following chapter. 
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5 Clinically relevant models of LV vaccination against influenza 
 
5.1 Introduction 
 
In this chapter we report an investigation of vFLIP-NP SC-IN vaccination in a series of 
models relevant to clinical application. These include: 
 the impact of SC-IN LV vaccination on lung injury and viral load 
 the duration of protection  
 recall of naturally acquired T cell memory in mice and humans 
 the impact of NP sequence variation on protection 
 the efficacy of safer, non-integrating LV in vaccination. 
 
5.1.1 Viral load, T cell response and lung injury 
 
The ideal T cell vaccine against influenza would prevent clinical disease rather than 
merely limit its severity or duration. vFLIP-NP SC-IN vaccination prevents outward 
clinical signs of infection but this does not reveal its impact on T cell responses, viral 
load and lung injury during infectious challenge. As discussed in the introduction, 
current models of the effects of mucosal T cells are extrapolated from data derived 
from primary T cell responses in mice. These predict that any starting number of CD8+ 
T cells less than 105 would have little impact on the peak viral load or clearance time213 
because early in infection the number of susceptible cells remains high (due to an as 
yet insufficient type I IFN response) and the clearance of infected cells is overwhelmed 
by rapid viral spread. Accurately modelling the effects of pre-challenge mucosal T cells 
on peak viral titres and clearance time has translational relevance in two key regards. 
Firstly, the relative contribution of viral burden (and its direct cytopathic effects) and T 
cell response (especially pro-inflammatory cytokine production) to lung injury remains 
incompletely understood. For example, do very high T cell numbers inevitably lead to 
lung injury irrespective of the viral load, or vice-versa?  
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Secondly, the peak viral load and time to viral clearance is a key determinant of the 
spread of a new influenza strain throughout a susceptible population. The basic 
reproductive ratio, R(0), is a threshold parameter that estimates the number of 
secondary infections in a wholly susceptible population resulting from an infected 
individual. If R(0) is less than 1 the epidemic dies out, whereas if R(0) is greater than 1, 
the epidemic persists. R(0) is sensitive to both peak viral load and average duration of 
infection which both determine duration of viral shedding. Tracking the effects of SC-
IN vaccination on influenza viral load after challenge thus has implications for the 
efficacy of this approach in limiting the spread of novel influenza strains in a 
population.  
The ability to generate large numbers of NP-specific T cells in the lung prior to 
challenge provides an opportunity to clarify the relationship between lung injury and T 
cells and determine whether viral load is sufficiently controlled to impact upon the 
dynamics of influenza spread through a population.  
 
5.1.2 Duration of protection 
 
One of the major challenges in mucosal T cell vaccination is generating long-lasting 
populations of tissue-resident memory T cells that confer protection for the duration 
of an infectious threat. As described above, T cell mediated heterosubtypic immunity 
against influenza in mice wanes in parallel with falling numbers of lung-based T cells 
some 15 weeks after primary infection234. In humans, the duration of heterosubtypic 
immunity conferred by infection is less clear. Early studies by McMichael et al 
estimated circulating CD8+ T cell responses to NP peptides after infection to have a 
half-life of 18 months233. However, recent work by the same author highlights the 
marked discrepancies between T cell responses in the periphery and lung (as isolated 
by BAL) after influenza infection470. In the previous chapter we described Ki67HI CD8+ T 
and CD4+ T cells in the airway which differ from the non-replicative lung-resident T 
cells previously described after primary infection. This, together the previously 
reported longevity of LV transduced alveolar macrophages, raises the possibility that 
lung-based T cell populations may be sustained after SC-IN vFLIP-NP vaccination - by 
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on-going antigen presentation and a persistent chemokine signal – longer than is 
observed after primary infection. In this chapter we examine whether protection is 
sustained over a prolonged duration (4 months) and also whether T cell memory 
generated by SC vaccination can be effectively recalled by intranasal vaccination after 
a similarly prolonged delay.  
 
5.1.3 Recall of naturally acquired T cell memory 
 
The recent SOH1N1 pandemic illustrated the problems with timely delivery of an 
antibody-based vaccine in the face of a rapidly spreading strain. Given that indefinite 
mucosal T cell protection may be unachievable (or undesirable due to potential 
disruption of immunoregulatory homeostasis in the lung) a stockpiled universal 
vaccine that temporarily boosts mucosal immunity upon emergence of a new influenza 
reassortment strain may be a feasible approach to pandemic control. A prime-boost 
vaccine regimen has logistical drawbacks so recall with intranasal boosting of pre-
existing influenza-specific T cells established by prior infection may be a more 
successful approach. To model this scenario we infected mice with A/Eng/195/09, a 
strain isolated from an individual with mild clinical disease during the recent pandemic, 
then attempted to recall memory T cells to the lung with intranasal vFLIP-NP.  
 
5.1.4 Cross protection 
 
The ability of T cell responses generated by vaccination against influenza NP to protect 
against multiple influenza subtypes is well established in mice. Emergent pandemics, 
however, frequently result from major reassortments from strains that were 
previously limited to non-human species which can include substantial variations in the 
conserved internal proteins. For example, the A/Eng/195/09 NP has only 91% amino 
acid homology with NP from A/PR/8/34. The degree to which a T cell response 
generated against one NP will protect against infection with a divergent sequence is 
likely to be determined by the degree of preservation of class I and class II restricted 
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epitopes. The latter differs between these strains. We therefore tested the ability of 
SC-IN vFLIP-NP, in which the NP is identical to A/PR/8/34 to protect against 
A/Eng/195/09. 
 
5.1.5 Vaccine safety 
 
Although lentiviral vectors are in use in clinical trials currently, safety concerns remain 
over the risk of insertional mutagenesis with use of integrating viral vectors. Clonal cell 
dysregulation after transduction with gamma retroviral vectors has led to leukaemias 
and myelodysplasias in several clinical trials471,472. Insertion of LTR elements next to 
proto-oncogenes appears to be the principal oncogenic mechanism in these cases. 
Mutagenic events following the use of LV based on HIV-1 in clinical trials, such as the 
treatment of X-linked adrenoleukodystrophy, have not been observed to date473. 
However, aberrant splicing events have been observed following the use of LV in 
humans, wherein cellular mRNA transcripts have been up-regulated following insertion 
into splice acceptor sites in the vector backbone474. 
One means of addressing this risk is through the use of integration-deficient lentiviral 
vectors. These have mutations in either the integrase, LTR or both. After cell entry and 
reverse transcription the vectors persist as circular DNA episomes. Homologous 
recombination within the two LTRs generates a circular episome with a single LTR, 
whereas less frequent non-homologous end-joining of the linear episome results in a 
circular episome with two adjacent LTRs. Since these have no origin of replication, 
expression is lost as the target cell divides but should persist in non-dividing cells such 
as neurones475 and muscle cells476. Our group has previously demonstrated that 
nonintegrating lentiviral vaccines generate a humoral and cellular response against 
encoded antigen126. Negri et al have shown that human monocyte derived DC and 
macrophages transduced with integrase-defective LV expressing influenza M1 can 
expand autologous M1-specific CD8+ T cells477. 
However, expression of the LV transgene from circular episomes is as little as 1/10th of 
that seen with integrating LV478,479. This may not impede generation of primary CD8+ T 
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cell responses which are less sensitive to antigen quantity, but may impair secondary 
responses, wherein antigen quantity is a major determinant of the magnitude of CD8+ 
T cell recall. This is pertinent to their ability to recall existing T cell memory by an 
intranasal route which is tested in the experiments described in this chapter. 
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5.2 Aims 
 
 To investigate the relationship between T cell number, viral load, cytokine 
response and lung injury during infection in mice with systemic CD8+ T cell 
immunity (SC vaccinated), mucosal T cell immunity (SC-IN vaccinated) and naïve 
mice 
 
 To determine whether protection conferred by vFLIP-NP SC-IN vaccination is 
preserved for the duration of an influenza season (approximately 4 months) 
 
 To determine whether T cell immunity generated by infection can be recalled 
by intranasal vFLIP-NP for protection, and whether human T cell memory can 
be recalled in vitro by autologous APCs transduced with LV 
 
 To determine whether SC-IN vFLIP-NP vaccination confers protection against 
A/Eng/195 containing a non-homologous NP.  
 
 To determine whether SC-IN vaccination with non-integrating LV can generate 
T cell responses against NP 
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5.3 Results 
 
5.3.1 Intranasal vaccination limits influenza replication without lung injury or 
cytokine accumulation 
 
Given that T cells are established mediators of inflammation during the influenza 
response, generating large populations of lung- and airway-based memory T cells 
by vFLIP-NP SC-IN immunisation has potential to enhance tissue injury upon 
challenge. We therefore examined the relationship between T cell number, 
secondary effector cytokine responses, viral load and lung injury after influenza 
infection in mice vaccinated with vFLIP-NP by SC or SC-IN regimens. Unimmunised 
mice (n=22) were challenged with a sub-lethal (0.8xLD50) dose of A/PR/8/34. vFLIP-
NP SC (n=20) group mice were immunized twice subcutaneously with vFLIP-NP 
50ng 2 weeks apart then challenged with 2xLD50 of A/PR/8/34 2 weeks after the 
final immunization. vFLIP-NP SC-IN (n=18) mice were immunised with vFLIP-NP 
50ng subcutaneously followed by intranasal vFLIP-NP 200ng 2 weeks later, then 
challenged with 2xLD50 of A/PR/8/34 2 weeks after the final immunization. In all 
groups 3 mice were analysed pre-challenge and on 3, 6, 9 and 15 days after 
challenge. 
 
Figure 5-1B shows that there were marked differences in the ability of 
subcutaneous or vFLIP-NP SC-IN immunized mice to control viral replication. In the 
SC-IN group, the presence of effector phenotype (CD62LLO) antigen-specific T cells 
in the airway and lung homogenate before challenge corresponded with rapid 
control of viral replication, which peaked 3 days sooner and at 14-fold lower levels 
than the subcutaneously immunised group. Notably, in the subcutaneously 
immunised group, NP-specific T cells did not start to accumulate in the lung and 
airway until 6 days after viral challenge. This corresponded with both the nadir in 
weight and peak viral load in lung homogenate. This response was nevertheless 
faster than the primary response in unvaccinated animals given a sub-lethal 
challenge, wherein numbers of effector phenotype CD62LLO NP-specific T cells in 
lung homogenate were 5-fold lower at this time-point.  
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Both T cell derived IFNγ and TNFα play a prominent role in lung injury480,481. In 
humans, strong and early CD4+ TH-17 responses have been associated with a more 
severe illness during the recent swine-origin H1N1 pandemic, and in knockout 
mouse models IL-17 has been shown to be essential for lung injury, weight loss and 
neutrophil infiltration but dispensable for viral clearance273,274. Similarly, IL-4 and IL-
10 CD4+ T cell responses potentiate lung injury and airway hypersensitivity in 
influenza infection of mice without enhancing viral clearance or protection272. We 
therefore examined levels of these cytokines before and after influenza challenge in 
lung homogenate (Figure 5-1C and Figure 5-2B). 
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Figure 5-1 Airway and total lung CD8+ NP147-155 pentamer+ T cell responses, viral loads 
and T cell cytokine burden after influenza challenge. Mice were immunised and 
challenged as described in the text (page 179) (A) CD8+ NP147-155 pentamer+ T cell 
numbers in 2x2ml BAL per mouse. Stacked bars show CD62 low and high populations. 
(B) CD8+ NP147-155 pentamer+ numbers in total lung homogenate. Overlaid polygon 
indicates viral load by plaque assay adjusted for wet lung mass. (C) Levels of T cell 
cytokines in lung homogenate (IFNγ, TNFα, IL-4, IL-10, IL-17) which have previously 
been implicated in lung damage during influenza infection. Levels are shown relative to 
the baseline (day 0) average across all three groups. (D) Splenic NP-pentamer 
responses during infection.  
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Figure 5-2. T cell and total 
cytokine responses in lung 
after influenza challenge. (A) 
Lung homogenate CD4+ and 
CD8+ T cell cytokine responses 
after PR8 challenge. Groups of 
mice were immunised as 
described in the main text. The 
adjacent histogram shows 
area-under the curve analysis 
for each immunization group 
over the 15-day study period. 
(B) Total cytokine levels 
(pg/ml) in lung homogenate 
post-influenza challenge from 
which fold-increase values in 
Figure 5-1 are derived. Error 
bars show +/-S.E.M. 
A B 
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Figure 5-3 Histological 
analysis of lungs after 
influenza challenge. One 
mouse per immunization 
group (as described on 
page 179) was withdrawn 
at day 6 for histological 
analysis of lung tissue 
(without prior BAL). 
Coronal sections were 
stained with hemotoxylin 
and eosin prior to analysis. 
Inset box shows 10x 
magnification from the 
proximal right lower lobe 
of each mouse. Bar 
indicates 500 μm. 
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Figure 5-4 Histological 
analysis of one mouse per 
group withdrawn at day 15. 
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In naïve and subcutaneously vaccinated mice, levels of TNFα, IFNγ, IL-10, IL-4 and IL-17 
rose in line with numbers of pulmonary NP-specific T cells and both reached 
significantly higher peaks in the subcutaneously vaccinated group, despite the higher 
peak viral titres in unvaccinated mice. However, in lung homogenates in the SC-IN 
group before and after challenge, these cytokines were minimal or absent (for 
absolute concentrations, see Figure 5-2). These differences corresponded to lung CD4+ 
and CD8+ T cell-specific IFNγ and IL-2 cytokine responses to overnight re-stimulation in 
vitro. Again, these were significantly greater and more sustained in SCx2 vFLIP-NP 
vaccinated mice than in SC-IN vFLIP-NP group or unimmunised mice by area-under the 
curve analysis (Figure 5-2A).  
 
Histological analysis of lungs taken from one mouse in each group at days 6 and 15 
revealed marked differences in the degree of lung injury (Figure 5-3 and Figure 5-4 
respectively). In SC-IN vaccinated mice, although T cell infiltration was evident, no areas 
of airway loss or consolidation were found at day 6 or day 15. In SCx2 vaccinated mice 
however, there were multiple areas of consolidation in which the airway lumen was 
obliterated by inflammatory cell infiltrate, epithelial cell hyperplasia and haemorrhage. 
These changes persisted at day 15. This focal damage appeared more severe than that 
seen following influenza infection of naïve mice despite higher peak viral titres in the 
unvaccinated group.  
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5.3.2 Antigen-specific CD8+ T cell populations and protection against influenza 
established by intranasal vaccination are sustained for at least 4 months  
 
Generating long-lived protection against influenza is critical to effective vaccination 
coverage during an influenza season or emerging pandemic. We therefore investigated 
whether lung T cell levels and protection would be sustained 4 months after SC-IN 
vFLIP-NP immunisation (“early recall” group). Whilst a clinically applicable vaccine 
would require rapid induction of mucosal immunity and thus a short interval between 
SC and IN immunizations, the antigen specific T cell population 2-weeks after 
subcutaneous vaccination is likely a mix of waning primary effectors and established 
memory T cells. In order to determine whether lung-based CD8+ T cells could be 
recalled from an established systemic memory population, we examined whether IN 
immunization with LV 4 months after SC vaccination could recall a memory-only T cell 
population (“late recall” group). 
 
Analysis of mouse lung homogenate 4 months after SC-IN immunization (“Early recall”, 
Figure 5-5) revealed no significant difference compared with total lung CD8+ T cell 
numbers in mice receiving vFLIP-NP IN 2 weeks before analysis (“late recall”). A large 
population of NP147-155 pentamer+ CD8+ T cells remained 4 months after intranasal 
recall with vFLIP-NP IN (“early recall”) which conferred complete protection from 
lethal influenza challenge. Similarly, the 4-month interval between subcutaneous 
prime and intranasal boost with vFLIP-NP had no effect on the level of T cell recall 
which was comparable to that resulting from the standard SC-IN 2 week interval in 
both quantity and degree of protection upon challenge. 
 
5.3.3 SC-IN vFLIP-NP protects against A/Eng/195/09 and intranasal vaccination NP 
can boost naturally-acquired cross-strain immunity 
 
Whilst the presence of memory T cells specific to influenza NP have been repeatedly 
shown to cross-protect against other subtypes sharing the same dominant T cell 
epitopes, a less examined question is whether this protection is preserved despite 
variation in NP sequence between strains. A/Eng/195/09 NP shares only 91% amino 
acid homology with A/PR/8/34 NP and the well-described H2-Kd-restricted CD4 
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epitope NP57-78 is non-identical. To determine whether the protection conferred by 
vFLIP-NP SC-IN vaccination was maintained despite this sequence variation, mice were 
challenged with 5x104 PFU of A/Eng/195/09 and monitored for weight loss. Whereas 
naïve mice developed a prolonged illness losing approximately 10% of baseline weight, 
vFLIP-NP SC-IN vaccinated mice showed no signs of disease or weight loss (Figure 
5-6B).  
 
Much of the human population has had prior influenza exposure and thus has cognate 
T cell memory. A subcutaneous vaccination may be dispensable if naturally-acquired T 
cell memory can be boosted by intranasal vFLIP-NP administration. To model this, we 
infected naïve mice with non-lethal A/Eng/195/09, an H1N1 strain isolated from a 
patient in the UK during the recent swine origin H1N1 pandemic causing mild clinical 
disease, and then examined the effect of intranasal boosting with vFLIP-NP. Prior 
infection with A/Eng/195/09 gave 44% protection against lethal A/PR/8/34 challenge 
64 days later, though all survivors lost considerable weight indicating the absence of 
cross-neutralizing antibodies against surface epitopes. However, vFLIP-NP intranasal 
boosting after non-lethal A/Eng/195/09 conferred 100% protection without weight 
loss against lethal A/PR/8/34 challenge (Figure 5-6A).  
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Figure 5-5 Longevity of SC-
IN vFLIP-NP protection and 
application in clinically 
relevant models. Long-
term preservation of lung-
based T cell memory 
populations 4 months after 
vFLIP-NP SC-IN and 
protection against lethal 
2xLD50 A/PR/8/34 
challenge. Top: Lung total 
CD8 and superimposed 
NP147-155 pentamer CD8+ T 
cells following intervals 
between subcutaneous 
and intranasal 
immunization and 
challenge indicated on the 
x-axis. Levels were 
compared using Students T 
test. All mice were 
challenged on day 140 
(n=10 per group) or 
withdrawn for analysis 
(n=5 per group). Survival 
(middle) and weight loss in 
survivors (bottom) 
following challenge with 
lethal A/PR/8/24 are also 
shown. 
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  Figure 5-6 (A) Recall of naturally-acquired T cell memory to the lung by intranasal 
vFLIP-NP LV. Top: Lung total CD8 and superimposed NP147-155 pentamer CD8+ T- 64 
days after non-lethal challenge with A/Eng/195/09, with and without intranasal 
vFLIP-NP boosting 2 weeks before analysis (n=4 per group). Percentages of total 
CD8+ T cells that are NP147-155 pentamer +ve are shown within bars. Survival and 
weight loss in survivors (n=12 per group) are shown beneath following challenge 
with lethal A/PR/8/24 64 days after prior non-lethal infection with A/Eng/195/09. 
Mantel-Cox tests and Gehan-Breslow-Wilcoxon Test produced similar p-values for 
observed differences in survival. (B) Cross-strain protection against A/Eng/195/09 
conferred by SC-IN immunisation with LV vFLIP-NP. Mice (n=10 per group) were 
challenged with 5x104 PFU of A/Eng/195/09 two weeks after the final immunisation 
and weights monitored as previously.  
 
 
A B 
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5.3.4 Nonintegrating LV prime systemic T cell responses but do not establish lung-
based T cell populations by intranasal recall 
 
vFLIP-NP LV were produced using a packaging plasmid encoding a defective integrase 
(vFLIP-NP NI). We and others have previously demonstrated this leads to an 
integration rate 10,000 fold lower than LV produced with a WT integrase475,478. Mice 
were vaccinated with a single dose of 200 ng RT vFLIP-NP NI SC and splenocytes 
analysed 2 weeks later for NP-pentamer+ CD8+ T cells or IFNγ responses upon re-
stimulation with NP peptide. This revealed that vFLIP-NP NI generates a detectable 
CD8+ T cell response as measured by pentamer and IFNγ expression after re-
stimulation. However, the responses were less than those seen with WT vFLIP-NP or 
Null-NP vaccination(Figure 5-7). SC-IN vaccination with vFLIP-NP NI failed to induce 
lung-based NP-specific T cells, despite giving a higher dose of 800 ng RT IN, although IN 
administration did appear to non-specifically increase the number of CD8+ T cells in 
BAL. This increase was approximately 7-fold, compared with a 60-fold increase induced 
by WT vFLIP-NP. Correspondingly, protection was not enhanced beyond the level seen 
with SC vaccination with WT vFLIP-NP. 
 
5.3.5 Human monocyte derived DC transduced with LV can recall NP-specific 
autologous CD8+ T cell responses.  
 
To test the principle that lentivirus-transduced APCs could recall human influenza T cell 
responses, we transduced monocyte-derived dendritic cells from HLA-A3 healthy 
volunteers (NP from A/PR/8/34 lacks a well-characterised HLA-A2 epitope) and co-
cultured with autologous PBMC. These were then analysed for expansion of IFNγ or 
TNFα-secreting CD8+ T cells in vitro. 5 out of 7 HLA-A3 volunteers demonstrated a 
discernible expansion of IFNγ-secreting CD8+ T cells following expansion with peptide 
pulsed, IFNγ/LPS matured DC.  This showed that monocyte-derived human DC 
transduced with vFLIP-NP LV stimulated significantly enhanced IFNγ and TNFα CD8+ T 
cell responses compared to Null-NP transduced DC, or DC matured with IFNγ and LPS 
and pulsed with the HLA-A3 restricted NP peptide. Use of LV expressing vFLIP with 
hepatitis B core (HBc) (or pulsing of LPS/IFNγ-matured DC with HBc peptide) did not 
induce an IFNγ T cell response, thus indicating these responses are NP-specific.  
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Figure 5-7 T cell responses in spleen, lung and airway after vaccination with non-
integrating (NI) vFLIP-NP LV. Integrating vFLIP-NP responses are shown in splenocytes 
for comparison.  
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Figure 5-8 Human monocyte-derived DC transduced with LV expressing NP recall 
autologous T cell responses in vitro. PBMCs from HLA-A3 positive healthy volunteers 
were co-incubated with autologous DC that had been transduced with LV (or matured 
with LPS and IFNγ and pulsed with the HLA-A3 restricted peptide NP265-274). Cultures 
were re-stimulated with NP265-274 peptide prior to cytokine detection. To control for 
non-antigen specific stimulation DC transduced with LV encoding HBc were used. Data 
shown is for 5 out of 7 HLA-A3 subjects who responded to matured DC plus NP 
peptide. The % positive CD8+ T cells in each group were compared by the Wilcoxon 
matched pairs test. 
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5.4 Summary 
  
The presence of NP-specific T cells in the lung and airway prior to challenge 
significantly shortens the duration of infection and peak viral titres compared with 
both naïve mice and those with systemic T cell immunity. The concurrence of high viral 
load and T cell number, rather than either in isolation, appears to drive cytokine 
production and lung injury. SC-IN vFLIP-NP vaccination leads to populations of lung-
based NP-specific CD8+ T cells that are sustained for at least 4 months after the final 
vaccination. These confer 100% protection against lethal influenza challenge with 
minimal weight loss. A 4-month gap between SC and IN boost does not impair the size 
of the recall response to the lung. Mucosal T cell populations can also be boosted 60 
days after primary infection with A/Eng/195/09 and confer complete protection 
against lethal A/PR/8/34, which is not neutralised by antibody mediated sterile 
immunity. SC-IN vFLIP-NP also protects against A/Eng/195/09 despite variation in NP 
sequence which includes the H2Kd-restricted CD4 epitope. SC vaccination with non-
integrating vFLIP-NP induces NP-specific CD8+ T cells and confers partial protection 
against lethal A/PR/8/34 challenge but with clinical disease. SC-IN vaccination with 
vFLIP-NP NI does not induce mucosal NP-specific T cell populations in lung 
homogenate or airway. Human DC transduced with LV can recall in vitro autologous T 
cell responses against NP in HLA-A3 healthy volunteers. The strength of the recall 
response appears to be enhanced by vFLIP.  
 
5.5 Discussion 
 
Moskophidis et al were the first to interrogate the relative contribution of viral load 
and influenza-specific T cell number to histopathological change and 
morbidity/mortality in detail. They manipulated viral load (through influenza 
inoculation dose) in RAG-/- mice (lacking B cells and T cells) and F5-Rag-/- mice 
expressing a uniform αβ TCR heterodimer mice such that 90% of CD8+ T cells are 
specific for an influenza A/NT/60/68 nucleoprotein epitope482. Unlike Rag-/- mice, F5 
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Rag-/- survived challenge at low challenge doses (<104 PFU A/NT/60/68). However, a 
key finding of this study was that F5-Rag-/- mice infected with a high inoculum (107 
PFU) died significantly faster than Rag-/- challenged with the same dose. Histological 
analysis showed that there was less histopathlogical change in lung sections from Rag-
/- mice than F5 Rag-/- mice at an equivalent level of viral load, and injury developed 
more rapidly in the latter. The addition of anti-IFNγ mAb during infection lessened 
histopathological damage but had no impact on survival. The authors concluded that 
“the challenge in creating a CTL-based vaccine directed against heterosubtypic 
influenza virus strains is to raise the abundance of CTL precursor cells early in the 
infection in order to increase the protective response without exacerbating a pathology 
that is also CTL dependent”. 
 
We have shown this is achievable through SC-IN vFLIP-NP vaccination, inducing a large 
lung-based CD8+ T cell population which secures rapid viral elimination and low peak 
titres such that stimulation of a deleterious secondary effector response is altogether 
avoided.  
 
Further important inferences can be made from these data: 
 
 Local, but not systemic, T cell responses are proportionate to viral load. The 
lower peak viral load seen in SC-IN vaccinated mice leads to lower peak lung T 
cell numbers but splenic memory NP-specific populations increase in line with 
those in SC vaccinated mice with 14-fold higher lung viral titres 
 
 Relatively few lung-based NP-specific CD8+ T cells are required pre-challenge 
(compared with peak T cell responses seen during infection) to clear a lethal 
challenge without clinical disease. 
 
 Viral titres in unvaccinated mice given a sublethal challenge reach a higher 
peak than SC vaccinated mice given a lethal dose, but a slower and less 
vigorous T cell response means peak and cumulative cytokine levels were lower 
in naïve mice. This suggests that the concurrence of high viral loads and T cell 
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numbers, rather than either in isolation, are necessary to elicit high cytokine 
levels and lung injury.  
 
 The absence of lung injury with the near-absence of a TNFα, IFNγ, IL-4, IL-10, or 
IL-17 response corroborates the previously described role of these cytokines in 
deleterious histopathological change in influenza.  
 
The shortened duration of infection and 14-fold lower peak viral loads seen in SC-IN 
versus SC vaccinated mice strongly supports the use of vaccination approaches that 
aim to maximise mucosal rather than systemic T cell immunity. The impact of this 
approach has yet to be modelled in the same way as the impact of systemic T cell 
memory on heterosubtypic immunity. As discussed in the introduction, extrapolations 
from models arrived at through analysis of lung CD8+ T cell number during primary 
and secondary responses predict that high numbers (>105) of lung-based T cells would 
be necessary to have any impact on peak viral load or clearance time482. This is 
because the rate at which infected cells are killed would have to be very high to limit 
replication if susceptibility of uninfected cells remains undiminished by the as yet 
minimal I IFN response in the first 2 days after infection. In absolute terms, SC-IN 
vFLIP-NP vaccination seems to achieve around 1.5-2x104 NP-specific T cells, although 
we have used a non-enzymatic extraction technique and true numbers may be 
significantly higher. Nevertheless, this is sufficient to achieve a level of protection that 
prevents signs of clinical disease and is likely to considerably reduce the infectiousness 
of the vaccinated individual. 
The duration for which this level of protection is maintained is unclear from these 
data, since it may extend beyond 4 months. Memory cells in the secondary lymphoid 
are stably maintained by IL-15- and IL-7-driven homeostatic proliferation 483–485. 
However, the factors that influence numbers of memory T cells at peripheral sites of 
infection (or vaccination) are unknown. T cells primed by skin-derived DC express a 
skin-homing phenotype including E-selectin and P-selectin ligands and chemokine 
receptor 4 (CCR4) and CCR10486–488. Similar “imprinting” for intestinal migration results 
from priming by specialized DC subsets in the Peyer’s patches or mesenteric lymph 
nodes489,490, inducing CCR9 and integrin α4β7 expression in activated T cells which 
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recirculate to the intestinal mucosal due to high selective expression of MAdCAM-1, 
the ligand for integrin α4β7, on the surface of high endothelial venules and constitutive 
expression of C-C chemokine ligand 25 (CCL25), the ligand for CCR9, on intestinal 
epithelial cells. It is not known whether lung-draining DC imprint a particular migration 
pattern favouring the lung parenchyma or the airway, or whether antigen or 
chemokine signals are each sufficient to maintain recruitment from the circulation 
which appears to be the principal means by which these populations are maintained 
after infection461,491492,. Using a series of parabiotic mouse pairings, Zammit et al 
explored the requirement for antigen to maintain lung and airway influenza-specific 
CD8+ T cells after infection. When mice recently infected with X31 were conjoined 
with syngeneic naïve mice, NP-specific CD8+ T cells from the donor rapidly equilibrated 
with the naïve mouse in the spleen and circulation but these appeared much later in 
the lung parenchyma of naïve mice and none appeared in the airway. If both mice 
primed with X31 infection prior to being conjoined, T cells from each mouse (CD45.1 
or CD45.2) would recirculate to the lung and airways of the other. To determine 
whether migration to the lung and airway was dependent on antigen or other 
inflammatory signals, mice primed intranasally with OVA-expressing listeria were 
conjoined with A/X31 infected mice. OVA-specific T cells could not be detected in the 
lung or airway of the latter, suggesting recruitment to this site is antigen-specific 
rather than dependent upon non-specific inflammatory signals. In a further 
experiment in this study, CFSE stained CD8+ T cells were transferred from F5 RAG-/- 
mice transgenic mice (described above) into mice infected 60 days previously with 
E61-13-H17 influenza (expressing the F5 TCR CD8 T cell epitope). Adoptively 
transferred T cells proliferated rapidly in the lung-draining lymph nodes but not in the 
lung parenchyma itself, indicating the presence of antigen in the former two months 
after infection. The absence of detectable influenza RNA at this time point suggests 
antigen is preserved without replicating virus, perhaps as immune-complexed antigen 
on the surface of follicular dendritic cells. How this lymph-node centred proliferation 
of influenza-specific T cells after infection maintains lung and airway T cells is unclear. 
Airway-based influenza specific CD8+ T cells appear to be recruited continually from 
the circulation with a rapid turnover (90% every 10 days). The precise signals 
governing this chemotaxis are unknown, although the expression of BTL-1 (the 
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receptor for leukotriene B4) and the α1β1 integrin VLA-1 which mediates retention of 
effector T cells at peripheral sites of inflammation may both play a role493,494. 
In Section 4.3.4  we identified a number of T cell chemoattractants that are secreted 
by vFLIP activated AM. A simple of means of identifying the relative importance of 
each of these in generating and/or maintaining CD8+ T cell populations in the lung and 
airway would be to examine the relative expression of their respective receptors on 
airway-based CD8+ T cells after intranasal LV. This would permit development of a 
more selective LV intranasal recall boost expressing NP and only the chemokine(s) 
necessary for T cell maintenance. This would avoid NFкB activation of large numbers of 
AM, which risks disrupting local immunoregulation and inappropriately heighten 
responses to innocuous inhaled antigen.  
We have not yet tested the longevity of lung-based T cell populations after boosting 
with Null-NP or vFLIP-GFP, which would determine the relative importance of antigen 
versus chemokine secretion in the recall signal for mucosal memory maintenance. The 
longevity of LV-transduced AM in other studies (which we have not yet examined in 
our model) hints at the possibility of maintaining antigen presentation in the airway 
and chemokine secretion indefinitely. Whether this is desirable or not is an important 
question, since prolonged antigen exposure may risk T cell exhaustion, or the presence 
of long term T cells with low levels of activation may have unforeseen deleterious 
consequences in the lungs such as stimulation of fibrosis.  
The ability to “switch off” antigen presentation or chemokine secretion by AM would 
afford on opportunity to investigate the requirements for maintenance of mucosal T 
cell immunity. Since clodronate liposomes (or intranasal diphtheria toxin in CD11c-DTR 
mice) eliminate all macrophages this approach kills untransduced AM and negates 
their immunoregulatory function. As discussed in Section 4.5, we have therefore 
developed a trivalent LV expressing antigen together with the diphtheria toxin 
receptor (either side of an internal ribosomal entry site (IRES)) driven by a PGK 
promoter, with vFLIP expressed from the SFFV promoter. Initial data suggests that AM 
transduced by an LV expressing GFP and DTR are completely eliminated by intranasal 
diphtheria toxin administered 4 days after LV, with preservation of large numbers of 
live untransduced AM. This approach may therefore provide a useful model by which 
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the impact of removal of transduced AM upon longevity of mucosal T cell populations 
can be studied.  
The ability of T cells specific to NP to confer heterosubtypic protection is well 
established in mice. This is typically demonstrated using A/PR/8/34 (H1N1) and X31 
(H3N2) which share identical nucleoprotein sequences. Variations in the 
immunodominant class I restricted epitopes between primary and secondary influenza 
infections are known to significantly impair heterosubtypic immunity in mice495. 
Fortunately there is a preponderance of influenza epitopes restricted by highly 
prevalent HLA subtypes which are both highly conserved and immunodominant. 
However, the degree to which variation in other less conserved epitopes impacts on 
cross-protection is less clear. Such variation may disrupt class II restricted epitopes and 
therefore impair CD4+ T cell secondary responses, or generate class I restricted 
epitopes that compete with the immunodominant epitope for processing and 
presentation. The emergence of A/Eng/195/09 during this work provided an ideal test 
of the ability of T cells generated by SC-IN vFLIP-NP vaccination to protect against a 
strain with only 91% NP amino acid homology (but preserved a preserved H2Kd 
restricted epitope). We have shown that A/Eng/195/09 infection does generate some 
degree of protection against A/PR/8/34, although all mice lose weight suggesting this 
is not mediated by sterilising antibodies against HA or NA. This immunity can be 
substantially boosted by intranasal vFLIP-NP to confer compete protection against 
A/PR/8/34 without weight loss. Furthermore, SC-IN vaccination with vFLIP-NP confers 
complete protection against A/Eng/195/09. Thus the absence of corresponding CD4+ T 
cell epitopes in the NP of A/PR/8/34 (and the LV vaccine) and A/Eng/195/09 does not 
appear to impair protection.  
 
The lower transcriptional activity of non-integrating LV compared with integrated 
vector has been established both in vivo and in vitro. All previous reports of the use of 
NI LV for vaccination have required higher doses (often 10-fold or more) of the vector 
compared with WT LV in order to induce equivalent T cell responses158,496,497. Since we 
delivered 200ng RT in 40 μL to each mouse, this required a minimum concentration of 
5 ng/μL which is at the upper limits of LV concentration using standard production 
protocols. Increasing this 10-fold is challenging (we have managed a maximum 
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concentration of 20 ng/μL). Scaling up production and increasing concentration for 
proof of principle in mice may be possible, but LV production for human clinical use 
would require a prohibitive magnitude of up-scaling with current production 
techniques. Furthermore, increasing the dose of NI LV may not necessarily correspond 
to increased efficacy, since there may be direct silencing of episomal DNA in murine 
AM. Further examination and optimisation of the level of expression of episomal 
transgenes in murine AM and DC is necessary. 
 
The enhanced in vitro recall of NP-specific autologous human T cell responses by 
monocyte derived DC transduced with vFLIP suggests that NFкB activation of APCs may 
enhance T cell function at recall as well as at priming. Memory T cell recall responses 
are conventionally regarded as independent of APC-delivered co-stimulation498,499. 
However, in some models of secondary acute viral infection in mice, such as murine 
gamma herpes virus 68 (MHV-68) and vaccinia virus, CD28 stimulation has been shown 
to be necessary for efficient CD8+ T cell recall500. In influenza, CD28-/- mice show 
impaired priming of influenza-specific CD8+ T cell responses and subsequent recall, 
although it is unclear to what degree the poor secondary expansion is a consequence 
of a failure to generate sufficiently responsive memory population at priming rather 
than at recall501.  
 
It is difficult to discount the possibility that the enhanced CD8+ T cell recall response 
seen with NFкB activation of DC is due entirely to increased MHC I expression and thus 
greater exposure of memory T cells to antigen. It would be useful to repeat this 
experiment using ex-vivo human AMs from BAL although this would be subject to the 
confounding factor of AM activation upon extraction from surfactant and the other 
immunoregulatory signals of the airway environment discussed above. AM can be 
transduced in vivo by aerosolisation of viral vectors in primate models502, although the 
majority of clinical gene therapy trials for cystic fibrosis have hitherto only attempted 
to demonstrate transduction of nasal epithelium in which transduction is more readily 
verified503.  
 
In summary, vFLIP-NP SC-IN vaccination shows promise across a range of scenarios 
analogous to its application in the clinical domain. However, in addition to the safety 
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concerns regarding integrating LV there are major hurdles to overcome for the 
expanded use of lentiviral vectors in Phase I/II clinical trials. This requires efficient, 
large-scale production under current Good Manufacturing Practice guidelines. A 
number of investigators, including this group, have addressed this by creating 
packaging cell lines to produce LV504–507. These can be grown in suspension in large 
bioreactors to generate high volumes of LV. Many of these have used inducible 
expression systems to avoid the cellular toxicity from HIV proteins and the VSV-G 
envelope. However, a recurring issue is vector gene silencing over time with increasing 
passage, resulting in reduced titres508. Furthermore, packaging cell lines still require 
stable transfection with the chosen expression vector and re-selection of clones for 
production which is time-consuming. Therefore whilst small scale clinical trials are 
feasible (and on-going), significant improvement of LV production would be required 
before they could be used cost-effectively in mass vaccination programmes.  
Thus, whilst the level and duration of protection achieved with LV SC-IN in mice is 
compelling, the value of this vaccination modality probably lies for now in its 
advantages as an investigative tool, in particular the ability to discern the 
immunogenic function of an encoded adjuvant from minimal vector-related responses 
and also to target a wide range of immune cells by different routes of administration 
and thus determine their role in immune responses. In the following chapter we 
exploit these characteristics to evaluate the potential of vectored 4-1BB ligand to 
enhance responses against co-encoded antigen.  
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6 4-1BBL as a vectored vaccine adjuvant 
 
6.1 Introduction 
 
6.1.1 APC activation versus selective co-stimulation  
 
Optimising T cell responses for prophylactic or therapeutic applications has for the 
most part focused on generating high quantities of functional memory or effector T 
cells, with a focus on their cytotoxic and cytokine-secreting capability. In previous 
chapters we have shown how vFLIP mediated specific NFкB activation of DC and AM 
leads to an activation phenotype that favours efficient T cell priming and recall 
respectively. Importantly, this generates high quantities of T cells which appear 
effective at clearing influenza-infected targets.  
However, sustained NFкB activation of AM (and epithelial cells) following intranasal 
administration of vFLIP-expressing vectors may be undesirable for several reasons. 
vFLIP has been shown to have oncogenic potential, as evidenced by an increased 
incidence of lymphoma in vFLIP transgenic mice. This appears to occur through 
constitutive up-regulation of NFкB and consequent increased sensitivity to mitogenic 
stimuli, such as c-myc509, rather than through directly inhibiting apoptosis, since Fas-
dependent apoptosis pathways are preserved510. There are alternatives to vFLIP for 
NFкB activation, such as vectored over-expression of an NFKB inducing kinase ( NIK) 
which has similarly been shown to enhance DC activation and T cell responses against 
co-encoded antigen511. However, this does not circumvent the potential problem of 
non-specific activation other pro-inflammatory cells by indefinitely activated DC, which 
may precipitate autoimmune disease.  
A safer, more targeted approach may be to transduce antigen presenting cells with 
antigen and a selected single co-stimulatory signal that is known to induce desirable 
characteristics in the T cell response. Lentiviral vectors are ideal for this purpose since 
their intrinsic low immunogenicity means that background vector-induced APC 
activation is minimised, isolating the effect attributable to the encoded co-stimulatory 
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signal. Supra-physiological up-regulation of a single co-stimulatory molecule has the 
potential to generate pathogen-tailored T cell responses in which phenotypes that 
clear infection are maximized and those that are redundant or contribute to 
inflammation and injury are minimized. The use of endogenous co-stimulatory 
molecules also has the benefit of avoiding the often pleiotropic and unpredictable 
effects of viral adjuvants and their associated safety concerns.  
In this chapter we explore the potential of a lentiviral vaccine expressing influenza 
nucleoprotein with the co-stimulatory molecule 4-1BB ligand (4-1BBL) which interacts 
with 4-1BB (CD137), a member of the tumour necrosis factor receptor (TNFR) family. 
The stimulation of 4-1BB on activated T cells by 4-1BBL expression on antigen 
presenting cells is increasingly recognised as an essential mechanism by which the 
longevity, size and functionality of T cell memory populations can be enhanced. 
Several aspects of this interaction make 4-1BB stimulation an attractive target for 
vaccination as discussed below.  
 
6.1.2 TNF-receptor family signalling in T cells 
 
The engagement of CD28 by its ligands CD80 or CD86 lowers the threshold for T cell 
activation and promotes IL-2 production in naïve T cells512. This is spatiotemporally 
associated with the interaction between the TCR and MHC-peptide complex and is 
thus termed “co-stimulation”. Following commitment to programmed expansion after 
recognition of antigen-MHC on an APC and CD80/86-CD28 co-stimulation, T cells 
continue to receive activation or survival signals throughout subsequent effector and 
memory stages. 
The TNF receptor family have emerged as essential mediators of survival signaling in T 
cell subsequent to initial activation by CD80/86-CD28 interaction. They are expressed 
on both innate and adaptive immune cells and correspondingly can influence T cell 
responses both directly and indirectly. The principle members of the TNFR/TNF ligand 
family that have a direct effect on the T cell response are shown in Figure 6-1. These 
include OX40/OX40L, CD27/CD70, 4-1BB/4-1BBL, HVEM/LIGHT, GITR/GITRL and 
CD30/CD30L. 
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Figure 6-1 TNFR family and ligands. The binding of TNF-receptor associated factors 
(TRAFs) to each receptor is shown. All TNFR are capable of binding TRAF3 which 
inhibits signalling. 
 
TNFR receptors can be sub classified into death-domain (DD)-containing receptors, 
decoy receptors and TNF receptor-associated factor (TRAF) binding receptors513. The 
first of these activate caspase cascades inducing apoptosis and include FAS, TNFRI and 
DR3. All TNFR involved in T cell signalling are able to recruit TRAF2 to their signalling 
complexes together with other TRAF proteins to varying extents, of which six have 
been identified so far514. The pattern of TRAF protein recruitment by different TNFR 
determines which downstream signalling pathways are activated and the 
consequential effects on T cell survival and functional differentiation.  
Much of the importance of TRAF proteins in T cell signaling has been elucidated 
through their modification by truncation of RING finger domains which renders them 
dominant negative (DN) proteins. T cells with DN-TRAF2 fail to activate p38 in response 
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to 4-1BB stimulation515 and have reduced survival following OX40 stimulation516. Other 
TRAF proteins seem less crucial to the central functions of T cell proliferation and 
survival. TRAF 5-/- T cells, for example, exhibit normal IL-2 secretion and proliferation 
but produce higher levels of TH-2 cytokines in response to OX40 or CD27 
signaling517,518. The principle TRAF proteins recruited by TRAF-binding TNFRs, their 
principle downstream signalling pathways and the functional consequences of 
stimulation in T cells are summarised in Table 6-1 below. 
 
6.1.3 4-1BB signaling on T cells 
 
4-1BB recruits both TRAF 2 and TRAF 1 after trimeric interactions between ligand and 
receptor. TRAF2 mediates stimulation of downstream signalling pathways NFкB 
(classical pathway) 519,520, JNK/SAPK521 and p38 MAPK522, whilst TRAF1 appears to 
enhance this interaction by reducing TRAF2 degradation523. T cell survival following 4-
1BB stimulation is promoted by both ERK-dependent ubiquitination of the pro-
apoptotic molecule BIM and by NFкB mediated expression of pro-survival members of 
the BCL-2 family, BFl-1 and Bcl-XL
524. Stimulation of cytokine production by 4-1BB 
signalling is mediated predominantly through TRAF2 dependent p38 activation515 such 
that JNK and p38 activation can occur independently of TCR signalling during 4-1BB 
stimulation. However, a TCR signal is required for 4-1BB signalling to induce IL-2 
production. This suggests there may be interaction between kinase pathways 
downstream of TRAF2 and the TCR although this has yet to be elucidated. 4-1BB may 
also reciprocally influence TCR signalling; cross-linking of 4-1BB has been shown to 
induce tyrosine phosphorylation of TCR-signalling molecules CD3ε, CD3ζ, Lck and SLP-
76 (SH2 domain containing leukocyte phosphorylation of 76 kDa) and co-localised 
these with TCR-MHC/antigen interactions in the immunosyapse525.  
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Receptor/ 
Ligand 
Receptor 
expression 
Ligand 
Expression 
Timing of 
expression of 
receptor in T cells 
TRAF receptor recruitment 
and downstream signaling 
Function in T cells 
OX40/OX40L T cell 
restricted. 
(CD4>CD8)526 
TH2>TH1527 
 
Activated B-cells528 
Avtivated T cells529 
CD40-ligand-
activated DC530 
Endothelial cells531 
48 hrs post T cell 
activation532 
TRAF 2,3,5 
NFKB activation533 
Sustains the expression of anti-
apoptotic BCl-2 family members 
following CD28 signaling in a P-I-
3K dependent manner534. 
 
Augments primary expansion and survival of 
CD4 memory T cells535.  
Enhances CD4 cytokine production532. 
Expands both CD8 and CD4 cells536. 
 
CD27/CD70 NK cells, B-
cells  
Naïve CD4 and 
CD8 T cells537 
Activated T cells, B-
cells and DC538 
Decreases post-
activation539  
TRAF 2, 5 and Siva-1 
Alternative and canonical 
activation of NFKB540 
JNK activation541 
IL-2 dependent enhancement of CD4 and 
CD8 T cell proliferation and cytokine 
production542. 
HVEM/LIGHT Resting T cells, 
monocytes, 
immature 
DC543 
 
Activated T cells544 Reciprocal 
expression of 
HVEM/LIGHT 
following T cell 
activation545 
TRAF 1,2,3,5 
CD28-independent NFkB 
activation546 
T cell cytokine production and proliferation 
soon after T cell activation547.  
CD30/CD30L Activated T 
cells, B-
cells,NK cells, 
eosinophils548 
Resting B-cells and 
activated T 
cells549,550 
 TRAF 1,2,3,5 
Alternative and canonical 
activation of NFKB551 
P38 MAPK activation552 
Enhancement of T cell proliferation and 
cytokine production (including TCR-
stimulation independent IL-13 
production)553.  
Table 6-1. Summary of TNFR family distribution, expression, TRAF recruitment, signaling pathways and function in T cells 
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GITRL/ 
GITR 
Activated T 
cells554 
CD4+CD25+ T-
regulatory 
cells555  
Endothelial cells 
B-cells, 
macrophages, BM-
derived DC556 
Peaks at 24hours 
post-activation of T 
cells557 
TRAF 2 & 3 Siva-1 
Apoptosis through Siva-1 
signaling558 
NFKB activation through TRAF 
2559 
Stimulates proliferation of T cells in the 
absence of CD28 or TCR stimulation560 
Enhances T cell cytokine secretion561. 
Enhances proliferation and survival of T-
regulatory cells562.  
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4-1BB expression in T cells is itself dependent upon NFκB activation following TCR 
engagement with antigen (with the exception of consitutive expression seen on 
CD4+CD25+ regulatory T cells)563. Therefore, 4-1BB expression on T cells may be 
regarded as a mechanism whereby antigen-mediated activation NFκB activation can be 
sustained in an antigen-independent manner in the presence of 4-1BBL stimulation.  
 
6.1.4 Regulation of 4-1BB expression and signalling in T cells and other tissues 
 
4-1BB expression is not restricted to T cells and has been noted on B cells, monocytes, 
macrophages, dendritic cells and eosinophils564–567. It has also been demonstrated in 
non-immune tissues such as endothelial cells, smooth muscles cells, neurons, microglia 
and astrocytes568–570. Tissue-specific regulation of 4-1BB expression may occur through 
production of transcript variants under the control of different promoter regions and 
also by alternative splicing. In the mid-1990s, Kwon et al identified two different 
species of 4-1BB cDNA with varying 5’ untranslated regions (UTR), raising the 
possibility that these are transcribed from different promoters571. Further analysis of 
the tissue-specific expression of these transcripts in the mouse revealed that the type I 
transcript is restricted to immune cells, whereas the type II transcript is ubiquitously 
expressed (and is also found in activated T cells). Three putative promoter regions 
were recently identified, of which promoter region 1 contains NFкB-binding elements 
and all of which contain AP-1 binding elements. The type I transcript (driven from 
promoter region 1) was increased following NFкB stimulation (induced by anti-CD3 
stimulation) and mutation of either NFкB or AP-1 elements prevented anti-CD3 
mediated activation of 4-1BB expression in T cells, with mutation of the NFкB element 
resulting in the greatest abrogation by far. Whilst this confirms previous observation of 
NFкB and AP-1 dependent expression of 4-1BB in T cells572, it does not account for the 
lack of expression of 4-1BB in all tissues despite ubiquitous detection of a second 
transcript variant that differs from transcript 1 in the 5’UTR only. It can be postulated 
that this variable region confers susceptibility to an as yet unknown post-
transcriptional regulatory factor although the function of such a regulatory mechanism 
is unclear. 4-1BB knockout mice develop normally, hence it seems unlikely that 4-1BB 
expression is required during development and later silenced at a translational level. 
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Furthermore, NFкB activation– of which all cells are capable - would seem an 
inadequate mechanism to account for tissue-specific expression of the Type I 
transcript. This suggests  additional regulatory mechanisms are involved.  
 
Alternative splicing of the type I transcript variant may be one such mechanism. This 
produces a soluble variant of 4-1BB (lacking exon 8) in a manner akin to several other 
members of the TNFR family (CD27, CD30, GITR, and Fas). These soluble variants are 
widely regarded as having an antagonistic role to their membrane-bound 
counterparts573,574. In T cells the soluble variant is induced to a similar degree as the 
normal variant by T cell activation. Transient transfection of increasing amounts of 
plasmid encoding soluble splice variant 4-1BB negatively inhibit T cell activation by 
stimulation through 4-1BB in a dose-dependent manner. This appears to occur, at least 
in part, through reduction in expression of the normal membrane-bound 4-1BB in the 
presence of the soluble variant. The production of the splice variant during T cell 
activation may thus provide a brake on potential positive feedback between 4-1BB and 
TCR signalling which prevents T cell hyperactivation575.  
 
 
6.1.5 4-1BB signalling on dendritic cells and other antigen presenting cells 
 
In 2002 Wilcox et al demonstrated that 4-1BB is expressed on both splenic and bone-
marrow derived murine DC of a CD11b+ CD11c+ I-AbHI phenotype. Stimulation of 4-
1BB on DC by co-culture with 4-1BBL-transfected P815 cells resulted in high levels of 
IL-6 in the supernatant and, in combination with LPS, IL-12 was also detectable. This 
effect was neutralized by anti-4-1BBL mAb and reproduced by stimulatory anti-4-1BB 
mAb. Administration of the latter in vivo to RAG-1 knockout mice improved the ability 
of splenic DC from these mice to stimulate proliferation of allogeneic T cells and OVA-
specific OT-1 cells, suggesting DC activation does not occur indirectly via 4-1BB 
activation on T cells. However, this study found no up-regulation of standard co-
stimulatory molecules (CD80, CD86, CD40, 4-1BBL, Ox40L) on the surface of 4-1BB 
stimulated DC. A similar result was obtained by Futagawa et al who again 
demonstrated increased IL-12 secretion by DC stimulated with 4-1BBL-transfected 
p815 cells, although in this instance CD80 and CD86 expression were also increased567. 
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This group also developed a mAb (TKS-1) against 4-1BBL capable of blocking DC 
activation in this system. The downstream signalling pathways activated by 4-1BB in 
DC is presumed to be the same as those in T cells hence it is postulated that DC 
maturation occurs through a combination of NFкB, ERK and p38 MAPK stimulation via 
4-1BB recruitment of TRAFs as described above. This complicates studies examining T 
cell responses to 4-1BB stimulation since this may occur both directly through T cell 4-
1BB expression and indirectly through DC activation. A further complication is the 
observation that reverse signalling occurs through 4-1BBL when expressed on DC. 
Soluble 4-1BB receptor cross-linked by Fc or anti-4-1BBL mAb induces proliferation of 
both human monocytes or mouse bone-marrow macrophages whilst also stimulating 
IL-6, IL-8 and TNFα secretion576,577. Two additional studies have shown that DC 
maturation can be achieved solely through reverse 4-1BBL stimulation, finding that the 
autocrine maturation action of TNFα secretion is the most likely mechanism578,579.  
Reverse signalling is not unique to 4-1BBL amongst the TNF receptor/ligand family, but 
little is known about the mechanism. Both human and mouse 4-1BBL cytoplasmic tails 
share a consensus sequence (ser/thr-X-X-ser/Thr) for phosphorylation by casein kinase 
I (CKI) which is required by another TNFR family ligand, Fas-ligand (FasL) for signalling 
through nuclear factor of activated T cells (NFAT)580. An alternative mechanism by 
which 4-1BBL may activate DC is through membrane-level interaction with TLR4, which 
has been shown to interact with 4-1BBL in yeast two-hybrid screens. This interaction 
requires the transmembrane and cytoplasmic domain of 4-1BBL but not the 
extracellular portion. Consistent with these findings, 4-1BBL deficient macrophages 
cannot sustain TNFα production in response to LPS beyond the time-point at which LPS 
normally induces 4-1BBL expression in these cells (12-18 hours). A similar defect was 
not observed in 4-1BB deficiency581. Importantly, however, 4-1BBL has no impact on 
early TNFα induction via TLR mediated stimulation of NFкB, AP-1, ERK or JNK 
activation, suggesting 4-1BBL expression assists the prolongation of DC 
immunoactivation rather than its initiation, similar to the role of 4-1BB in T cell 
activation.  
The complexities of 4-1BBL/4-1BB signalling do not end there. The fact that both 
receptor and ligand can be expressed on activated DC, and both can signal, suggests 
some reciprocal control of their expression must exist without which a positive 
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feedback loop of stimulation might be readily generated. Indeed, 4-1BB appears to 
strongly suppress expression of the ligand. This is demonstrated by the up-regulation 
of 4-1BBL in LPS-stimulated DC from 4-1BB-/- deficient mice to a far greater degree 
than is seen in WT 582. The reverse does not appear to be true, since 4-1BBL-/- deficient 
mice show only minor increases in 4-1BB expression. It is as yet unknown whether the 
surface down-modulation of 4-1BBL by 4-1BB is achieved through their respective 
signalling mechanisms or direct protein interaction in the membrane or cytoplasm. 
 
6.1.6 The role of 4-1BBL:4-1BB signalling in T cell responses 
 
Early studies of the proliferative potentiation by 4-1BB stimulation of T cells found it 
comparable to anti-CD28 stimulation in mouse splenocytes in vitro, whilst also 
preventing apoptosis of daughter cells as measured by DNA fragmentation583. The 
relative potency of 4-1BB stimulation versus other forms of co-stimulation is 
highlighted in knock-out mouse models in which CD28 co-stimulation is absent. In 
these systems, 4-1BB co-stimulation alone can readily generate T cell division, survival 
and effector function584. Indeed as an adjuvant delivered in adenovirus-based vaccines, 
4-1BBL can generate more fully differentiated CD8 T cells against EBV or influenza 
antigens than co-expression of CD80585.  
These effects appear to be most pronounced in CD8+ rather than CD4+ T cells. A 
population of IFNγ- secreting and cytotoxic CD8+ T cells appeared to be selectively 
maintained by 4-1BB stimulation leading to more rapid graft rejection in a murine graft 
versus host disease (GVHD) model586. Correspondingly, systemic administration of anti-
4-1BB antibodies to mice expands CD8+ T cells to a greater degree than CD4+ T cells587. 
Natural T-regulatory CD4+ T cells are an important exception to this, since these 
constitutively express 4-1BB without antigen activation588 and readily undergo 4-1BB-
stimulated expansion589. 4-1BB stimulation of CD4+ T effector cells, however, 
simultaneously renders them refractory to suppression by T-regulatory cells, 
suggesting a mechanism whereby 4-1BB stimulation drives a more potent T cell 
effector response but at the same time promotes accumulation of a regulatory 
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population that will be on hand to rapidly suppress effector T cell function once 4-1BB 
stimulation ceases.  
The selectivity of CD8+ T cell stimulation over CD4+ may be attributed to greater 
expression of the 4-1BB receptor on activated CD8+ compared with CD4+ T cells590. 
This is borne out in an influenza and lymphocytic choriomeningitis virus (LCMV) model 
of infection of 4-1BBL deficient mice, wherein 4-1BBL appears to be necessary only for 
CD8+ T cell memory generation. In human anti-HIV591and anti-influenza585 T cell recall 
responses, 4-1BB co-stimulation enhanced expansion of CD8+ T cells with 
polyfunctional cytokine secretion and higher perforin and granzyme A staining upon 
re-stimulation in vitro. This was particularly striking in long-term HIV-infected 
individuals suggesting 4-1BB co-stimulation may rescue CD8+ T cells from their 
“exhausted” state during chronic infection, restoring functionality through TRAF 
mediated BIM downregulation592. This highlights an important unresolved question - 
whether 4-1BB stimulation actually modulates T cell effector function directly or 
instead promotes survival of the most differentiated effectors. In mouse influenza 
models, the presence of 4-1BB stimulation at priming appears to dictate only the 
number of antigen –specific CD8 + T cells rather than proportions of polyfunctional 
effector T cells593. Furthermore, in the chronic LCMV clone 13 infection model, 4-1BB 
expression on CD8+ T cells is persistently high yet these cells remain functionally 
impaired consistent with an exhausted phenotype. 
The duration and severity of infection appear to be important factors in 4-1BB-
mediated T cell stimulation since they determine both 4-1BB expression on T cells and 
expression 4-1BBL on APCs. Non-replicating antigens (such as ovalbumin) result in only 
transient 4-1BB expression on T cells whereas persistent antigen presentation, as seen 
in chronic or severe infection or allograft rejection, leads to prolonged up-regulation of 
4-1BB594. In influenza models of BALB/c mice, A/PR/8/34 infection leads to sustained 
expression of 4-1BB on lung CD8+ T cells, whereas the milder, non-lethal X31 strain 
results in only transient 4-1BB expression. Correspondingly, 4-1BBL expression is only 
significantly up-regulated in lung monocytes in A/PR/8/34 influenza and not infection 
with the milder A/X/31 strain. The mechanisms governing increased 4-1BBL expression 
in APCs in severe or prolonged infection remain largely uninvestigated. However, it has 
been observed that 4-1BBL deficient mice infected with A/PR/8/34 accumulate fewer 
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CD8+ T cells in the lung correlating with higher peak lung viral titres and increased 
mortality595.  
4-1BB stimulation at T cell priming appears to modify not only the primary effector T 
cell response but also the secondary response upon antigen re-encounter. In a study 
by Hendriks et al, the relative contribution of three TNFRs – CD27, OX40 and 4-1BB - to 
T cell responses to influenza (strain A/NT/60/68) were compared by creating various 
crosses of recombinant mice lacking one or more of these receptors596. This revealed 
that both CD27 and 4-1BB made non-redundant contributions to the primary CD8+ T 
cell response to infection. In addition, however, an adequate CD8+ T cell memory 
expansion upon secondary challenge relied upon the presence of 4-1BB and OX-40 
signalling during the primary infection. Since memory T cells are slow-cycling597 and 
the capacity for enhanced secondary expansion in conserved for at least 6 weeks after 
priming in the context of 4-1BB stimulation, the authors speculate that this entails 
programming at the molecular level during the primary response.  
In some circumstances, 4-1BB stimulation at priming appears dispensable for primary T 
cell effector expansion and activation. This may apply to situations in which there is 
strong TCR stimulation and co-stimulation through CD28 at priming, rendering the 
contribution from 4-1BB to the primary response redundant. For example, 4-1BBL has 
little impact on primary T cell responses to anti-CD3 stimulation598 or in allograft 
rejection models599. In PR8 influenza infection, which is more severe and prolonged 
than in the A/NT/60/68 model used above, 4-1BBL is redundant for the primary 
response but remains essential for adequate secondary expansion upon antigen re-
encounter593. Supporting this, 4-1BB signalling only seems to impact the primary 
response in situations where CD28 co-stimulation is limiting, such as in vaccination 
with lipopeptide without adjuvant600, or infectious challenge of CD28-/- mice601. In the 
latter context, a single dose of anti-4-1BB antibody given during infection with 
influenza can correct the defective secondary response of T cells primed in the 
absence of CD28602. 
 
Even in the presence of strong CD28 co-stimulation during the primary T cell response, 
4-1BB signalling appears to influence the capacity for secondary T cell expansion. This 
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seems to apply only to situations in which antigen is rapidly cleared, such as in either 
A/PR/8/34 or A/NT/60/68 infection. This can be modelled with a non-replicative 
antigen and powerful adjuvant, such as with OVA plus LPS vaccination in the OT-1 TCR-
transgenic model, wherein 4-1BBL is dispensable for primary responses but necessary 
for recall reponses603. Conversely, where antigen is persistent in latent or chronic 
infection, such as γ-herpes virus MHV-68 infection, 4-1BBL-deficient mice have 
quantitatively equivalent antigen-specific T cell responses compared with wild-type. 
However, secondary effector CD8+ T cells in 4-1BBL-deficient mice display deficient 
degranulation and viral loads are consequently higher. Therefore whilst the presence 
or absence of 4-1BB signaling may not influence T cell number in the presence of 
persistent antigen, it may promote survival of cells with higher effector functions or 
directly modify cytotoxic T cell function604. This is consistent with the observation that 
anti-4-1BB antibody stimulation ex vivo can rescue function of “exhausted” T cells in 
chronic HIV infection, which occurs via modulation of the pro-apoptotic molecule 
BIM605.  
In most of these studies, the “programming” effects of 4-1BB signalling at priming 
appear to influence memory T cell capacity for expansion independently of the size of 
the memory pool generated by the primary response. However, tonic signalling 
through 4-1BB has also been shown to influence the size of memory T cell populations. 
Transfer of OVA-stimulated OT-1 TCR –transgenic T- cells into 4-1BBL-deficient mice 
results in a 2-3 fold decrease in adoptively transferred cells 3 weeks later compared to 
transfer into WT mice. This is despite a similar number of cell divisions in the 
transferred population over this time period, suggesting 4-1BB stimulation promotes 
survival rather than proliferation606. This raises the question of where 4-1BBL is 
expressed so that memory CD8+ T cells populations can be maintained in the absence 
of antigen. Given the enrichment of memory CD8+ T cells in the bone marrow, some 
have hypothesized that the 1-3% of CD34+ cells there that express 4-1BBL are the 
principal source of this tonic 4-1BB stimulation to memory T cells607. This lack of data in 
this area highlights how much more is known about the role, control, signalling and 
distribution of 4-1BB expression in immune cells than is known about the ligand. 
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In summary, 4-1BB signalling (Figure 6-2), appears to provide a “back-stop” to ensure 
an adequate primary response where CD28 co-stimulation is limiting and ensures 
memory T cell survival in the absence of prolonged antigen exposure. In chronic 
infections, 4-1BB signaling may influence T cell effector function rather than numbers, 
although whether this occurs via promotion of survival of more functional cells or by 
direct functional modification remains to be determined.  
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Figure 6-2 Summary of 4-1BBL-4-1BB signaling between DC and T cells. Red arrows 
indicates the dominant 4-1BB signaling pathway in T cells.  
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6.1.7 Current applications of 4-1BB stimulation for immunotherapy and vaccines 
 
4-1BB stimulation thus modulates immune responses in a number of ways which may 
be suitable for enhancing responses to vaccination: 
1. 4-1BB stimulation enhances T cell memory longevity and responsiveness to 
secondary stimulation 
2. 4-1BB is expressed on activated but not naïve or resting memory T cells, hence 
stimulation through 4-1BB will enhance concurrent antigen-specific T cell 
activation but not non-specific T cell activation and autoimmunity. 
3. The co-stimulatory signal is more potent for CD8+ T cells than CD4+, which may 
be useful in circumstances where a cytotoxic response is more desirable than 
pro-inflammatory T-helper cytokine responses.  
4. 4-1BB stimulation may functionally enhance T cell responses, improving CD8+ T 
cell degranulation and preventing an “exhausted” T cell phenotype in 
prolonged infection. 
Stimulation of 4-1BB has therefore been applied to improving T cell responses to 
infection and cancer, in both prophylactic and therapeutic contexts. This is achieved in 
a number of ways including anti-4-1BB mAb, use of soluble trimeric 4-1BBL and 
transgenesis of 4-1BBL either directly (using viral vectors or plasmids) or indirectly (via 
injection of 4-1BBL over-expressing cells).  
 
4-1BB immunotherapy for cancer 
 
Studies by Melero et al were the first to demonstrate stimulation of 4-1BB using 4-1BB 
specific mAb could promote effective anti-tumour T cell responses608. Further 
experiments by Miller et al showed that treatment with 4-1BB mAb was most effective 
soon after tumour challenge rather than before or during it609, corroborating the 
observation that 4-1BB expression on T cells occurs more than 12 hours after 
activation in vivo and in vitro610. These improved anti-tumour responses appear to be 
CD8+ T cell dependent and are not abrogated in IL15-/- mice where NK cell 
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development is deficient or in MHC II-/- mice wherein CD4 responses are not 
elicicted609.  
An interesting observation in Miller et al’s study was synergy between treatment of 
tumour-bearing mice with 4-1BB mAb and flt3L, a cytokine that promotes proliferation 
of DC in vivo. This was attributed to the enhanced antigen presentation capacity 
increasing the number of CD8+ T cells on which 4-1BB could act, but since at the time 
4-1BB expression on DC was not yet established, an alternative mechanism of 4-1BB 
stimulation of DC was not entertained.  
Other investigators have transfected tumour cells with 4-1BBL and showed impaired 
growth together with induction of long-lasting tumour-specific T cells611 or combined 
4-1BB mAb stimulation with blockade of immunoinhibitory signalling through PD-1 to 
augment tumour responses (Xiao et al., 2007). 
Translation of these findings to the clinic has been rapid, accelerated by the 
development of a well-tolerated panel of fully humanized anti-4-1BB mAb which was 
developed by Medarex Inc. One clone, 10C7, has been tested by Bristol-Myers Squibb 
in several Phase I and Phase II trials of solid tumour immunotherapy either as a single 
agent or with chemotherapy. Several of these trials, including a trial in unresectable 
melanoma patients, concluded in 2009 but results have yet to be formally reported.  
 
4-1BB stimulation for vaccination against infection 
 
Harnessing 4-1BB stimulation to improve prophylactic or therapeutic T cell responses 
against infection has not yet progressed to clinical trials but has been evaluated in a 
number of animal models. Among these, studies assessing the effect of 4-1BB 
stimulation on anti-HIV or -SIV responses are the most numerous. Harrison et al found 
that 4-1BBL, when included in the boost but not the prime of a vaccinia/fowl-pox 
prime-boost regimen, enhanced CD8+ T cell responses in mice against dominant HIV 
GAG and POL epitopes612. Ganguly et al similarly showed that expression of 4-1BBL in a 
DNA vaccine co-expressing GAG resulted in superior CD8+ T cell responses following 
MVA boost613. This study also investigated the expression of 4-1BBL in cis versus trans 
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with GAG and found the latter failed to enhanced CD8+ T cell responses above antigen 
alone, proposing that both antigen and 4-1BBL need to be expressed on the same co-
transfected antigen presenting cell for optimal co-stimulation to antigen-specific T 
cells. A further interesting finding of this study was that anti-4-1BB mAb administered 
with DNA priming with GAG was a weaker adjuvant than co-expression of 4-1BBL with 
GAG, which achieved both greater CD8+ T cell and also antibody responses against 
GAG. Similar enhancement of CD4+ and CD8+ responses to DNA HIV-GAG vaccines was 
observed by Kanagavelu et al with the addition of DNA encoding a soluble form of 4-
1BBL that is fused with surfactant protein D (SP-D), which forms a plus-sign-shaped 
molecule with four trimeric arms, thus multimerising 4-1BBL and ensuring cross-linking 
of target 4-1BB receptors614.  
The necessity for co-expression of 4-1BBL in cis with antigen in DNA vaccines was also 
not borne out in the study of Du et al which compared CD4+, CD8+ and humoral 
responses to an HBsAg DNA vaccine co-injected with a DNA plasmid expressing either 
4-1BBL, OX40L or CD70 in trans615. 4-1BBL was consistently the most effective adjuvant 
in all three indices.  
Much of the role of 4-1BB signaling in T cell responses has been established in mouse 
models of influenza. Accordingly, the effects of additional 4-1BB stimulation in T cell 
vaccination strategies against influenza have also been investigated. Moraes et al 
found that an intranasally administered adenovector expressing 4-1BBL and influenza 
NP generated superior lung CD8+ T cell responses and protection against PR8 
challenge than an adenovector expressing NP alone. CD107a expression in antigen 
specific memory-T cells was also enhanced by inclusion of 4-1BBL in the adenovector. 
However, this difference was only demonstrable at low vaccination doses (104 PFU per 
mouse) leading the authors to postulate that the adjuvanticity of the immunogenic 
adenovector overwhelms any additional co-stimulation provided by 4-1BBL above this 
dose616. Furthermore, IM vaccination yielded no differences in T cell responses at any 
dose in the spleen or lung, which were only demonstrable following IN administration. 
In this study the authors also sought to discriminate the relative contribution to T cell 
expansion by direct 4-1BB stimulation of T cells and indirect stimulation via activation 
of non-T cells, such as 4-1BB expression on antigen presenting cells. To do this, bone 
marrow chimeric mice were established in which 4-1BB deficient mice were re-
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constituted with a mixture of wild-type and TCR-/- bone marrow or a mixture of 4-1BB-/- 
and TCR-/-bone marrow. The former group have 4-1BB expression on all haematopetic 
cells whereas the latter only on non-αβ T cell haematopeotic cells. Mice were then 
vaccinated with adenovector expressing NP or NP and 4-1BBL and antigen-specific 
CD8+ T cell responses quantified by tetramer at day 10 in lung, MLN and spleen. 
Intriguingly, T cell responses in all compartments were significantly enhanced even in 
the absence of 4-1BB expression on T cells, although not to the same degree as in 
WT/TCR-/- mice in which 4-1BB expression was normal on both T cells and non-T cells.  
In related work from the same group, 4-1BBL expressed with influenza NP on an 
adenovector has been shown to enhance human CD8+ T cell recall responses against 
influenza. Peripheral-blood derived monocytes were transduced with adenovectors 
expressing 4-1BBL (or empty) and pulsed with influenza (or EBV) peptides before 
incubation with autologous PBMCs and analysis of expansion and functional 
characteristics of peptide-specific T cells. This demonstrated greater expansion of 
peptide-specific T cells by vectors encoding 4-1BBL, together with up-regulation of 
granzyme-A, perforin and enhanced cytolytic activity at day 9617.  
 
6.1.8 A Lentiviral vaccine expressing 4-1BBL 
 
K562 cells, which lack MHC expression and therefore do not induce allogenic T cell 
responses, have been stably transduced with lentiviral vectors expressing 4-1BBL to 
generate a stimulatory antigen-presenting cell line capable of long-term T cell 
expansion in vitro for immunotherapy purposes618. However, the potential of lentiviral 
vectors expressing TNFR family ligands as vaccines has not previously been explored. 
The ability of LV to transduce non-dividing antigen presenting cells and their relatively 
low intrinsic immunogenicity make these ideal vectors to explore the potency of 4-
1BBL as a vectored adjuvant. In addition, the long-term expression achieved by 
integrating lentiviral vectors may have benefits for T cell memory longevity, since tonic 
4-1BB stimulation has been suggested as a means by which memory populations are 
sustained independently of antigen. The high capacity of LV and ability to co-encode 
whole antigen together with 4-1BBL may ensure co-localised expression of both 
221 
 
antigen and co-stimulation, avoiding the pleiotropic and non-antigen specific 
immunostimulatory effects observed in mice after administration of anti-4-1BB 
antibody. Furthermore, since cross-linking by trimeric ligand is thought to provide the 
most potent stimulation through 4-1BB619, presentation of ligand on the surface of 
transduced cells may provide a more potent 4-1BB signal than soluble ligand or anti-4-
1BB antibody.  
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6.2 Aims 
 
The aims of this study were: 
1. To determine whether 4-1BBL expression together with influenza NP in a 
lentiviral vector (4-1BBL-NP) enhances T cell responses and/or protection 
against influenza in a mouse model of A/PR/8/34 infection compared with LV 
expressing NP alone. 
 
2. To investigate indirect T cell stimulatory effects of vectored 4-1BBL, in 
particular via activation of DC. 
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6.3 Results 
 
6.3.1 Lentiviral vectors encoding 4-1BBL transduce 293T cells and BM derived DC 
resulting in surface expression of 4-1BBL 
 
Lentiviral vectors were cloned as described in the methods (page 93). Expression of 4-
1BBL (mouse or human) was verified by surface staining of transduced 293T cells, BM-
derived mouse dendritic cells, or human monocyte-derived DC on day 3 after 
transduction (Figure 6-3).  
Endogenous 4-1BBL was not detected above isotype control staining on either mouse 
or human DC on day 4 of in vitro differentiation from bone marrow or peripheral 
monocyte precursors respectively. Transduction with mouse (m) or human (h) 4-1BBL 
resulted in substantial overexpression of 4-1BBL in mouse DC, 293T cells and human 
DC (Figure 6-3B). Dose-dependent expression of 4-1BBL was confirmed by addition of 
varying quantities of 4-1BBL-GFP to mouse DC (Figure 6-3C). 
 
6.3.2 4-1BBL-NP enhances antigen-specific T cell responses  
 
In order to determine whether vectored 4-1BBL enhanced T cell responses against co-
encoded antigen, BALB/c mice were vaccinated subcutaneously with 4-1BBL-NP, Null-
NP or saline and sacrificed 14 days later for splenocyte analysis (Figure 6-4).  
CD4+ and CD8+ T cell IFN responses were assessed by ELIspot after overnight re-
stimulation with class II or class I restricted peptide respectively as described in the 
methods. This revealed significantly greater CD8+ and CD4+ T cell responses to 
vaccination with 4-1BBL-NP than Null-NP in with both class I and class II peptide re-
stimulation respectively. As in previous experiments with vFLIP-NP, CD8+ T cell IFNγ 
responses were more prominent than in CD4+ T cells. Splenocytes were also re-
stimulated in vitro for 4 days with class II restricted peptide and supernatants analysed 
by cytometric bead array for a panel of 10 cytokines including IFNγ, TNFα, IL-4, IL-10, 
IL-17, GMCSF, IL-1α, IL-5 and IL-6. Significantly greater concentrations of TNFα, IFNγ 
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and GMCSF were found in supernatants in responses to class II restricted peptide re-
stimulation in splenocytes cultures from 4-1BBL NP vaccinated mice compared with 
mice vaccinated with Null-NP. This resembles the findings of Li et al who demonstrated 
increased IFNγ and GMCSF secretion by T cells (and reduced TH-2 cytokine secretion) 
in tumour-draining lymph nodes following stimulation with anti-4-1BB antibody in 
vivo620.  
Intracellular cytokine staining of splenocytes after overnight re-stimulation with class I 
NP147-155 peptide revealed a trend towards greater GzmB, IFNγ and TNFα expression in 
CD8+ T cells in the 4-1BBL-NP versus Null-NP vaccinated groups but this did not reach 
significance. 
No significant difference in the percentage of NP147-155 pentamer positive CD8+ T cells 
was seen in splenocytes from 4-1BBL-NP and Null-NP vaccinated mice, although there 
was a trend towards greater GzmB and Ki67 expression in antigen-specific CD8 T cells 
from the 4-1BBL vaccinated group, suggesting greater cytotoxic and proliferative 
potential.  
 
6.3.3 4-1BBL vaccination enhances survival against lethal A/PR/8/34 challenge 
compared with mice vaccinated with Null-NP 
 
14 days after subcutaneous LV vaccination mice were challenged with a lethal 2xLD50 
dose of A/PR/8/34 and monitored for weight loss (Figure 6-5). As previously stipulated, 
mice were sacrificed if they lost more than 25% of their bodyweight. As in previous 
experiments with subcutaneous vaccination, all mice developed severe clinical 
syndrome of weight loss, tachypnoea, piloerection and hunched posture. However, 
around day 5, 6 out of 10 mice vaccinated with 4-1BBL-NP began to recover weight 
and returned to baseline at day 12, compared with only 2 out of 18 mice in the Null-NP 
group (p=0.003, Log Rank Mantel-Cox test). Thus 4-1BBL-NP vaccination conferred a 
significant survival benefit upon lethal influenza challenge compared with LV 
expressing NP alone.  
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Figure 6-3 (A) Lentiviral vectors were cloned and produced as described in the 
methods. Constructs for mouse experiments used the ubiquitin (UBI) promoter at the 
second promoter, those for human experiments used the phosphoglycerokinase 
promoter (PGK) because the UBI promoter was found to be substantially weaker in 
human DC than murine. (B) Expression of mouse (4-1BBL(m) and human forms of 4-
1BBL (4-1BBL(h)) in 293T cells, mouse bone marrow-derived DC (Mu DC) and human 
monocyte-derived DC (Hu DC). (C) Dose-dependent expression of 4-1BBL(m) (blue) and 
GFP (green) in mouse DC after transduction with 4-1BBL-GFP at varying doses. 
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ii i iii iv Figure 6-4 4-1BBL enhances 
mouse T cell responses 
against LV co-encoded NP. 
(A) CD4+ T cell responses 
after overnight re-
stimulation with class II 
restricted NP peptide. (i) 
IFNγ ELIspot. (ii-iv) cytokine 
levels in the supernatants at 
day 4. (B) CD8+ T cell 
responses after (i) IFNγ 
ELIspot after overnight re-
stimulation with class I 
restricted NP peptide. (ii-iv) 
Intracellular staining and 
FACS analysis. (C) CD8+ T 
cell NP pentamer responses 
(i) NP pentamer percentages 
of total CD8+ T cells in 
spleen (ii) percentage of 
GzmB and Ki67 positive NP-
specific CD8+ T cells ex-vivo 
day 14 ( no re-stimulation). 
(D) Vaccination and analysis 
schedule. 
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Figure 6-5 Survival (A) and weight loss (B) of BALB/c mice after subcutaneous 
vaccination and lethal influenza challenge according to schedule described in (C). Both 
Mantel-Cox tests and Gehan-Breslow-Wilcoxon Test produced similar p-values for 
observed differences in survival. 
 
  
*** 
A 
B 
C 
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6.3.4 SC-IN vaccination with 4-1BBL leads to improved survival compared with 
subcutaneous vaccination  
 
We next examined the potential of 4-1BBL-NP LV to generate lung-based NP-specific T 
cell responses using subcutaneous priming and intranasal recall (SC-IN) as described in 
previous chapters. The resultant T cell response in BAL and PBMC separated from 
exsanguinated lung lysate was compared to that generated by Null-NP SC-IN 
vaccination and to dual subcutaneous vaccination with either 4-1BBL-NP or Null-NP. 
Mice were also challenged with lethal A/PR/8/34 as previously described.  
Although there was a clear trend towards greater NP-pentamer positive CD8+ T cell 
responses in the lung lysate with SC-IN vaccination, these showed a much higher 
degree of variability in the SC-IN groups compared with SCx2 groups and consequently 
observed increase did not reach significance. In the BAL, however, SC-IN vaccination 
with either 4-1BBL-NP or Null-NP was significantly superior at inducing NP-specific 
CD8+ T cells whereas SCx2 vaccination induced negligible numbers of CD8+ T in this 
compartment.  
Mice vaccinated SC-IN showed greater survival and less weight loss than was observed 
with subcutaneous vaccination. However, numbers of NP-specific CD8+ T cells isolated 
with a single 2mL BAL were not significantly different between 4-1BBL-NP and Null-NP 
SC-IN groups and there was no difference in survival or weight loss between these 
groups.  
vFLIP-NP SC-IN was not included in parallel therefore absolute quantitative 
comparisons of NP-pentamer positive CD8+ T cells may not be valid. However, 
comparison of proportions of total lung CD8+ T cells that are NP-pentamer positive 
indicate that 4-1BBL-NP SC-IN generates a significantly lower proportion of NP-specific 
T cells in the lung than vFLIP-NP SC-IN ( 34.15% vs. 5.51%, p=0.0036).  
It is unclear why the survival advantage of 4-1BBL NP SC vs. Null-NP SC is not observed 
with SC-IN vaccination. It may be the case that the marginally superior functional CD8+ 
and CD4+ systemic T cell responses after subcutaneous vaccination (but equivalent 
quantitative NP-specific CD8+ T cell response) seen with 4-1BBL NP over Null-NP are 
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relevant only in the context of post-challenge recruitment and expansion of T cells to 
the lung and airway, which may be accelerated by superior CD4+ T cell help and CD8+ 
memory cells with greater cytotoxic and proliferative potential. In the context of 
populations of lung-and airway- based CD8+ T cells present prior to challenge, 
however, this may be of less relevance. We could detect no difference in terms of 
functional surrogates (GzmB or Ki67) for cytotoxic or proliferative potential in lung-
based T cell populations. As discussed in the previous chapter, the recall of T cells to 
the airway with vectors expressing antigen alone seems sufficient to substantially 
enhance GzmB production and Ki67 in these populations (4.3.5, page 158), and this 
increase may well overwhelm the more marginal differences seen between 4-1BBL-NP 
and Null-NP splenic CD8+ T cell populations seen in splenic memory populations. 
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A 
B 
C 
Figure 6-6 CD8+ T 
cell responses after 
SC-IN and SCx2 
vaccination. Mice 
were vaccinated 
according to the 
schedule shown in 
Figure 6-7. (A) 
Quantitative 
analysis of NP147-155 
pentamer specific 
CD8+ T cells after a 
single 2ml BAL or 
separation from 
total lung 
homogenate (B) 
comparison of 
GzmB or Ki67 
expression in 
antigen-specific 
CD8+ T cells in the 
BAL. (C) Percentage 
of CD8+ T cells in 
the lung lysate that 
are NP-pentamer 
positive. vFLIP-NP 
SC-IN was not 
analysed in parallel 
with the other 
groups but is 
included for 
comparison.  
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Figure 6-7 Weight loss (A) and survival (B) after lethal PR8 challenge of SC-IN 
vaccinated mice according to the vaccination schedule shown in (C). No significant 
differences in survival or weight loss in survivors were observed.  
A 
B 
C 
232 
 
6.3.5 4-1BBL has limited effects on T cell chemoattractant secretion by AM 
 
We postulated that 4-1BBL-NP may generate inferior T cell recall responses in the lung 
compared with vFLIP-NP because transduction with 4-1BBL does not activate AM or 
induce chemokine secretion. We therefore examined the chemokine profile of BAL 
after intranasal administration of 4-1BBL-GFP as described previously. In addition, 
adherent cells from BAL were cultured for 4 days and chemokine levels measured in 
the supernatant thereafter.  
Analysis of CD11c+F4/80+ AM in the BAL after administration of 200ng RT of 4-1BBL-
GFP revealed equivalent rates of transduction (80%) as seen with vFLIP-GFP or Null-
GFP and high specificity of transduction of this group (>99%). Correspondingly, 
transduced adherent cells that were cultured were exclusively of the AM phenotype. 
Analysis of both BAL and cultured cell supernatants revealed relatively low levels of T 
cell chemokine production following intranasal 4-1BBL-GFP administration compared 
with vFLIP-GFP (Figure 6-8). IP-10, MCP-1 and MCP-3 were all found in the BAL at levels 
significantly higher than control or Null-GFP recipients. However, these were not 
detected in the supernatants of cultured adherent cells suggesting they do not 
originate from AM.  
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Figure 6-8 Analysis of chemokine levels in BAL and cultured supernatants (2 mL) of adherent cells from BAL following the same method as Figure 4-5 
page 156. Cultured cells were phenotyped before and after culture by FACS, showing >99% of transduced cells were AM (F4/80+ CD11c+).
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6.3.6 4-1BBL activates mouse bone marrow-derived DC, but the greatest activation 
is observed in untransduced bystanders 
 
We postulated that overexpression of 4-1BBL may activate T cells indirectly by 
activating DC thereby increasing other DC co-stimulatory signals. DC activation has 
been shown to occur by both 4-1BBL reverse signalling and by stimulation through 4-
1BB expressed on DC using monoclonal antibody or multimerised soluble 4-1BBL.  
Using the same assay described previously for DC activation with vFLIP-GFP, we 
analysed expression of 4 activation markers (CD40, CD80, CD86 and ICAM-1) on DC 
following in vitro transduction with 4-1BBL-GFP.  
This resulted in potent DC-activation, often surpassing that observed with LPS. 
However, activation markers were significantly more up-regulated on GFP- 
(untransduced) than GFP+ DC (Figure 6-9) within the target population in the same 
well. By contrast, vFLIP-GFP transduction resulted in minimal or no significant up-
regulation of activation markers in untransduced cells and significant activation was 
only seen in the transduced population. 
A number of mechanisms were hypothesised to explain the transactivation of 
untransduced DC: 
 
1. 4-1BBL induced activation may occur through forward signalling via 4-1BB 
and 4-1BBL over expression down-regulates 4-1BB on the same cell. 
 
2. 4-1BBL matures DC by reverse signalling at low levels of expression but that 
at high levels of transduction this signal becomes inhibitory. 
 
3. 4-1BBL reverse signalling induces a cytokine that induces activation of 
bystander DC, but simultaneously down-regulates responsiveness to this 
signal in producer cells.  
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Figure 6-9 Analysis of four markers of DC activation at day 4 after transduction with 4-
1BBL-GFP, Null-GFP or vFLIP. Expression of each marker is expressed as a factor of 
increase relative to untransduced DC (with the dotted line at 1 indicating no increase). 
Analyses of paired transduced (GFP+) cells and untransduced (GFP-) cells from the 
same well are joined by a connecting line. Each circle represents a separate 
experiment. T-tests comparing log(fold increase) were used to determine the p-value 
of observed differences between paired groups (significance level is shown over 
brackets) or whether the mean observed increase in expression is significantly greater 
than 1 (no increase) indicated by * over each population group. The gating strategy is 
shown above. NS= not significant. 
236 
 
6.3.7 4-1BBL DC transactivation is independent of reverse signalling, requires cell-
cell contact and is abrogated by anti-4-1BBL antibody 
 
To investigate the role of potential reverse signalling in DC maturation, we created a 
truncated mutant lacking the cytoplasmic N-terminal domain which includes two 
putative casein kinase I signalling regions. This mutant was expressed on the cell 
surface to an equivalent degree as wild-type (Figure 6-10). 3 independent repeats of 
the DC activation assay revealed stronger up-regulation of activation markers in the 
untransduced population as previously observed. 
However, comparison between DC transduced with 4-1BBL WT and truncated 4-1BBL 
(4-1BBLTc) revealed the increase in activation markers was significantly higher in the 
WT group (Figure 6-11). This suggests that reverse signalling may play some role in 
activation of the transduced population. No significant differences were observed in 
DC activation in the untransduced populations in these groups.  
Addition of 4-1BBL-GFP transduced DC to the upper well of transwell plates did not 
increase the activation of untransduced DC in the lower well, suggesting cell-cell 
contact is necessary for transactivation of DC by 4-1BBL, rather than a cytokine 
mediated mechanism (Figure 6-12). Furthermore, addition of anti-4-1BBL blocking 
antibody (clone TKS-1) consistently abrogated activation of the untransduced 
population in these experiments (Figure 6-11), regardless of whether 4-1BBLTc-GFP or 
4-1BBL-GFP was used.  
Taken together, these data strongly suggest that the DC activation observed in a total 
population of DC after addition of 4-1BBL-GFP occurs to a small degree by reverse 
signalling through 4-1BBL in transduced cells (with a contribution from LV-induced TLR 
stimulation as previously discussed), but to a much greater degree by forward 
signalling to untransduced bystander DC. This presumably occurs through 4-1BB 
receptor expression on mouse DC. Given that 4-1BB expression has been reported to 
suppress 4-1BBL expression, we postulated that the reverse may also be true, such 
that over-expression of 4-1BBL may suppress 4-1BB expression on the same cell, thus 
rendering the transduced population less responsive to 4-1BBL expression on 
neighbouring cells.  
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Figure 6-10 Truncation of 4-1BBL to remove the cytoplasmic N-Terminal domain (4-
1BBLTc). This had no effect on expression level (A) or transactivation of untransduced 
DC in the target population (B). 
B 
A 
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Figure 6-11 The degree of activation of transduced DC is significantly lower in DC 
transduced with 4-1BBLTc than wild-type. The degree of activation seen in the 
untransduced cells in target populations is not significantly affected by the N-terminal 
truncation.  
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Figure 6-12(A) Transactivation of untransduced DC is abrogated in the presence of 
anti-4-1BBL blocking antibody clone TKS-1. This occurs in both 4-1BBL WT and Tc 
transduced populations. (B) In transwell experiments, addition of 4-1BBL transduced 
DC to an upper well separated from a lower well containing untransduced DC (by a 
0.4um pore membrane) failed to induce their activation suggesting cell-cell contact is 
required for transactivation. 
 
  
A B
B 
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6.3.8 Membrane expression of 4-1BBL and 4-1BB are reciprocally controlled  
 
4-1BB deficient mice express higher levels of 4-1BBL on the surface of LPS-activated 
DC, suggesting 4-1BB negatively modulates 4-1BBL expression. To examine the 
relationship between membrane expression of 4-1BBL and 4-1BB, bone-marrow 
derived murine DC were transduced with increasing quantities of 4-1BBL-GFP or 4-
1BBLTc-GFP and extracellular and intracellular (after permeabilisation) of the ligand 
and receptor was analysed 2 days later. 
Around 40% of untransduced mouse DC at day 6 post-maturation expressed 4-1BB. 
This 4-1BB+ve group were equally susceptible to transduction as 4-1BB-ve (Figure 
6-13A) as evidenced by an equivalent proportion of GFP positive DC after addition of 
Null-GFP. However, following transduction with 4-1BB-GFP, 4-1BBL expression 
appeared to be restricted to the 4-1BB- population (Figure 6-13B – 1 ng RT/200000 DC) 
and was not expressed in 4-1BB+ transduced cells. Furthermore, as the amount of 4-
1BBL-GFP expression increased with addition of higher concentrations of 4-1BBL-GFP, 
there was a steep decline in the proportion of DC expressing 4-1BB, eventually 
becoming undetectable on all cells at levels of maximal 4-1BBL-GFP transduction.  
On intracellular staining however, with increasing 4-1BBL-GFP transduction, 4-1BB 
detection rose initially before a slight overall decline. Internalisation of 4-1BB is not an 
epiphenomenon of LV transduction itself, since increasing quantities of Null-GFP 
transduction have no effect upon 4-1BB membrane expression (Figure 6-14). 
These data suggest restriction of 4-1BBL expression by surface 4-1BB at low MOIs, but 
if 4-1BBL expression is increased it can overwhelm this inhibition and instead down-
modulate surface 4-1BB expression. Given that 4-1BB remains detectable 
intracellularly, it is feasible that down-regulation at the surface is achieved reciprocally 
by internal sequestration of 4-1BB by direct interaction with 4-1BBL. 
A further possibility is that 4-1BB undergoes ligand-mediated down-regulation after 
contact with 4-1BBL expressed on other cells. However, the presence of a high 
concentration of anti-4-1BBL TKS 1 (sufficient to block staining with fluorochrome-
conjugated antibody) had no effect on 4-1BB down-regulation as 4-1BBL transduction 
was increased (Figure 6-15A). Similarly, increasing concentrations of anti-4-1BB 
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stimulatory antibody (clone LOB-1) failed to induce down-regulation of 4-1BB (Figure 
6-15B). 
4-1BB down-regulation was also observed with transduction with 4-1BBLTc (Figure 
6-13), suggesting that any interaction between 4-1BBL and 4-1BB leading to 
intracellular retention occurs between the extracellular or transmembrane domains of 
ligand and receptor.  
This down-regulation of 4-1BB with increasing 4-1BBL expression would explain the 
observed differences in activation between transduced and untransduced DC seen in 
the same well after addition of 4-1BBL-GFP, since transduction with 4-1BBL-GFP would 
down-regulate 4-1BB on the same cell and inhibit responsiveness to 4-1BBL expressed 
on neighbouring cells. DC which have low levels of transduction or are untransduced 
would retain 4-1BB expression and undergo activation by neighbouring 4-1BBL 
transduced DC.  
The simplest model to explain this phenomenon would be an interaction between 4-
1BB and 4-1BBL intracellularly that prevents trafficking of both ligand and receptor to 
the membrane. A logical assumption would be that this occurs in the same way as 4-
1BBL -4-1BB interaction at an intercellular synapse by canonical ligand-receptor 
binding at their extracellular domains, perhaps between ER-bound vesicles expressing 
both ligand and receptor. This “internal sequestration” mechanism would prevent 
both ligand and receptor from being expressed on the surface of the same cell, which 
would otherwise risk loops of sustained activation in the presence of similar DC. 
However, given that we could not detect 4-1BBL expression on untransduced DC and 
only very minor up-regulation with LPS stimulation on the 4-1BB negative population 
(data not shown) it seems likely that a scenario in which 4-1BBL is overexpressed to 
the degree that 4-1BB is suppressed is not physiologically relevant, and this 
mechanism probably serves to limit ligand expression on receptor positive DC only.  
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Figure 6-13 Reciprocal limitation of expression of 4-1BBL and 4-1BB on bone-marrow 
derived mouse DC. (A) DC express 4-1BB but not 4-1BBL. Both 4-1BB+ and 4-1BB- are 
transduced by LV with equal efficacy (histogram). (B) 4-1BBL expression is suppressed 
in 4-1BB+ cells but as MOI is increased 4-1BB expression is supressed by increasing 4-
1BBL expression. This also occurs with increasing expression of 4-1BBLTc. Intracellular 
4-1BB remains detectable suggesting suppression of extracellular expression only.  
A 
B 
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Figure 6-14 Interrelationship of extracellular and intracellular expression of 4-1BBL and 4-1BB derived from FACS plots in Figure 6-13. For 
comparison, data is shown with increasing transduction of DC with Null-GFP, which does not alter 4-1BB or 4-1BBL expression. 
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Figure 6-15 Blocking 4-1BBL-4-1BB interaction has no effect on reciprocal down-
regulation (A). Stimulation/crosslinking of DC with anti 4-1BB mAb does not induce 4-
1BB down-regulation (B).  
  
A 
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6.3.9 4-1BBL transactivation of DC occurs in vivo in BALB/c and Bl/6 mice 
 
To test whether DC transactivation occurs in vivo, we injected groups of 4 mice at 
separate sites with different vectors in the flank and hindquarter and then collected 
draining inguinal lymph nodes (Figure 6-16). The original intention was to inject at site 
A with a vector expressing Thy1.1 only, and then at site B with either 4-1BBL-GFP or 
Null-GFP. Thy1.1-expressing DC in the lymph node would then be analysed for 
activation markers to determine whether 4-1BBL-GFP in trans may enhance their 
activation. However, Thy1.1 +ve DC were detectable in small amounts (<100) in 
draining LN at day 4 which made meaningful analysis difficult. We therefore examined 
total GFP- DC in draining lymph node at day 4. This revealed both greater numbers of 
CD11c+ MHCII+ GFP- cells in the draining lymph node of mice receiving 4-1BBL in trans 
vs Null-GFP in trans and higher numbers of DC expressing CD80, CD86 or both. 4-1BBL 
thus appears to both recruit and activate DC in draining lymph nodes. To further 
characterise the degree of up-regulation of CD80 and CD86, BL/6 mice were injected 
but lymph nodes pooled between groups of 4 mice and CD11c+ cells isolated by bead 
separation. Cells were then stained for CD11c, MHC II and CD80 or CD86. 
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Figure 6-16. 4-1BBL LV induce transactivation of 
untransduced DC in vivo. (A) Mice were injected 
with a Thy1.1 expressing LV at site A and either 4-
1BBL-GFP or Null-GFP at site B, both of which drain 
to the inguinal lymph node. On Day 4, Lymph node 
cells were harvested and stained for CD11c, MHC II, 
CD80 and CD86. (B) Analysis of degree of expression 
of CD80 and CD86 in untransduced cells from lymph 
nodes pooled from 4 mice and CD11c+ cells isolated 
by magnetic bead separation.  
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6.3.10 4-1BBL enhances antigen-specific CD8 T cell function when expressed in trans 
 
Reciprocal control of 4-1BB by 4-1BBL raises a fundamental problem with the use of 4-
1BBL as a vectored adjuvant co-encoded with antigen. We have shown here that 
potent transactivation of DC occurs with 4-1BBL overexpression and this may account 
for a significant proportion of the observed enhancement of T cell responses together 
with direct stimulation of 4-1BB on T cells. The use of 4-1BBL encoded in cis with 
antigen, however, means that transduced DC will themselves be insusceptible to 4-
1BBL mediated transactivation due to 4-1BB down-regulation. This would potentially 
limit the activation status of transduced DC and thus co-stimulation provided to T cells. 
This implies that 4-1BBL may be a more effective adjuvant if expressed in trans with 
antigen.  
To test this, groups of 4 mice were vaccinated subcutaneously on one side in two 
separate sites which drain to the inguinal lymph node. These combinations of 
vaccinations provided 4-1BBL in cis and in trans with antigen and  are shown in Figure 
6-17. Lymph nodes and spleens were harvested and T cell responses were then 
assessed 14 days later.  
NP147-155 pentamer responses in the spleen were equivalent between all 4 groups of 
vaccinated mice. However, mice receiving 4-1BBL-GFP in trans with Null-NP 
demonstrated higher GzmB expression in CD8+ T cells after overnight stimulation with 
peptide than was observed in mice receiving 4-1BBL-NP and Null-GFP in trans. In the 
lymph node, the mice receiving 4-1BBL-GFP in trans with Null-NP were the only group 
to demonstrate significantly greater GzmB expression upon re-stimulation compared 
with mice vaccinated with Null-NP and Null-GFP in trans.  
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Figure 6-17 4-1BBL enhances the quality of the CD8+ T cell response when expressed in 
trans Mice were immunised at 2 sites in the flank with lentiviral vectors then analysed 
after 14 days. The percentage of NP147-155 pentamer+ CD8+ T cells (of total CD3+CD8+) 
in spleen (A) GzmB+ CD8+ T cells in spleen (B) and granzyme B+ CD8+ cells in the 
draining lymph nodes (C) are shown.  
 
  
A 
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6.4 Summary 
 
LV co-expressing 4-1BBL and NP induced superior functional CD8+ and CD4+ T cell 
responses against NP following subcutaneous vaccination compared with LV 
expressing NP alone. We did not observe significant differences in numbers of NP147-155 
pentamer positive CD8+ T cells generated by 4-1BBL-NP compared with Null-NP 
vaccination, although it is possible that analysis at 14 days is too early to detect any 
prolongation of memory T cell survival conferred by 4-1BB stimulation. Vaccination 
with 4-1BBL-NP confers greater protection against lethal A/PR/8/34 challenge than 
vaccination with Null-NP, but 4-1BBL-NP and Null-NP induce equivalent lung- and 
airway-based T cell numbers and protection when given intranasally after 
subcutaneous priming. Unlike vFLIP, 4-1BBL does not induce significant chemokine 
secretion in AMs.  
4-1BBL-GFP induces in vitro mouse DC maturation in transduced cells, but activation is 
greater in untransduced cells in the same target population. Transactivation of 
untransduced cells is blocked by anti-4-1BBL antibody and requires cell-cell contact 
and 4-1BBL also transactivates DC in vivo. 4-1BBLTc-GFP has an equivalent effect upon 
untransduced cells, but transduced DC are matured to a lesser degree than with 4-
1BBLWt. Membrane expression of 4-1BBL and 4-1BB are reciprocally controlled in DC. 
Whilst LV encoded 4-1BBL is an effective adjuvant when expressed in cis or trans with 
antigen, expression in trans may result in functionally superior T cell responses.  
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6.5 Discussion 
 
Despite the widespread experimental use of 4-1BB stimulation to enhance anti-tumour 
T cell responses, few studies have attempted to isolate the degree to which this occurs 
through 4-1BB expressed on T cells or DC. Zhu et al have addressed this by adoptively 
transferring CD8+ T cells from 4-1BB KO (Thy1.2+) mice into recipients and then 
stimulating with anti-4-1BB mAb in vivo. They found expansion of adoptively 
transferred WT CD8 + T cells but not 4-1BB deficient T cells. However, this experiment 
did not involve antigen, therefore the duration of any co-stimulation of the T cell 
response through 4-1BB activated DC would be abbreviated by the absence of 
concurrent antigen-presentation and MHC-TCR interaction. A further confounder is 
that 4-1BB deficient T cells do not behave normally (irrespective of 4-1BBL stimulation) 
compared to WT, undergoing hyperproliferation in the absence of TCR stimulation and 
reduced cytokine secretion, phenomena which are as yet unexplained.  
 
A growing number of studies have observed high 4-1BB expression on maturing DC 
and DC activation by either anti-4-1BB mAb or transfected ligand567,621,622. Triggering 4-
1BB signalling on DC results in enhance IL-6 and Il-12 secretion, up-regulation of CD80 
and CD86 DC and enhanced allogeneic mixed lymphocyte reactions623 and 4-1BB 
deficient DC exhibit poorer survival and are less able to sustain CD4+ T cell responses 
to pulsed antigen624.  
 
Here we have shown that 4-1BB mediated DC activation by 4-1BBL up-regulation on 
adjacent DC, and a lesser degree of activation by reverse signaling through the over-
expressed ligand. In vivo subcutaneous injection of LV expressing 4-1BBL appears to 
recruit large numbers of untransduced, activated DC to the local lymph node. This non-
specific transactivation of DC may have a number of physiological roles. The traditional 
paradigm of antigen presentation by dendritic cells involves uptake of antigen in the 
periphery and migration to local lymph nodes for presentation of processed antigen to 
naïve T cells. This is often known as the Langerhans cell paradigm, since skin-derived 
DC are the most extensively studied DC subset in the context migration and T cell 
priming. However, the identification of multiple subtypes of dendritic cell with distinct 
homing, life-cycle and antigen presenting capabilities has challenged this model625–627. 
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Importantly, CD8+ lymphoid resident DC have been shown to be capable of cross-
presenting antigen transferred from incoming migratory DC. Indeed, in some models 
of infection (such as dermal HSV-1 infection) Langerhans DC do not directly prime 
naïve T cells after migration to local lymph nodes, a function instead performed by 
CD8+ lymph node-resident DC (LN-DC) after antigen transfer. 
  
The mechanism of antigen transfer between DC remains unknown. Furthermore, the 
means by which migratory DC, having been activated by inflammatory mediators at 
the site of infection, pass on this activation pattern to recipient LN-DC is also unknown. 
This will partly be achieved by the transfer of antigen and therefore stimulation of the 
same pattern recognition receptors to which the migratory DC was subjected, 
provided the antigen is sufficiently intact. However, LN-DC will not be exposed to 
antigen-independent activatory signals present only at the site of infection. A 
mechanism must therefore exist whereby migratory DC transduce these signals to 
antigen recipient DC in the lymph node. Some have proposed this occurs indirectly 
through activation of lymph node CD4+ T cells by migratory DC and subsequent 
licensing of LN-DC by T-helper cytokines such as IL-4628.  
Mouse splenic and bone-marrow derived DC constitutively express high levels of 4-1BB 
and are therefore susceptible to 4-1BBL induced activation. 4-1BBL is only expressed 
on DC following stimulation with, for example, anti-CD40 antibody or LPS629. We may 
therefore postulate a mechanism whereby LN-DC are directly transactivated by 
incoming, activated migratory DC. This interaction may also reinforce activation of the 
instigator by reverse signalling through 4-1BBL. However, 4-1BBL expression in 4-1BBHI 
transactivated LN-DC would risk propagation of activation to DC bearing other 
unrelated antigens or self-antigens. We have demonstrated that even when over-
expressed through strong viral promoters in transduced murine DC, 4-1BBL expression 
at the membrane is limited to the 4-1BB negative DC population. Likewise, 4-1BB 
expression can be overwhelmed by 4-1BBL transduction. This stringent reciprocal 
regulation of 4-1BB and 4-1BBL would mitigate the risk of 4-1BBL/4-1BB mediated 
propagation of PRR-independent activation through a DC population.  
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This may also explain our observed results that 4-1BBL is more effective at generating 
GzmB T cell responses against LV-encoded antigen in trans rather than in cis, which 
may be of importance in the context of using 4-1BBL as a vectored adjuvant.  
4-1BBL NP SC-IN vaccination did not induce larger airway or lung-based NP-specific T 
cell populations than Null-NP SC-IN and this corresponded to poor induction of a T cell 
chemoattractant response by AM to 4-1BBL-GFP transduction. We found that AM, 
unlike mouse bone-marrow derived DC, did not express 4-1BB which may explain the 
absence of AM activation by this approach. Correspondingly, 4-1BBL-NP SC-IN 
vaccination showed no benefit over Null-NP SC-IN in terms of surrogates of T cell 
function or protection against challenge. However, we did not examine the longevity 
of the T cell response induced by 4-1BBL-NP versus Null-NP. Given that 4-1BB 
stimulation enhances survival of T cells, longer term analysis may reveal advantages of 
4-1BBL-NP over vaccination with LV expressing antigen alone. This raises the 
interesting question of whether lung-resident T cell responses are more effectively 
maintained dynamically, by ensuring a prolonged T cell chemo attractant signal and 
antigen expression, or statically by increasing resident T cell memory survival.  
In summary, expression of 4-1BBL in LV enhances T cell responses and protection in an 
influenza model against co-encoded antigen, but a significant share of this activation 
may be attributable to transactivation of DC. Exploring the relative contribution of 
direct and indirect T cell stimulation via 4-1BB has previously been approached by use 
of 4-1BB and 4-1BBL knockout models which are confounded by abnormal T cell 
proliferation and function in the absence of 4-1BB stimulation. In future work we aim 
to address this issue by vaccination with LV co-encoding shRNA against 4-1BB together 
with antigen, co-injected with 4-1BBL LV in trans at a separate site draining to the 
same lymph node. Given that mouse T cells are resistant to LV transduction, any 
reduction to the adjuvantic effect of 4-1BBL given in trans could then be attributed to 
the shRNA mediated loss of 4-1BB expression in DC transduced with antigen and 
consequent diminished DC activation.  
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7 Conclusions, limitations and future directions 
 
This study set out to test the efficacy of lentiviral vectors as vaccines for the generation 
of T cell responses against acute viral infection. Influenza was chosen as a disease 
model not only because it provides a robust challenge for this potential vaccine 
modality but also because, as the recent SOH1N1 pandemic revealed, it is a highly 
relevant example of a fast-mutating, multi-subtype infection for which there is a 
pressing need for a universal vaccine. 
We evaluated the adjuvantic potential of the NFкB-activator, vFLIP, and stimulation of 
the 4-1BBL:4-1BB signalling axis. Both approaches yielded unexpected mechanisms by 
which these molecules may enhance T cell responses to LV vaccination. For example, 
vFLIP-mediated NFкB stimulation of AM failed to prime T cell responses against co-
transduced antigen, but generated a potent chemokine response that enhanced recall 
of pre-existing NP-specific T cells to the lung, even when originating from small 
numbers of adoptively transferred AM. 4-1BBL expression strongly transactivated DC 
through 4-1BB, an important indirect pathway contributing to T cell activation.  
These findings have underscored the utility of two attributes of LV: the ability to 
transduce non-dividing cells with high efficiency which permits manipulation of a range 
of immune cells accessed by different routes, and their intrinsic low immunogenicity, 
which allows discernment of the effects of co-encoded transgenes. These attributes 
underlie the significant potential of LV both as clinical vaccines and also as 
immunological tools for unravelling molecular interactions between immune cells.  
 
7.1 LV vaccines as immunological tools 
 
LV are currently the most popular modality for experimental gene transfer or 
knockdown (typically encoding short-hairpin RNA, shRNA) of targets for both in vitro 
and in vivo use. Substantial investment by the life sciences industry mean mouse and 
human cDNA expression libraries are available in lentiviral backbones and LV 
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expressing multiple candidate shRNAs against a knock-down target of choice can be 
purchased “off-the-shelf”. As discussed previously, LV can then be pseudotyped in a 
variety of ways to target particular cell types. In this study we have examined the 
relatively simple approach of over-expression of chosen immunogenic adjuvants using 
an LV with a broad tropism, but have not explored the potential of knocking-down 
gene expression, or targeting particular cells of the immune system. There are a 
number of limitations and questions raised in the work presented here which may be 
readily addressed with experiments that exploit the full functional range of LV. 
 
Is transduction of alveolar epithelial cells with vFLIP-NP sufficient to induce T cell 
recall to the lung?  
We have shown that LV-transduced AM are sufficient for T cell recall to the lung, even 
in small quantities, but we have not conclusively demonstrated that they are 
necessary. This is not trivial, since a central hypothesis arising from this work is that 
chemokine production by AM is pivotal to the potency of LV as mucosal T cell vaccines. 
To confirm this would requires exclusion of transduced epithelial cells as a major 
source of T cell chemoattractant after intranasal vFLIP-NP. We have developed a 
trivalent LV that expresses two transgenes under the control of one promoter (SFFV), 
separated by an internal ribosome entry site (IRES) and another under a separate 
promoter. An LV with the DTR receptor driven by an F4/80 promoter and vFLIP/antigen 
under the SFFV IRES cassette could be used to selectively kill transduced, F4/80 
positive cells with intranasal diphtheria toxin, leaving transduced epithelial cells intact. 
This avoids the confounding, pro-inflammatory consequence of AM depletion by 
clodronate or diphtheria toxin in the CD11C-DTR mouse model.  
 
Is antigen or T cell chemoattractant (or both) required to maintain lung based T cell 
memory?  
A central question in immunology is whether persistent antigen presentation is 
required to maintaining tissue-resident T cell populations in the longer term. A 
trivalent LV expressing the DTR receptor could also be used to “switch off” antigen 
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(and/or expression of a chosen chemokine) at a chosen point after intranasal boosting 
by administration of intranasal and/or intravenous diphtheria toxin.  
 
What are the functional and quantitative requirements for T cell mediated 
protection against influenza viral challenge? 
Despite the widespread reliance upon splenocyte IFNγ ELispot, pentamer/tetramer 
quantification and splenocyte cytotoxicity assays in the literature as surrogates of T cell 
vaccine efficacy, the relative importance of quantitative and qualitative T cell 
responses in protection against influenza remains unclear. It is noteworthy that neither 
vFLIP nor 4-1BBL co-expression with antigen significantly increased the magnitude of 
NP-specific CD8+ T cell responses to SC vaccination compared with LV expressing NP 
alone. Functional markers (such as IFNγ secretion upon re-stimulation and GzmB 
expression) and survival after lethal challenge were significantly improved by these 
adjuvants, but the greatest enhancement in the degree of protection was observed by 
the SC-IN prime-boost strategy. Even using LV expressing NP alone, SC-IN vaccination 
conferred substantially greater survival and less weight loss than SC vaccination with 
vFLIP-NP or 4-1BBL-NP. This would suggest that the spatiotemporal numbers of T cells 
generated by vaccination are far more important than functionality. However, SC-IN 
Null-NP vaccination, even in the absence of vFLIP, generated GzmB-rich T cell 
populations not found in the spleen after SC vaccination. This indicates functional 
modification of memory T cells upon recall to the lung. One shortcoming of this work is 
that is unclear to what degree the increased GzmB expression observed in airway and 
lung NP-specific T cells after vFLIP-NP SC-IN vaccination compared Null-NP SC-IN is due 
to functional programming at priming (by vFLIP-transduced DC) or functional 
enhancement at recall (by antigen or other signals from vFLIP-activated AM or 
epithelial cells). It is also unclear from these data whether it is the superior numbers of 
lung and airway NP-specific CD8+ T cells or superior GzmB content (or indeed both) 
that determine the superior protection conferred by vFLIP-NP SC-IN vaccination over 
Null-NP SC-IN. These questions could be readily addressed by cross-over combinations 
of vaccination with vFLIP-NP and Null-NP, SC and IN.  
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This is an important issue to resolve, since little is known about the quantitative and 
functional thresholds that must be met for an effective mucosal T cell vaccine against 
influenza and other respiratory pathogens. The recent finding of Lambe et al, that 
large numbers of IFNγ secreting lung-based CD8+ T cells could be generated by an 
NP+M1 Adenovector-MVA SC-IN vaccination (~30% of total CD8+) is of interest 
because this failed to confer significant protection against influenza challenge with 
A/PR/8/34464. This mirrors the relatively weak cytokine responses we observed in lung 
and airway T cells after SC-IN vaccination to peptide re-stimulation despite complete 
protection. It is tempting to assume cytotoxic function, indicated by high GzmB 
staining, is therefore the more important requirement for effective protection. 
However, a limitation of this work is that we have not definitively shown this with 
cytotoxicity assays. In vitro assays would not replicate the immunotolerant 
environment of the airway, and attempts to deliver target cells intranasally for an in 
vivo measure of airway T cell cytoxicity were confounded by a high death rate of both 
peptide pulsed and un-pulsed cells. It could be argued, however, that monitoring T cell 
number, cytokine responses and viral load during infection in “real time” gives a more 
realistic assessment of the relative importance (or lack, thereof) of the cytokine 
response to viral clearance. Although beyond the scope of this work, such data permit 
mathematical modelling of the response to influenza infection in the context of pre-
existing mucosal T cells – a key step towards establishing the quantitative thresholds at 
which local memory T cells confer protection without clinical disease for a given 
pathogen.  
 
To what degree is the enhancement of T cell responses seen with 4-1BB stimulation 
due to direct T cell stimulation or indirect through transactivation of DC?  
Whilst we have demonstrated that 4-1BBL over-expression contributes indirectly to T 
cell responses through DC activation, we have not quantified this impact relative to 
direct T cell 4-1BB stimulation. This has important implications for the current use of 4-
1BB stimulation for T cell-based therapeutic or prophylactic vaccination strategies. 
Treating unimmunised mice with anti-4-1BB antibody results in non-specific CD8+ 
memory T cell expansion but also a number of pathologies such as anaemia, 
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thrombocytopaenia and substantial liver inflammation630. Repeated doses of 
administration of anti-4-1BB to hepatitis B transgenic mice, for example, substantially 
worsens liver inflammation and promotes the progression to hepatocarcinoma632 and 
a recent review reported that anti-4-1BB agonist therapy for human melanoma 
resulted in grade IV hepatitis in some individuals633. It was recently demonstrated that 
the latter cannot be entirely mediated by activation of liver-resident memory T cells 
through 4-1BB, since 4-1BB-/- mice reconstituted with 4-1BB-sufficient memory T cells 
do not develop hepatic inflammation when stimulated with doses of anti-4-1BB mAb 
that induce hepatitis in WT mice631. 4-1BB expression on both T cells and non-T cells is 
therefore required to induce immunopathology with anti-4-1BB stimulation.  
We propose that non-specific activation of DC by 4-1BB stimulation, as demonstrated 
in this study, may explain the loss of tolerogenic antigen presentation in organs such as 
the liver, and subsequent T cell-mediated tissue injury. In order to maximise the 
efficacy and safety of 4-1BB stimulation for vaccination, the relative contribution of 
direct and indirect T cell stimulation mediated by this approach needs to be quantified.  
One way of achieving this in our vaccination model would be to down-regulate the 
responsiveness of antigen-bearing DC to 4-1BB stimulation by 4-1BB knockdown. 
Vaccination of mice with an LV expressing antigen with or without an shRNA against 4-
1BB could be combined with anti-4-1BB antibody therapy (or vaccination with an LV 
expressing 4-1BBL given in trans at a separate site draining to the same lymph node). T 
cell responses in the spleen or lymph node could then be compared. This experiment is 
now underway. 
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7.2 LV as mucosal vaccines for lung disease 
 
The delicate architecture of the lung, adapted for gas exchange, is highly susceptible to 
disruption by inflammation. Homeostatic mechanisms thus exist to ensure a high 
threshold for inflammation initiation and its suppression after infection clearance. This 
makes both priming and maintaining a protective T cell memory population in the lung 
difficult. We have exploited the tropism of LV for AM to develop a SC-IN vaccination 
regimen that protects against an otherwise lethal challenge with a highly pathogenic 
influenza strain, without signs of clinical disease. This is achieved through the 
generation of high numbers of lung and airway NP-specific T cells, summarised in 
Figure 7-1. We observed rapid viral elimination after vFLIP-NP SC-IN vaccination, 
without accumulation of pro-inflammatory cytokines or histopathological signs of 
injury. Contrastingly, both the secondary T cell response seen in subcutaneously vFLIP-
NP immunized mice and also the naïve response were characterised by high total 
cytokine burdens during infection. These levels were greatest when high T cell 
numbers and viral titres coincide, but low in the absence of either component. 
Accordingly, a very large resident memory T cell population can achieve such rapid 
influenza elimination that stimulation of a deleterious secondary effector cytokine 
response is altogether avoided. 
Uniquely amongst mucosal T cell vaccines developed to date (to our knowledge), the 
protection conferred by these lung-resident T cell populations is sustained for at least 
4 months after SC-IN vFLIP-NP vaccination. This suggests significant potential in the 
clinical domain. We have demonstrated several other attributes of SC-IN vaccination 
that point towards clinical utility, such as cross-strain protection despite NP sequence 
variation, boosting of infection-acquired T cell memory and in vitro recall of human T 
cell responses against NP.  
At the time of writing, LV are being assessed as therapeutic vaccines in HIV in human 
trials66. However, the clinical potential of LV for prophylactic vaccination against 
influenza is limited, for now, by the theoretical risks of insertional mutagenesis which 
outweigh the potential benefits to healthy individuals. Non-integrating LV failed to 
generate significant lung-based T cell populations and will require substantial  
259 
 
 
 
 
  
260 
 
Figure 7-1 LV vaccination routes and generation of mucosal T cell memory populations. 
(A) In the steady state, central memory T cells supply a circulating effector memory 
population that migrates into lung parenchyma and the airway. Numbers of airway T 
cells are very low and AM maintain an high threshold for local priming of naïve T cells. 
Sub-lethal Influenza challenge will iniate a slow primary effector T cell response which 
takes 6-9 days to generate significant lung and airway influenza-specific T cell 
populations. (B) SC vaccination with LV vFLIP-NP transduces Langerhans cells which 
migrate to lymph nodes and prime and expand NP-specific primary effector T cells. NP-
specific central and effector memory T cells are later proportionately represented in  
the lung and airway but here T cell numbers are equivalent to those in the naïve 
mouse. Lethal influenza challenge results in recruitment and expansion of circulating 
NP-specific effector memory T cells which approach peak numbers between day 3 and 
6, mediating viral clearance and recovery in the majority of vaccinated mice but not 
without substantial lung injury. (C) IN LV vaccination with vFLIP-NP results in secretion 
of T cell chemoattractants by large numbers of transduced AM. Expression of co-
stimulation molecules by AM is minimal, however, and IN vFLIP-NP fails to prime a 
detectable NP-specific T cell response. Netiher non-specific recruitment of circulating 
effector memory T cells to the lung nor NFкB activation of AM has any impact on the 
clinical course of lethal influenza challenge. (D) IN vFLIP-NP vaccination in mice 
subcutaneoulsy primed with the same vaccine (or with NP-specific T cell memory 
established by prior infection) recruits large numbers of NP-specific circulating effector 
memory T cells to the lung and airway, therein enriched through antigen-driven 
proliferation by  presentation of NP epitopes by large numbers of LV-transduced AM. 
Lethal influenza challenge is rapidly cleared by the large, sustained tissue-resident 
population of NP-specific effector memory T cells, before an injurious secondary 
effector T cell cytokine response is initiated.  
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improvement of levels of expression and persistence of transgenes in order to 
establish and maintain protective lung-based T cell populations.  
 
However, SC-IN LV vaccination may have applications in other lung diseases where the 
cost and risk limitations of prophylactic vaccination in healthy individuals do not apply. 
Inoperable lung cancer and extensively drug resistant (XDR) TB have similarly poor 
prognoses and both are prime candidates for T cell-based therapeutic strategies. We 
are now testing the efficacy of SC-IN LV vaccination as a means of generating T cell 
responses against the TB antigen Ag85 and against epidermal growth factor receptor 
(EGFR) in a murine lung cancer model. 
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